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3. Summary 
Matrix metalloproteases (MMPs) play a crucial role in tissue homeostasis. Profuse literature has 
studied their roles in cell migration and tissue invasion during cancer metastasis, as well as in 
inflammatory processes. Although the literature covering MMPs function is abundant, the 
intracellular trafficking of these proteins remains poorly understood. The aim of the present 
work was to identify the molecular mechanism of intracellular trafficking of MMPs, with 
particular focus on MMP2.  
A novel mass spectrometry approach revealed nucleobindin-1 (NUCB1), a major regulator of 
Ca2+ homeostasis at the Golgi, as a potential candidate for the regulation of MMP transport. 
Using a synchronized cargo trafficking assay, it was possible to demonstrate that in the absence 
of NUCB1 the intracellular trafficking of MMP2 is delayed. Moreover, this work reveals that 
NUCB1-dependent MMP2 trafficking is restricted to the Golgi, exclusively delaying its intra-
Golgi trafficking at the cis compartment and, as a consequence, decreasing MMP2 mediated 
cell migration and matrix invasion. Furthermore, my findings show that not only MMP2, but 
also MT1-MMP intra-Golgi trafficking is impaired, implying that this mechanism could also 
influence the trafficking of other MMPs. 
Interestingly, experiments performed with a NUCB1 Ca2+-binding deficient mutant showed 
that Ca2+ is required, both for the interaction, as well as for proper MMP2 trafficking, 
suggesting that a specific impairment of cis-Golgi Ca2+ homeostasis, rather than an overall 
Ca2+ deficiency, is essential for proper MMP2 intra-Golgi trafficking. 
Taken together the results of this thesis contributed to enlighten the mechanism of MMP2 
intracellular trafficking by identifying NUCB1 as a critical player in MMP transport. 
Importantly, this work highlights the requirement of Ca2+ for proper trafficking, not just at 
the TGN, as has been documented, but also at the cis-Golgi. Although this is a big step 
towards the understanding of MMP intracellular trafficking, further investigations are required 
to gain a better understanding of the retention mechanism of NUCB1 at the cis-Golgi lumen 
and a deeper insight into the regulation of intra-Golgi protein trafficking. 
 
  
 8 
4. Introduction 
4.1 Protein trafficking in the secretory pathway 
The cell is a highly dynamic unit where multiple parallel processes happen to maintain ionic 
and nutrient homeostasis. Major players in this dynamic environment are proteins that act as 
messengers, triggers, anchors, transporters and receptors1. Some proteins are constitutively 
synthesized, meaning that the cell produces them constantly throughout its lifetime; however, 
there are also many proteins, such as MMPs, that require an external signal that induces their 
production2.  
 
Figure 1. Schematic view of the secretory pathway. Protein cargo is accumulated at ER-exit sites, 
packed in COPII coated vesicles to reach the cis-Golgi and transported thorough the stacks until it 
reaches the TGN, where proteins are sorted and packed to be delivered to their targeting 
destination. 
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After DNA transcription, most of the proteins are synthesized by ribosomes located in the 
cytosol3,4. Although some proteins remain there after their synthesis, many others are directed 
to different compartments such as mitochondria, lysosomes or the extracellular millieu3,5. This 
compartmentalization creates the need of specific transport mechanism to correctly target 
newly synthesized proteins to their final destination6. In this regard, eukaryotes use 3 major 
protein mechanisms of active transport: (1) gated, which keeps a bidirectional trafficking of 
proteins between the nucleus and the cytosol; (2) transmembrane, which deals with the 
transport of proteins anchored to a membrane; and (3) vesicular, where membrane-enclosed 
intermediates are in charge of the delivery of proteins from one compartment to another6. 
Vesicular transport is the basis of the trafficking mechanism in which this section is focused: 
the secretory pathway. 
The most common route used for soluble protein trafficking is the secretory pathway, also 
called the constitutive or canonical pathway7. In this pathway, proteins are synthesized, 
translocated into the endoplasmic reticulum (ER), then transported to the Golgi apparatus, 
where they traverse its stacks until reaching the trans-Golgi network (TGN, Figure 1), the 
sorting station of the pathway and the place where proteins are packed into vesicles and 
targeted to their final destination7–10. The details of this pathway are described in the following 
sections. 
4.1.1 Protein translocation to the ER 
Most secreted proteins, and to some extent also transmembrane proteins, possess a N-terminal 
sequence, termed signal peptide, that enables their recognition by a signal recognition particle 
(SRP) and directs their translocation to the endoplasmic reticulum3,11,12. Although initially 
thought as conserved sequence motifs, signal peptides are highly diverse and barely 
homologous11. Nevertheless, they are similar in size (~20-30 amino acids) and possess a similar 
3-domain structure: a basic N-terminal domain, a hydrophobic middle region and a slightly 
polar C-terminal domain11. Besides their function in protein relocation, signal sequences are 
not highly informative and, therefore, easily interchangeable11. 
Protein translocation to the ER starts with signal peptide recognition by SRP5,11–13. SRPs were 
first identified in 1971 and later identified as the 11S ribonucleoprotein (RNP) particle in 
mammalian cells5,12,14. SRP is a protein complex unit containing 2 main domains: the S-domain, 
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which binds to the signal sequence and promotes translocation, and the Alu domain, which 
arrests protein elongation (Figure 2)12,15.  
The S-domain is formed by the assembly of half of the 7S RNA SRP, and the subunits SRP19, 
the heterodimer SRP68/72 and SRP 543,12. The latter recognizes the signal sequence and 
interacts with the SRP receptor in a GTPase-dependent manner12. On the other hand, the Alu 
domain is composed of the 5’ and 3’ ends of 7S RNA SRP and the SRP9-14 heterodimer, 
important for Alu domain activity3,12.  
 
Figure 2. Mammalian SRP structure. (A) Molecular model of the S-domain and Alu-domain of 
SRP in mammals. The recognized signal sequence is represented in green. H: RNA helices. (B) 
Cryo-EM map of the complexed formed between SRP and the ribosome. Ribosome subunit 40S is 
depicted in yellow, 60S subunit in blue, signal sequence in green and SRP in red. (C) 70˚ rotation 
of the image depicted in (B) illustrating both S- and Alu domain of SRP. Figures modified from 
Halic et al. (2004)12. 
As mentioned above, protein elongation arrest is fundamental to promote translocation of 
nascent proteins to the ER, so how can SRP at the same time recognize the signal peptide, 
bind to the ribosome and prevent peptide elongation? Given that SRP and ribosomes do not 
have an equimolar distribution in the cytoplasm, a previous signal sequence scan is required for 
SRP to find a functional signal peptide16. To initiate such a scanning process, the SRP S-
domain interacts initially with the 60S ribosomal subunit, which induces a conformational 
change that allows the S-domain to initiate a signal peptide scanning12. Once it recognizes a 
functional signal sequence, SRP binds to it and changes to an open conformation, enabling the 
high affinity binding between SRP and the ribosome12.  
A B C
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Structural studies of the Alu domain revealed that its contact sites with the ribosome are the 
same used by the eukaryotic elongation factor 2 (eEF2), which is in charge of promoting 
protein elongation3,12. Given the higher affinity of the Alu domain for ribosomes, the 
interaction with eEF2 is lost and peptide elongation ceases3,12.   
The formation of a complex between SRP and the ribosome-nascent chain (SRP-RNC) 
enables its recognition by an SRP receptor (SR) that is formed by 2 subunits: α, which 
identifies the SRP54 unit and binds to SRP-RNC, and β, which is bound to the ER 
membrane12. The binding is mediated by GTPase activity and promotes the transfer of RNC to 
a translocon channel that finally delivers the protein into the ER lumen (Figure 3)3,4,16. 
 
Figure 3. Mechanisms for secretory cargo translocation to the ER. (A) Co-translational insertion 
of proteins is mediated by SRP recognition of signal peptide (see text above). Proteins can also be 
translocated into the ER via at least 2 alternative pathways: (B) Post-translational insertion of 
proteins requires cytosolic chaperones that keep protein cargo in an unfolded state prior to 
translocation. Hsp70 ATPases (e.g. like Ssa1 in yeast) play this role until the delivery of the protein 
to Sec63 complex, or (C) Protein insertion via the Get-transmembrane domain recognition 
complex (TRC) system. Here, tail-anchored proteins are inserted into the ER membrane aided by 
Get3 (in mammals TRC40), which targets them to Get1/Get2. Get: proteins encoded by the Golgi 
to ER trafficking deficiency genes in yeast. Figure taken from Barlowe & Miller (2013)4. 
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4.1.2 The Endoplasmic Reticulum (ER) 
The ER is the protein quality control checkpoint of the secretory pathway10. Here proteins 
arrive in an unfolded state and are continuously challenged by ER resident proteins until 
finding an optimal thermodynamic state that enables their transport to the next 
compartment10. 
The ER is also the largest intracellular compartment, with a single continuous membrane and a 
reticular distribution that extends throughout the cell, occupying up to 30% of its entire 
volume (Figure 4)7,10. It comprises the nuclear envelope and the peripheral ER, which 
membranes are categorized in two types: the rough (RER) and the smooth (SER)7,17. RER is 
characterized by a tubular shape that is in contact with translating ribosomes, whereas the SER 
is organized in a cisternal shape and is where lipid biogenesis and calcium regulation take 
place7. 
 
Figure 4. Representation of the ER and its multiple membrane contact sites (MCS). (A) ER and 
MCSs formed with organelles and the plasma membrane. Brown circles depict contact sites. (B) 
Electron micrographs of MCSs between ER-organelles (mitochondria and Golgi from rat epithelial 
A B
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cells), ER-lipid droplets (from yeast cells) and ER-plasma membrane (from mouse neurons). Right 
column depicts the zoomed area delineated on the left column. Figure modified from Wu et al. 
(2018)18. 
The ER tubules have also ribosome-free regions that mediate membrane contact with other 
organelles and the plasma membrane18,19. Although for years each organelle was considered as 
an independent entity, now is clear that organelles “get in touch” with each other and 
communicate via membrane contact sites (MCSs, Figure 4)18,19. Given the broad distribution of 
the ER throughout the cell, the diversity of ER MCSs is extensive19. Interestingly, these contact 
sites are maintained even during trafficking, fusion and fission of the contacted organelle, 
illustrating its importance in multiple cellular processes18.  
Soluble resident proteins within the ER are required for the proper chaperoning and transport 
of secreted proteins10,20. They all possess a C-terminal sequence motif, i.e. H/KDEL, that 
permits their retrieval from the Golgi and retention in the ER and many display Ca2+-
dependent activity, making of the ER the largest Ca2+ reservoir inside the cell7,21–24. Its role as 
Ca2+ storage compartment will be discussed further in this section. 
Once proteins are properly folded, they accumulate in specialized and highly organized 
subdomains denominated ER-exit sites (ERES)7,10,17,25. ERES are numerously distributed in the 
ER and constitute the exit point for secretory cargo that needs to be transported to the ER-to-
Golgi intermediate compartment (ERGIC)7,10,13,25. At ERES proteins that are incorrectly folded 
are also actively removed and only properly folded ones are allowed to accumulate and be 
packed into COPII vesicles to be delivered to the ERGIC (Figure 5)7,10.  
The recruitment of protein cargo to ERES is mediated by cargo receptors10. These are proteins 
that recognize properly folded proteins and can recycle back to the ER once their cargo is 
delivered into the next compartment10,26,27. Twenty-four cargo receptors have been identified in 
mammalian cells, although only few of them bind soluble cargo proteins10. ERGIC53, a 
transmembrane protein that recognizes quality checked pro-cathepsin, α1-antitrypsin and 
coagulation factors VI/VIII is one of those few identified receptors27,28.  
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Figure 5. Schematic representation of COPII vesicle formation. COPII assembly begins with the 
recruitment of Sar1 and its binding to GTP, which allows to recruit the Sec23/Sec24 complex to 
the ERES membranes. The latter then binds then properly folded cargo, anchoring it to the 
membrane, while Sec13/31 is recruited. The recruitment of the last complex induces a 
morphological change in the curvature of the ERES that generates vesicle structures, which later 
bud and bring cargo to the next compartment in an anterograde manner. Sec16 is a scaffold 
protein located in the cytosolic face of ERES. Sec16 is thought to stabilize the COPII coat by 
interaction with the other components, although is not a component of the COPII coat. In 
addition, TANGO1-cTAGE5 can associate with Sec23A, inhibiting the interaction with Sec13-
Sec31 and delaying the vesicle fission. Such a delay has been associated with an increase of size in 
the carrier that would allow the transport of larger cargo such as procollagen29.  Figure modified 
from Barlowe & Helenius (2016)10. 
After cargo binding, the assembly of COPII initiates with the recruitment of Sec12, an integral 
membrane protein, that mediates the exchange of GDP to GTP (Figure 5)7,10,30. Then, Sar1 
binds to GTP and recruits Sec23-Sec24 complex, which in turn induces the recruitment of 
Sec13-Sec31 complexes10. These surround the Sec23-Sec24 complex and deform the 
membrane in a “cage-like” structure that subsequently buds as an anterograde transport 
vesicle10,13,29,30.  
Although this mechanism is used in general for most of the cargo transported via the secretory 
pathway, other variables influence protein export and require the use of different 
transporters24,29,31,32. Therefore, in addition to COPII vesicles, Sec16 and TANGO1/cTage5 
complexes also coordinate the formation of different transport carriers24,29.  Nowadays there is 
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no consensus in a single trafficking mechanism, and it is rather alleged that the cell uses in 
parallel more than one29. How does the cell then know which mechanism to choose? The 
answer relies on characteristics of the cargo such as size and the time frame between fission 
and fusion of vesicles29. This topic will be reviewed with greater detail in a following section.  
4.1.3 The ERGIC 
Initially ERGIC was not considered a separate compartment but rather the accumulation of a 
vesicular fraction from the ER33 or the cis-Golgi34,35 in transit to the next compartment. 
Nevertheless, currently it is widely accepted that it constitutes a separate and highly dynamic 
pre-Golgi compartment24,35. However, a consensus model that could explain its characteristics 
and dynamics is still under debate10,24,35.  
Recently, Saraste & Marie (2018) summarized the current 3 models to explain the nature of 
ERGIC (Figure 6): the first one is based on the concept of transient transport carriers and 
claims that ERGIC is formed from the fusion of COPII elements that assemble at ERES and 
move via microtubules coordinated by dyneins in a “stop-and-go” manner (Figure 6a)35. In this 
model, ERGIC is permanently made de novo at ERES and fused with cis-Golgi, so no difference 
between transport from ER-to-ERGIC and ERGIC-to-Golgi is made35.  
 
Figure 6. Models of ERGIC biogenesis. (a) Transient transport carriers’ model. In this model, 
the ERGIC (here named IC: intermediate compartment) is formed by the fusion of ERES-derived 
COPII vesicles (orange coat) that form tubulovesicular carriers (TC) and mobilize towards the cis-
Golgi in a “stop-and-go” manner. COPI vesicles can bud from these TCs, and delivery to the 
Golgi could proceed in a stationary (though vesicles) or maturing fashion (by fusion of several 
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TCs). Importantly, transport carriers are the same from ER-to-ERGIC and from ERGIC-to-Golgi. 
(b) Stationary ERES-associated membrane clusters model. Here ERGIC is a defined intermediate 
compartment with tubulovesiclular clusters residing close to ERES. Cargo transport is 
accomplished by COPII vesicles from ER-to-ERGIC and by a different anterograde carrier (AC) 
from ERGIC to cis-Golgi. (c) Permanent network of dynamic vacuoles and tubules model. This is 
the most recently proposed model and combines elements of the two previously described ones. 
Here ERGIC is mobile but permanent and connects to ERES and Golgi through an 
interconnected network. Saraste & Marie (2018) define it as a Biosynthetic Recycling Compartment 
(BRC), where cargo dynamically moves both in an anterograde and retrograde manner. Figure 
taken from Saraste & Marie (2018). 
In the second model (Figure 6b), ERGIC is an independent organelle that communicates with 
ERES via “tubulovesicular clusters (VTCs)” and has different transport carriers to receive and 
deliver cargo: from the ER, COPII vesicles arrive, are then fused to ERGIC and newly packed 
in an anterograde carrier that will deliver cargo to the cis-Golgi35. This model is supported by 
the experiments performed with cells previously treated with brefeldin-A (BFA, a compound 
that disrupts Golgi membranes)36. In these experiments, Ward et al. (2001) observed that 
ERGIC53 was not fused with the ER, but rather remained associated to ERGIC membranes36. 
Also, Ben-Tenkaya et al. (2010) showed that ERGIC does not localize to the Golgi, and 
Farhan et al. (2008) demonstrated that in neurons, an additional signal is required for GABA-
transporters to leave the ERGIC37,38.  
Finally, the third model describes a combination of both previous models (Figure 6c)35. Here, 
ERGIC is considered a permanent, though mobile organelle that is connecting ERES and 
Golgi via a network that constantly fuses and fissions anterograde, but also retrograde, 
vesicles35. These vesicles and tubules are transported via microtubules in a “stop-and-go” 
manner35. Such a model is supported by recent findings from Park et al. (2015) who showed 
that COPI vesicles, largely considered exclusive for retrograde transport, could participate in 
anterograde trafficking to the Golgi and also generate tubules that connect Golgi stacks39.  
ERGIC is not only an important station for anterograde, but also for retrograde trafficking10. 
Currently, 2 mechanisms for the retrieval of ER proteins and membranes have been described: 
COPI trafficking and Rab6-mediated tubular elements10. COPI vesicles are directed to the ER 
either from the ERGIC or the cis-Golgi and mediate retrograde trafficking by recognition of a 
retrieval signal on the cytosolic side of ER proteins10,40. Meanwhile, Rab6-mediated retrograde 
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transport requires the formation of tubules from the cis-Golgi (Rab6 will be described with 
more detail in a further section)40.  
Although the precise mechanism for Rab6-tubulation is not known, Heffernan & Simpson 
(2014) proposed that the antagonist activity of cytosolic phospholipase 2 α (cPLA2α) and 
lysophospholipid acyltransferases could induce tubulation of ER accumulated cargo at the cis-
Golgi and recruit Rab6 for the subsequent retrograde translocation40. Whether this hypothesis 
holds true requires further investigation.  
4.1.4 The Golgi complex 
The Golgi apparatus was described for the first time in 1898 by Camilo Golgi as an “internal 
reticular apparatus”41. Later on, with the development of electron microscopy (EM), Palade 
and Fahrquar developed cytochemical stainings that allowed to identify the cis-to-trans polarity 
in the Golgi42.  
 
Figure 7. The Golgi complex. Model of part of the Golgi ribbon from a 3D reconstruction. For 
this example, the Golgi has seven cisternae, colored from cis (in light blue) to the TGN (in red). 
The white spheres represent both clathrin coated and non-clathrin coated vesicles, illustrating its 
central role in vesicles trafficking. Figure taken from Marsh & Kowell (2002).  
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Nowadays, the improvement of CryoEM and 3D-EM techniques, plus the development of 
fluorescence light microscopy techniques, has allowed to visualize ultra-thin sections of down 
to 3 µm and to a better understanding of the trafficking dynamics at the Golgi (Figure 7)43,44.  
The Golgi is also the master of the secretory pathway45. Here, proteins are glycosylated, 
segregated and properly sorted into vesicles targeted to the plasma membranes or another 
specific compartments44. Furthermore, lipids and carbohydrates are also constantly 
participating in these processes44. The next sections will focus on how Golgi successfully 
accomplishes cargo trafficking, sorting and delivery in the secretory pathway. 
4.1.4.1 Structure 
In order to achieve its multi-tasking role, the mammalian Golgi is segregated into 4 main 
compartments or cisternae, namely: cis, medial, trans and trans-Golgi network (TGN, Figure 
8)46. Each of these compartments is organized in such a way that cargo can be modified post-
translationally and mature upon its arrival to the TGN8,47,48. To do so, specific proteins are 
associated with each cisterna and a gradient of both Ca2+ and pH is maintained by the 
constant influx and efflux of ions and membranes44,49–52.  
Figure 8. Membrane trafficking models in the Golgi. (a) The stable compartment model claims 
that each compartment is static or fixed and defined by a specific set of resident Golgi proteins. 
Cargo is therefore transported in vesicles to the next compartment.  (b) The cisternal maturation 
model states that each compartment is formed de novo and progress by permanent vesicle 
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trafficking until reaching maturation (TGN). In this model, cargo never leaves the compartment. 
Figure taken from Glick & Nakano (2009)47. 
The mechanism by which this compartmentalization is maintained is still under debate; 
however, two main models of membrane trafficking are considered more likely: the fixed 
compartment model and the cisternal maturation/progression model (Figure 8)47,48,50,53–56. In 
the fixed compartment model, the Golgi is seen as a closed membrane that actively transports 
cargo across stacks by constant vesicle fission and fusion (Figure 8a)29,56–58.  
On the other hand, the cisternal maturation model claims that the process is more dynamic 
and cargo never leaves the Golgi (Figure 8b)46,47,59. Instead, the cisterna matures until becoming 
TGN and distributes to vesicles that are either recycled to the ER or exported to the target 
compartment or the plasma membrane46. Although the secretory pathway is highly conserved, 
the cisternal maturation model is mainly supported by data from yeast, whereas the 
compartment model better explains protein trafficking in mammalian cells57.  
The controversy between those mechanisms remains because up to date there is evidence 
supporting both56,60–62. However, a consensus towards a combination of both mechanisms is 
lately taking place. In this regard, Kurokawa et al. (2019) showed how in yeast, transmembrane 
secretory cargo is restricted to an area in the maturing cisterna and then localizes towards a 
mature zone inside it. Although the data would support the cisternal maturation model, their 
observations show that the cisternae are not static, and therefore another kind of continuities 
between Golgi compartments, such as the ones described by Beznoussenko et al. (2014) would 
be required for cargo transport48,61. 
Golgi compartments are determined by the stack: an accumulation of cisternal membranes one 
on top of another that are laterally interconnected with tubules (the non-compact zone) and 
localizes, mainly, in the perinuclear area44,63. The accumulation of these structures is known as 
the Golgi ribbon, and is what gives it its particular shape63. Given the continuity in structure, 
but also the compartmentalization of each stack, how can the Golgi maintain at the same time 
continuity and separation? 
4.1.4.2 Golgi organization 
Golgi ribbons are characterized by a flat morphology in the middle (10-20 nm) that expands 
towards the rims (~100 nm)44. Importantly, the Golgi rims display tubular structures 
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denominated fenestrae, which promote cargo trafficking by increasing “the surface-to-volume 
ratio of the cisternae and (…) the fraction of the membrane that is highly curved”47, which 
stimulates the accumulation of cargo at the rims and the synthesis of vesicles to transport 
cargo to the next compartment (Figure 9)43,44,47,56,64.  
 
Figure 9. Golgi schematic view with associated membrane network. pVTC: peripheral 
tubulovesicular carriers; cVTC: central tubulovesicular carriers; CV: condensing vacuole. Figure 
taken from Klumpermann (2011)44. 
In general, Golgi morphology is maintained by Golgi ReAssemble Stacking Proteins 
(GRASPs) and Golgins, structural proteins that keep the stacks together and shape the 
Golgi44,65–67. In particular, GRASPs are synthesized in the cytoplasm and subsequently recruited 
to the cytoplasmic face of the Golgi via N-glycinemyristoylation and binding to Golgins66,68. 
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They are characterized by a conformation that enables either cis or trans interaction with other 
GRASPs and, depending on the orientation, this promotes GRASPs accumulation or tethering 
with an opposing membrane (Figure 10)63,65–67,69,70. 
Two GRASPs have been identified as components of the Golgi structure: GRASP55 at the 
medial-trans-Golgi interphase and GRASP65, located at the cis-Golgi compartment66,67,69,71. 
Previous reports have demonstrated that in the absence of GRASPs, the Golgi can cope with 
keeping the stack integrity, but the trafficking of protein cargo is impaired66,67. Interestingly, in 
this scenario, protein trafficking is faster, and cargo is not properly glycosylated, suggesting a 
role in timing control of trafficking to allow proper protein glycosylation67. 
 
Figure 10. GRASPs and Golgins are responsible for Golgi membrane tethering during membrane 
trafficking (A), ribbon formation (B) and stacking (C). Figure taken from Barinaga-Remeneria 
Ramirez & Lowe (2009). 
Together with GRASPs, Golgins also participate in trafficking, ribbon formation and 
stacking65,72. Golgins are coiled-coil proteins mainly involved in vesicle “catching” and 
tethering63,65,73. They bind via the C-terminal domain and associate in a direct (via 
transmembrane domains) or indirect manner (via protein-protein interactions) with the 
cytosolic face of Golgi membranes73. Their distribution is varied both across the membrane 
compartments, as well as within a stack, with some Golgins having preference for the flat 
center of the ribbons (like GM130 at the cis-Golgi) and others for the rims (i.e. giantin and 
golgin-84)65,73.  
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Most Golgins bind Rab GTPases (Rabs), mediating their membrane recruitment in this way 74. 
Rabs belong to the Ras family of small GTPases, which were initially identified in yeast75. More 
than 70 different Ras-like proteins have been identified in mammals and, among these, around 
20 are associated with the Golgi, with Rab6 being the most abundant one75. Rabs function as a 
molecular switch, activated by binding to GTP76. This activation is mediated by Guanine 
Exchange nucleotide Factors (GEFs), whereas their inactivation is induced by GTPase 
activating proteins, which induce GTP hydrolysis to GDP76.  
 
Figure 11. Model depicting the role of Golgins as “tentacles” projecting from the Golgi surface. 
Golgin tethering can occur via bend (flexible joint that brings membranes together), concertina 
(bringing membranes together in a “spring-like” manner) and Rab hop (moving the income carrier 
through differential Rab binding towards the final fusion site). Figure taken from Barinaga-
Remeneria Ramirez & Lowe (2009). 
These activation/inactivation cycles regulate Rab recruitment of downstream effectors, such as 
motor proteins and tethering factors, modulating specificity and adequate vesicle targeting to 
their respective cytoskeletal motor protein or membrane receptor75. Recently, it has been 
shown that Rabs can define the polarity of the secretory pathway by the establishment of Rab 
cascades, namely the organized sequential recruitment of Rabs due to the differential presence 
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of effectors along the pathway75. However, the discovery and linking of all GEFs and GAPs 
distributed along the pathway is still required to establish how cells define and “maintain 
secretory and endocytic pathways”75.  
The interaction between the described elements constitutes the basis for trafficking regulation. 
In this regard, it is known that the complex formed between GRASP65 and GM130 acts as 
Rab1 effector that regulates the fusion of COPII vesicles at the cis-Golgi71. Furthermore, 
GRIP-domain Golgins –i.e. Golgins with an Arl1 Rab GTPase binding site– are widely 
localized at the TGN and mediate the retrieval of endosomal cargo back to the Golgi (e.g. 
TGN46)77,78. Besides their tethering and fusion mediating role, some Golgins have been 
involved in the formation of transport carriers; this is the case for Golgin-160, which mediates 
Golgi sorting of the GLUT4 glucose transporter in adipocytes65.  
Such diversity in interactions is reflected by the tentacle model proposed by the Munro group, 
where Golgins are attached to the Golgi surface like tentacles that capture different vesicles, 
tubules and other Golgi elements via different Rab binding sites72,79. In this way, Golgins can 
promote vesicle or tubular transport along the membranes towards their target destination, 
resulting in fusion or anchoring to their target membranes (Figure 11)72,79. So now, how do 
vesicles fuse to the cis-Golgi and initiate their maturation process? 
4.1.4.3 Membrane dynamics 
Intracellular vesicle fusion is mainly mediated by Soluble N-ethylmaleimide-sensitive factor 
Attachment protein Receptors (SNAREs)73,80. These membrane-associated proteins have 2 
characteristic motifs, the vesicle-root SNARE (or vSNARE) and the target membrane-
associated one (tSNARE)73,80,81.  
Structurally, SNAREs assemble in a bundle composed by three Q-SNARE chains (belonging 
to tSNARE) and one R-SNARE chain (from vSNARE), according to their positions in the 
tethering area (Figure 12A)80,81. The described chains can bind from N- to C-termini in a 
zipper-like manner, bringing two membranes close enough to promote fusion (Figure 12B)80,81. 
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Figure 12. SNAREs as membrane tethers. (A) Model of the complex SNARE-Munc18 (a 
chaperone protein). The SNARE bundle is formed by VAMP2 (R-SNARE) and the Q-SNARES 
Syntaxin-1, SNAP-25C and SNAP-25N. (B) Detail of the zipper binding between R-SNARE and 
the three Q-SNARE helices. Figure modified from Rathore et al. (2011).  
A critical aspect of SNARE-mediated fusion is the requirement of Ca2+81–83. One of the best 
described mechanisms for vesicles fusion was first documented in neuronal cells, where it is 
known that synaptic vesicles fuse only after an increase in the surrounding Ca2+ concentration 
of around 10-100 fold83,84. In synaptic neurons, for example, synaptotagmin-1 is anchored to 
the membrane and binds Ca2+ in order to enable Q-SNAREs (such as Syntaxin and SNAP-
25) to make the bundle with the R-SNARE synaptobrevin81,82. This minimal fusion machinery 
highlights the importance of Ca2+ in membrane trafficking.  
4.1.5 Importance of calcium in the secretory pathway 
In the secretory pathway, Ca2+ has been shown to be essential for signaling38,83,85,86, polarity 
maintenance49,87,88, trafficking regulation83,89,90, vesicle fusion91,92 and sorting52,93–96. Two kind of 
proteins regulate intracellular Ca2+ levels: (1) luminal or cytosolic Ca2+ binding proteins that 
act as buffers regulating Ca2+ without changing the total amount inside the cell, and (2) 
transmembrane proteins that regulate Ca2+ concentration in intracellular compartments by 
active or passive Ca2+ transport across membranes85,86. 
The ER is considered the biggest Ca2+ reservoir in the cell, with luminal concentration 
ranging from 300-700 µM52,92. Ca2+ influx at the ER is regulated by the SarcoEndoplasmic 
Reticulum Ca2+ transport ATPase (SERCA), whereas Ca2+ efflux takes place via inositol 
1,4,5-phosphate receptors (IP3Rs) and ryanodine receptors (RyRs, Figure 13)97,98. Importantly, 
the maintenance of Ca2+ pools is essential for the formation of Ca2+ gradients for protein 
trafficking51,83,85. It has been shown that Ca2+ leakage is necessary for vesicle fusion with the 
Golgi, as Ca2+ chelators block intra-Golgi transport83,99. Moreover, Porat & Eleazar (2000) 
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showed that it is actually the Ca2+ gradient what regulates fusion events in the secretory 
pathway99. 
In order to keep a Ca2+ gradient, several pumps and channels are also expressed in a gradient 
manner along the Golgi compartments51,52,98,100–102. In this regard, the cis-Golgi requires SERCA 
pumps for Ca2+ influx and IP3 channels for Ca2+ release, whereas, at the trans-Golgi 
compartment, Ca2+ transport is mainly regulated by the Secretory Pathway Ca2+ ATPase type 
1 (SPCA1, Ca2+ influx) and RyRs (Ca2+ efflux, Figure 13)49,51,52,89,90,98. Although still not 
thoroughly studied, it has been suggested that the medial-Golgi would then harbor a mixture 
of IP3Rs and SERCA on its cis face and RyRs and SPCA1 on the trans side51,52. 
 
Figure 13. Ca2+ gradient along the secretory pathway. Ca2+ concentration reduces from ER to 
Golgi owing to the presence of different Ca2+ pumps and ionic channels along the secretory 
pathway. SPCA: Secretory Pathway Ca2+ ATPases; SERCA: SarcoEndoplasmic Reticulum Ca2+ 
transport ATPase; RyR: ryanodine receptors; IP3R: inositol 1,4,5-phosphate receptors; TRP: 
Transient Receptor Potential channel; TPC: Two Pore Channel. Concentration shown on the right 
side indicate Ca2+ concentrations in each compartment. [Ca2+]cyt: Ca2+ concentration in the 
cytosol. Figure taken from Micaroni (2012)85. 
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Micaroni et al. (2010) documented changes in cytosolic Ca2+ upon arrival of cargo at the cis-
Golgi and found that Ca2+ concentration increases in the cytosol during cargo passage 
through the Golgi83. They evidenced that the cytosolic Ca2+ gradually changes as long as cargo 
traffics towards the TGN and therefore suggest that such behavior could be explained by 
changes in pH caused by the disruption of membrane connections 83,99. 
The Ca2+ concentration at the Golgi diminishes from cis to trans (300 – 150 µM), reaching the 
lowest concentration at the TGN (50 – 100 µM)52. Noticeably, there is a marked separation 
between the trans-Golgi and the TGN, which are segregated by membrane diffusion with no 
Ca2+ flow between them52. 
In addition to membrane channels and receptors, luminal Ca2+ binding proteins also localize 
in a gradient manner within the Golgi lumen103–106. Here, three proteins are considered the 
major Ca2+ regulators: nucleobindin-1 (NUCB1) in the cis-Golgi104,106, DNA-binding EF-hand 
Acidic amino acid-rich non-glycosylated Ca2+-binding protein (NEFA/p54) in the medial87 
and Cab45 in the trans-Golgi and TGN95,96,103,107. Given the presence of specialized Ca2+ 
buffers in each cisterna, it is speculated that impairment in cargo trafficking would strongly 
affect Ca2+ concentrations within the Golgi85. 
 
Figure 14. Structure of the EF-hand domain (A) and ribbon diagram of tertiary fold of human 
NUCB1’s EF-hand domains. Figures adapted from (A) Carafoli & Krebs (2016)86 and (B) de Alba 
& Tjandra (2004)108. 
The three mentioned luminal proteins belong all to the Ca2+ binding EF-hand family, a 
protein group that shares a homologous region called the EF-hand domain (Figure 14)86,109,110. 
This domain consists in a helix-loop-helix motif that binds Ca2+ with high affinity86,95,109. The 
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denomination of EF-hand arose from the orientation of the 5th (E) and 6th (F) α helices at 
enclosing the Ca2+ binding loop, which resemble a hand shape (Figure 14A)86,110.  
Among the 3 proteins described, Cab45 has been the best characterized. It belongs to the 
CREC family of proteins (CREC: Cab45, Reticulocalbin, ER55 and Calumenin), a group of 
EF-hand proteins localized in the secretory pathway22,111. Its role in this pathway is still under 
study, however, research from the von Blume Lab has advanced our knowledge of its role in 
protein sorting.  
The group first showed that Ca2+ is required to retain Cab45 at the TGN107. Then, Crevenna 
et al. (2016) characterized the six EF hand motifs of Cab45 and demonstrated its 
oligomerization upon SPCA-induced Ca2+ influx95. Further on, Deng et al. (2018) 
demonstrated that Cab45 EF-hand domains are organized in 3 different pairs, and that EF 
pairs 1 and 3 are essential for Ca2+ binding and proper Cab45 localization in the Golgi; 
moreover, they propose that oligomerized Cab45 binds to cargo and regulate its sorting into 
sphingomyelin-rich vesicles (Figure 15)96.  
 
Figure 15. Cab45-mediated protein sorting model. Deng et al. (2018) propose in this model that 
Cab45 oligomerizes upon Ca2+ influx to the TGN. This influx is provided by SPCA1, which is 
activated by the interaction with ADF/Cofilin. Once oligomerized, Cab45 binds cargo in an 
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unknown manner, and promotes its sorting into sphingomyelin-rich vesicles96. Figure taken from 
Deng et al. (2018).   
In contrast, the role of NUCB1 in protein trafficking, is poorly characterized. Although Lin et 
al. (1999) showed that it is a major regulator of Ca2+ homeostasis in the cis-Golgi, and that its 
activity is influenced by SERCA, no role in trafficking has been defined so far112. NUCB1, also 
known as CALNUC in humans or Nuc in rats, displays 2 isoforms, one of which localizes to 
the Golgi and a cytoplasmic version (sNUCB1), lacking the first 26 amino acids of its signal 
sequence106,113. The latter has been studied more thoroughly and is known to regulate Gai3 
activation114–117, to inhibit amyloid precursor protein (APP) aggregation118,119 and to participate 
in LRP9 receptor recycling120,121. NUCB1, unlike Cab45, possesses only two EF-hand motifs, 
though both have been shown to be essential for interaction with G-proteins and the 
maintenance of Ca2+ homeostasis108,112.  
Finally, NEFA, or p54/NEFA, is the least characterized of these three proteins. It was initially 
found in a human leukemia cell line and besides its two EF-hand domains (Figure 14B), which 
show high homology with the ones of NUCB1, it has a DNA-binding domain and a leucin-
sipper domain122,123. Morel-Huaux et al. (2002) identified it as a medial-Golgi resident protein 
by co-localization analysis with mannosidase II87. Further investigation is required to determine 
the function of p54/NEFA and its role in protein trafficking.  
As mentioned before, Ca2+ entry at the Golgi is tightly regulated by SERCA and SPCA1, but 
how does this Ca2+ regulation actually influence protein trafficking? One of the first studies 
that evaluated the role of Ca2+ in cargo trafficking evidenced that a low cytosolic Ca2+ 
concentration is required for cargo trafficking, since increases above ~100 nM inhibit protein 
transport at the Golgi99. Moreover, Porat & Elazar (2000) demonstrated that Ca2+ efflux was 
required for protein trafficking at the Golgi, an observation that was later confirmed by 
experiments from Vanoevelen et al. (2005), who showed that inhibition of SERCA and SPCA1 
reduced Ca2+ release to the cytosol.101 Furthermore, experiments using histamine-induced 
Ca2+ signaling showed that Golgi integrity is necessary for intracellular Ca2+ signaling101.  
Later on, Lissandron et al. (2010) showed that inhibiting SERCA stimulated faster Ca2+ 
refilling at the TGN probably due to an increase in cytosolic Ca2+, whereas SPCA1 silencing 
provoked a delay of cargo trafficking, although not a complete block49. Moreover, Aulestia et 
al. (2015) demonstrated a higher Ca2+ affinity at trans-Golgi, than at the cis-Golgi or ER, 
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consistent with the higher affinity of SPCA1 for Ca2+ compared to SERCA52. They suggest 
that the differences in affinities could be explained by the need of keeping stable Ca2+ 
concentrations at the trans-Golgi and TGN to avoid impairments in protein trafficking52. 
In addition to the described Golgi-resident Ca2+ channels, pumps and buffers, another group 
of proteins, that do not permanently localize to the Golgi, can be recruited upon changes in 
the cytosolic Ca2+ concentration85. This group encompasses kRas, Ras-GRP, Ca2+-sensor 
proteins (such as hippocalcin) and cPLA2, which will be discussed in more detail below68,85.   
cPLA2 has been shown to be a key element in the regulation of Golgi and ER membrane 
tubulation38,48,59,85,124. cPLA2 is a protein that shuttles between the plasma membrane and the 
Golgi upon changes of Ca2+ concentrations in the cytosol, with increasing Ca2+ favoring its 
re-location to the Golgi38,59.  
 
Figure 16. cPLA2α penetrates the membrane upon Ca2+ binding and induces changes in 
membrane curvature. (A) Structure of the C2 domain of cPLA2α membrane association. Upon 
Ca2+ binding, the C2 domain interacts with 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine 
(POPC) membranes via its two Ca2+ binding domains. Image obtained using electron 
paramagnetic resonance (EPR). (B) WT C2 domain of cPLA2α induced membrane curvature 
changes in the presence of 500 nM CaCl2 to POPC containing GUVs, but not tubulations. These 
A
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were only observed when the full-length protein was evaluated. Figure modified from Ward et al. 
(2012)124. 
Although cPLA2 activity initiates the arachidonic acid cascade, an α isoform of the protein 
(cPLA2α) “hydrolyzes the fatty acids (FA) at the middle ester bond of cylindrical 
phospholipids to form wedge-shaped lysophospholipids”85. This reaction is of particular 
importance since it is known that the accumulation of wedge-like lysophospholipids promotes 
a spontaneous curvature of the membrane, and this in turn can transform flat membrane 
cisternae into cylindrical tubular shapes –membrane tubules–, and therefore connect Golgi 
stacks59,85,125,126.  
Moreover, Ward et al. (2012) demonstrated that the N-terminal C2 domain of cPLA2α 
penetrates the membrane in a Ca2+-dependent manner, whereas its catalytic C-terminal 
domain was required for activity. Therefore, the insertion of the full-length protein is required 
for Golgi tubulation (or vesiculation) as the insertion of the C2 domain only induces curvature 
albeit not tubulation (Figure 16)124.  
Altogether this evidence highlights the importance of Ca2+ in signaling, protein translocation, 
Golgi architecture, and protein trafficking. However, the components participating in Ca2+-
dependent protein trafficking remain poorly understood. Therefore, a better understanding on 
the mechanisms behind the regulation of intracellular trafficking would shed light into the 
dynamics of cell-to-cell or cell-to-matrix communication. Given that a big percentage of the 
secreted proteins are crucial for the transformation of the extracellular matrix, the components 
and dynamics of cell-to-matrix communication will be detailed in the next section. 
4.2 The Extracellular Matrix  
The extracellular matrix (ECM) is the ensemble of proteins, glycans and other molecules that 
provide structural support for the cells to develop into tissues127,128. Besides its scaffold role, it 
serves as a platform for cell signaling, migration, proliferation and regeneration129. The ECM is 
a 3D network that undergoes permanent remodeling in order to keep tissue homeostasis, 
which is reflected by the multiple diseases developed upon mutations in genes encoding ECM 
components, such as cancer, osteoarthritis, Ehlers-Danlos syndrome, Marfan syndrome, 
congenital muscular dystrophies, among others127,128. 
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The ECM can be classified in two kinds: the basal or basement membrane, which is located 
basolaterally to the epithelium and endothelium, is more compact and provides the support for 
epithelial cells, and the interstitial connective tissue, which is more flexible and serves as a 
scaffold for the building of tissue (Figure 17)127,128. ECM is remarkably important for the 
immune system as it provides an insoluble organized structure where leukocytes can migrate 
and communicate by integrating different signals130. In this regard, the ECM provides the 
platform for leukocytes to trans migrate from blood vessels to the injured tissue and initiate 
healing processes130. 
More than 300 proteins constitute the ECM in mammals, among them 43 collagen subunits, 
36 proteoglycans and more than 200 complex glycoproteins127. The interaction of these 
components with cell receptors and signal molecules enables the complex and dynamic 
remodeling of the ECM127. 
 
Figure 17. Schematic representation of the skin ECM depicting its main components. Figure 
taken from Bhattacharjee et al (2019)131. 
 
4.2.1 Composition 
The major components of the ECM can be classified in six main groups, namely collagens, 
elastin, laminins, fibronectin, matricellular proteins and proteoglycans128. All of them can be 
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differentially expressed according to the physical structures of the tissue, as well as the cell 
signaling of health or disease states128. These components are briefly described hereunder: 
4.2.1.1 Collagens 
Collagens are the most abundant component of the ECM128,132. Their structure consists of 
triple helices formed by the interconnection of 46 polypeptide α chains, which are formed by 
the helical interaction of collagen polypeptide chains rich in proline and glycine132. Twenty-
eight different collagens classified in 6 different groups according to their functionality128: (1) 
fibrillar, the most abundant and widespread (collagens I-III, V, XI, XXIV and XXVII); (2) 
network forming, which build more complex molecular structures (IV, VIII and X); (3) fibril-
associated with interrupted triple helices, which regulate fibrillogenensis (IX, XII, XIV, XVI, 
XIX-XXII); (4) membrane associated with interrupted triple helices, which can act as surface 
receptors and play a role in cell adhesion and motility (XIII, XVII, XXIII and XV); (5) self-
assembled collagens, which connect other components within the tissue (VI, VII, XXVI and 
XXVIII); and finally, (6) multiplexing collagens, which are characterized by a non-collagenous 
C-terminal and can mediate the interaction of the basal membrane with connective tissue128,133. 
4.2.1.2 Elastin 
Elastin is the main component of continuous stretching tissues, providing elasticity via its 
intrinsically disordered structure128. Tropoelastin, its precursor, is rapidly assembled into 
complex structures upon secretion to the ECM. The high content of hydrophobic amino acid 
on its structure facilitates the assembly of elastin and constitutes a key aspect for the 
maintenance of elasticity on the tissue134. 
4.2.1.3 Laminins 
Laminins are among the main components of the basal membrane and can initiate its assembly 
by binding to cells, other laminins or other basal membrane components, such as collagen 
IV135. In addition, they mediate anchoring of cells to the basal membrane via interaction with 
surface sulfated glycolipids, integrins and dystroglycan receptors that connect the extracellular 
matrix with the cytoskeleton135. Sixteen different combinations of a, b and g chains interacting 
via their coil-coiled domain have been identified in vertebrates in vivo, assembled either in rod-, 
Y- or cross-shapes128,135. Altogether, laminins play an important role in cell differentiation, 
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adhesion and migration via their interaction with integrin and proteoglycan receptors in 
epithelial cells136. 
4.2.1.4 Fibronectin 
Fibronectin is described as a fibril forming glycoprotein with ubiquitous localization128. It 
interacts with other components of the ECM (such as collagens and fibrin, as well as with 
glycosaminoglycans (GAGs) and integrins, providing a scaffold for matrix organization and 
playing an important role in cell-matrix interactions128. Such interactions facilitate growth and 
differentiation during development, as demonstrated by embryonically lethal fibronectin 
mouse models136. 
4.2.1.5 Matricellular proteins 
This is a large group of non-structural matrix glycoproteins that localize both in the extra- and 
intracellular milieu128. Trombospondins, secreted protein acidic and rich in cystein (SPARC), 
Tenascins, Osteopontin and cartilage oligomeric matrix protein (COMP) constitute some of 
the most representative members of this group128. They mediate interactions between cells and 
the surrounding ECM acting as scaffolds for the binding of components such as small leucin 
rich proteoglycans (SLRPs), decorin and versican137. Some of the proteins in this group are 
essential for cancer progression by altering redox signaling and inducing a hypoxic 
environment around the tumor mass137. 
4.2.1.6 Proteoglycans 
Proteoglycans (PGs) are a family of proteins with an amino acid core attached to a chain of 
GAGs of variable chain length138. PGs can be secreted, membrane bound or intracellular 
(Figure 18)138. Among the secreted PGs, two main subfamilies are present in the interstitial 
matrix: the hyalectans or aggrecans, which interact with hyaluronan (such as aggrecan, versican 
and brevican), and the small leucine-rich PGs (SLRPs), which are involved in matrix 
organization, collagen fibrillogenesis, inflammation and cell signalling (for example, decorin, 
syndecan and fibromodulin)138. The third group of secreted PGs, also known as modular or 
pericellular PGs (perlecan, agrin and collagens IX and VIII), are mainly components of the 
basal membrane and provide stability via interaction with integrins138. 
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Transmembrane PGs are essential for cell migration and signaling128. This group is mainly 
represented by syndecans and glypicans139. Syndecans are molecules that actively participate in 
cell adhesion, migration and cytoskeletal organization by binding integrins and growth factor 
receptors139. Glypicans, on the other side, are GPI anchored proteins that play an essential role 
in signaling via regulation of associated receptors such as tyrosine kinase128,138. 
 
Figure 18. Diversity of PGs. Secreted PGs (upper 2 panels) are mainly involved in matrix 
organization and stability. Meanwhile, transmembrane PGs participate in signaling processes and 
intracellular PGs are involved in the formation of inflammatory granules. Figure taken from 
Teocharis et al. (2016)140. 
Currently only serglycin has been characterized as an intracellular PG in secretory 
compartments128. Serglycin is essential for the formation of secretory granules, as well as the 
packaging and secretion of growth factors and cytokines in hematopoietic cells, which are 
released upon stimulation during inflammation140,141. Furthermore, serglycin has been found 
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associated with CD44 in order to induce collagen type I adhesion and synthesis of matrix 
metalloproteases141. 
4.2.2 Cellular interactions with the ECM 
Cells interact via different receptors with the ECM, namely: integrins, discoidin domain 
receptors (DDRs), cell surface PGs, hyaluronan (HA) receptors and Layilin (Figure 19)129. 
These receptors not only anchor the cellular cytoskeleton to the ECM, but can also initiate 
signaling cascades, direct cell migration and modulate the forces experienced by the cell142. The 
roles of these receptors in mediating cell to ECM interactions are briefly described hereunder. 
 
Figure 19. Diagram of different ECM transmembrane receptors mediating cell anchoring to the 
matrix. Syndecan: transmembrane PG (see section 2.2.1.6); CD44: HA hyaluronan receptor. 
Figures taken from Multhaupt et al. (2016)139. 
4.2.2.1 Integrins 
Integrins are heterodimeric receptors formed by the combination of 18 a-subunits and 8 
different b-subunits that directly heterodimerize after synthesis at the ER141,143. They interact 
with the ECM either via an epitope in both subunits or a domain of the a-subunit143. Integrins 
can be regulated both biochemically (by a change in conformation from a bend to an extended 
state) as well as mechanically (by ligand-binding kinetics, integrin clustering, conformation and 
activation)143,144.  
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The biochemical regulation can be generated by inside-out or outside-in mechanisms, 
according to the activating signal (Figure 20)145. Inside-out activation occurs via interactions 
with the integrin cytosolic domains, mainly mediated binding to talin, kindlin or focal adhesion 
kinase (FAK); this signal constitutes the first step in activation and allows the subsequent 
binding of other factors143,146. Conversely, outside-in activation occurs by interaction with 
specific ECM ligands, which generates force on the integrin cluster and induces recruitment of 
scaffold and adapting proteins, such as talin and vinculin, that couple the actin cytoskeleton to 
the integrin cluster143,145,146.  
 
Figure 20. Integrin activation mechanisms. Inside-out activation occurs by binding of active talin 
to the β subunit of integrins, whereas outside-in activation is triggered upon binding of integrins to 
components of the extracellular matrix. Figure modified from Moreno-Layseca et al. (2019)145. 
Integrins mediate ECM interactions via focal adhesions (see section 4.2.3.1), therefore they 
experience constant force both from the ECM and the cytoskeleton143. In this scenario, 
integrins can form clusters to redistribute the force per integrin unit143. Integrins can the 
accumulate in cross-linked clusters bound to actin, where the recruitment of another integrin 
subunit will reduce the force per unit and stabilize the focal adhesion143,145. Integrins can also 
“diffuse laterally” according to the substrate and mechanics governing the interaction, or 
induce membrane bending by clustering in order to interact with the ECM143. Such is the case 
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of the glycocalyx, which has been shown to impose a steric barrier for integrin-ligand 
binding143. There, the membrane bending induces a “kinetic trap”, where integrins that diffuse 
are closer to the substrate and can favorably interact with the substrate143. 
Overall, integrins are the main receptors mediating ECM interactions with cell 
cytoskeleton139,143. Their role as mechanical sensors, their ability to modulate the growth of FAs 
as well as their capacity to mediate cell-cell interactions allows them to promote directed cell 
migration139,143,147,148.  
4.2.2.2 Discoidin domain receptors (DDRs) 
DDRs are tyrosine-kinase receptors (RTKs) that can spontaneously bind collagen149. They are 
type I membrane proteins containing a collagen-binding discoidin domain, an extracellular 
discoidin-like domain and a cytosolic tyrosine-kinase domain (TK)149.  
 
Figure 21. DDRs in healthy and damaged tissue. In healthy tissue, DDRs cannot bind collagen, 
however, tissue injuries causing proteolytic damage, expose collagen and enables binding of DDRs. 
Binding to collagen activates DDRs, which in turn induce MMP expression and subsequent cell 
migration. Figure taken from Itoh (2018)149. 
Given that DDRs do not attach to a soluble substrate, their regulation is different from most 
RTKs in that their dissociation from collagen is usually mediated by ectodomain shedding149. 
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This process is facilitated by ADAMT-10, (a disintegrin and metalloprotease with 
thrombospondin motif, further described in the next section)149 and MMP14 (matrix 
metalloprotease 14, also known as MT1-MMP)150.  
Functionally, DDRs are very important in cell migration and as environmental sensors (Figure 
21)149. In 3D cell migration, they can modulate matrix metalloprotease (MMPs) expression, as 
shown in smooth-muscle DDR1 knock out cells by Hou et al. (2002)151. As environmental 
sensors, they can activate the expression of MMPs upon collagen rupture due to tissue 
inflammation, which induces phosphorylation of their tyrosine-kinase domain and stimulates 
MMPs upregulation149. Given their impact on the regulation of migration processes, DDRs 
have been postulated as therapeutic cancer targets149–152. However, due to their heterogeneous 
expression in model cell lines, further investigation is required to provide specific solutions.     
4.2.2.3 Hyaluronan receptors 
Besides their role in the assembly of the ECM, proteoglycans can act as signaling receptors that 
initiate intracellular signaling cascades, as is the case for HA-receptors153,154. Hyaluronan (HA) 
is the only GAG synthesized outside the Golgi and it binds to proteoglycans via specific 
binding motifs, which allows the assembly of a wide range of molecular weight HA chains153,154. 
Although long HA aggregates promote anti-inflammatory responses, wound healing and tissue 
repair141,154, short cleaved HA fragments generate pro-inflammatory signals that prevent ECM 
remodeling, impairing cell invasion and migration and subsequently stimulating pathological 
conditions154–157.  
HA plays a role in these processes mainly by triggering signaling cascades via interaction with 
several HA receptors154. Among them, CD44, is the main receptor and serves as an anchor for 
the cytoskeleton to the ECM154,158. Besides HA, CD44 binds also osteopontin, fibronectin, 
laminin, MMPs and collagens via its extracellular domain154. Via the interaction with signaling 
receptors such as Erb2 and EGFR, as well kinases of the Src family and RabGTPases, HA-
CD44 can trigger pro-inflammatory signaling cascades and stimulate cell invasion and 
migration, as has been shown by several studies in cancer cells156,157. 
Recently, another HA receptor named layilin, aroused as an important receptor for adhesion 
and tumor invasion via HA binding156. Layilin can bind talin head via its intracellular domain 
and HA via a C-type lectin domain on the extracellular face155. Layilin localizes mainly in 
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membrane ruffles, actin-rich protrusions of the plasma membrane that are considered the step 
preceding cell migration in macrophages159. Also, it shares some similarities with CD44, such as 
the weak binding affinity with HA and the capacity to bind ERM molecules intracellularly. 
Finally, layilin has been catalogued as the main HA-induced effect receptor in the intestine 
given its role in directly influencing cell invasion in gastric cancers155,156. 
4.2.3 Dynamics 
The ECM is an extremely dynamic environment that is in constant modification due to the 
synthesis, degradation and reassembly of its components127. The mechanisms involved in such 
rearrangements can be classified in six different processes: adhesion, contraction and 
alignment, degradation, internalization, deposition, and cross-linking (Figure 22)129.  
 
 
Figure 22. Mechanisms of ECM remodeling. Adhesion is mediated by integrins and focal 
adhesion proteins, conctraction and alignment by actomyosin, degradation by MMPs, 
internalization by endosomal internalization followed by lysosomal degradation, deposition by 
induced synthesis of ECM component s and crosslinking by post-translational modifications. 
Figure taken from Ford & Rajagopalan (2018)129. 
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Together adhesion, contraction, alignment and degradation are processes that define the 
mechanical interaction of cells with the ECM and allow to maintain tissue homeostasis127–129,160. 
Furthermore, these processes shape the adequate environmental conditions for a cell to 
migrate and this migration can only take place once a cell adheres and is able to use its internal 
tension to move in a 2D environment, as rolling leukocytes on the endothelial cells, and in 3D 
scenarios, as transmigrating leukocytes through the endothelial monolayer, invasive 
macrophages in inflammatory conditions or cancer cells in metastasis127–130. For the purpose of 
the present study, this section will be focused on the first three processes. 
4.2.3.1 Adhesion 
Adhesion is an essential step in cell migration, a process occurring due to the simultaneous 
assembly and disassembly of these cellular structures128,143,161. Currently several kind of adhesive 
structures between cells and ECM have been described, e.g. focal adhesions, focal complexes, 
fibrillar adhesions and invadopodia162. However, these different structures can be organized in 
2 main groups: focal adhesions and invadosomes (podosomes and invadopodia, see section 
4.3.3.1)162,163. 
 
Figure 23. Scheme depicting the formation of cell adhesions. Figure taken from Parsons et al. 
(2010)161. 
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Cell migration is first driven by the protrusion of the leading edge, which is stabilized by the 
proliferation of focal adhesions that subsequently stabilize the cell-ECM contact, generate 
tension and contraction forces to promote movement161. On the other hand, cells expressing 
podosomes move rather in a gliding way162.  
Focal adhesions are actin rich structures stabilized by integrins that localize in a tangential 
manner to the ECM and are mostly associated with matrix remodeling161,162. The formation of 
a focal adhesion initiates with the appearance of nascent adhesions, short-lived small 
structures, formed upon actin polymerization at the cell leading edge (Figure 23)161. They 
localize immediately behind the leading edge, after nucleation of 3 to 6 integrins, and are 
characterized by high turnover, of approximately 60 seconds161,164. According to increasing 
tension, nascent adhesions will mature into focal complexes, structures of around 0.5 to 1 µm 
diameter with a dot-like shape that are connected to the actin network via moderate 
tension161,162.  
As migration continues and the integrin cluster increases in size, focal adhesions are 
formed161,164. These structures have elongated shapes of around 2 µm wide and 3 - 10 µm long, 
are associated with stress fibers and disassemble at the rear once subjected to traction 
forces161,162. The assembly of focal adhesions in fibronectin matrices can give place to fibrillar 
adhesions, long-lived and highly elongated structures that are not prominent in migrating 
cells161.  
In this regard, contractile cells, such as fibroblasts, endothelial and smooth muscle cells 
preferentially express focal complexes and adhesions that help to stabilize in a longer term the 
cell-ECM interaction161. On the contrary, most of the migrating cells, e.g. cells belonging to the 
myeloid lineage, express preferentially small, short-lived structures such as nascent adhesions 
and invadosomes161–163,165. 
4.2.3.1.1 Adhesion dynamics 
Two processes dictate the assembly or disassembly of adhesions, namely, actin polymerization 
and tension generated by myosin II161. Actin polymerization at lamellipodia (Figure 23) starts 
with the activation of the Arp2/3 complex, which is regulated by the Rho GTPases Rac1 and 
CDC42 that act via effectors from the WASP (Wiskott-Aldrich syndrome protein) and WAVE 
(WASP-family verprolin homologue, also known as SCAR) families of proteins161. Such 
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activation provokes actin nucleation and the formation of branch-like actin at the leading edge, 
which in turn generates a retrograde force due to the limitations imposed by the membrane in 
response to actin polymerization161. 
At the same time, actin bundles located in the lamellum, undergo retrograde flow but in a 
slower manner, generating a reorganization of actin into bundles at the transition zone161. Once 
these bundles grow thicker, they become stress fibers that start adhering to the ECM on the 
dorsal sides of the adhesion161. Then, ventral stress fibers arise from dorsal ones and anchor 
the cell to the ECM via FAs in both ends (Figure 23)161. These ventral stress fibers also 
connect to the so-called transverse acts: not anchored actin bundles that start forming by 
annealing of myosin II bundles and Arp2/3-nucleated actin in lamella161.  
Actin polymerization in nascent adhesions is mainly regulated by focal adhesion kinase (FAK), 
which recruits the Arp2/3 complex in the first place161,164. The activation of FAK, as well as 
paxillin, induces talin binding to the cytosolic tails of integrins164. Talin, as well as kindlin, 
stimulates Rac1 activity, which in turns inhibits Rho GTPase and induces actin 
polymerization164.  
4.2.3.2 Contraction and alignment 
The antagonist process resulting after adhesion is contraction129. Here, the force exerted at the 
stabilized FA will generate such a tension that, upon surpassing a threshold, will make the cell 
contract129. In this regard, non-muscular myosin II (referred here as myosin II) is the primarily 
source for contraction (Figure 24)161,166. Upon binding to the ECM, actin filaments containing 
myosin IIa elongate and can generate mechanical tension by myosin IIa induced sliding of the 
filaments, creating contractile forces161,166. 
Myosin II contraction activity and tension influence only mature adhesions by mediating the 
contraction of actin stress fibers161. Nascent adhesion formation does not depend on myosin II 
activity, however, as long as the adhesion elongates, talin and vinculin bind active integrins to 
actomyosin via a mechanical linkage denominated “the molecular clutch”164. This engagement 
is first triggered by the exposure of a talin actin binding site (ABS, ABS3 usually), which 
enables F-actin binding and induces “stretching of the talin rod”, subsequently exposing a 
vinculin binding site (VBS)164. Upon vinculin binding, talin is able to engage with F-actin via 
ABS2 to increase the force transmission164. This in turn unfolds helical structures at the talin 
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rod, making available more VBSs and further consolidating the recruitment of F-actin and 
stabilizing the FA164.  
 
Figure 24. Myosin II structure and role in maturing adhesion during cell migration. (a) scheme of 
myosin II conformation depicting the regulatory light chains (RLC). (b) During migration myosin 
II acts mainly in mature FAs where it mediates retraction and disassembly at the rear end. Figure 
taken from Parsons et al. (2010)161. 
Myosin II activity is regulated by the phosphorylation of regulatory light chains (RLC), and can 
also influence FA retraction and disassembly during migration at the rear end (Figure 24)161.  
Combining adhesion and contraction not only controls the formation of focal adhesions, but 
also aligns components of the ECM, which in turn facilitates directed cell migration and force 
transmission129. In addition, the realignment of ECM components modifies physical properties 
of the matrix, such as stiffness, facilitating 3D matrix invasion as well as tissue organization129. 
4.2.3.3 Degradation 
The cleavage of ECM proteins is generally referred as degradation129. However, Apte and Parks 
(2015) suggest to subdivide the ECM proteolytical degradation in three categories: the 
turnover, which constitutes the regular physiological breakdown and replacement of ECM 
proteins; the remodeling itself, which encompasses the breakdown and clearance of tissues 
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under transformation, like resorption during development; and the degradation, which they 
suggest, should be applied only to the uncontrolled ECM proteolysis seen in disease 
contexts160. In general, all the processes described above require the breakdown of ECM 
components by secreted proteases, their cellular internalization and their subsequent 
degradation in the lysosomes129. 
 The proteases of the metzincin family, a group of zinc-dependent proteases that possess a 
methionine-turn sequence, are the main enzymes responsible for ECM proteolysis160,167,168. 
They can be secreted or membrane associated, and are synthesized, mostly, as pre-pro-
polypetides that require activation127,160. There are 6 families of metzincins, among these the 
most relevant for mammalian ECM degradation are: astacins, adamalysins and matrix 
metalloproteases (also known as matrixins), which are the main focus of this study and will be 
thoroughly described further below127,160,168.  
4.2.4 The metzincin family of proteases 
As mentioned previously, metalloproteases are the most important proteases during ECM 
remodeling. Although their catalytic regions are highly conserved, other domains are greatly 
variable, which explains the versatility of these proteins and their capacity to influence cellular 
processes independent of ECM remodeling160.  
Traditionally MMPs have been considered the only participants in the ECM remodeling, 
however, studies performed in the last two decades have challenged this assumption127,169,170. 
Other metalloproteases such as ADAMTs, Meprins and BMP1/tolloid-like proteinases are also 
crucial for the maintenance and turnover of ECM160.  These main groups of ECM remodelers 
are described below, with the exception of MMPs, which are widely described in the next 
section and constitute a central topic of the present study. 
4.2.4.1 Astacins 
This group of metalloproteases is only present in animals and bacteria168. Interestingly, some 
parasite nematodes, like Hydra, express astacins during development and also secrete them as 
zymogens to their host ECM in order to move through it168. Among vertebrates, astacins are 
represented by three subgroups: egg hatching enzymes, (bone morphogenetic protein) BMP-
tolloid proteases, and meprins168,171. In particular, humans express 7 different astacins encoded 
by six genes172:  
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• BMP-1, mammalian tolloid (mTld), tolloid-like 1 (Tll-1) and 2 (Tll-2) are involved in 
dorsal/ventral patterning during embryogenesis. 
• Ovastacin, responsible of preventing polyspermy during fertilization. 
• Meprin-a and meprin-b, proteases that stimulate the maturation of fibrillar collagen. 
BMP-1 is a zinc metallopeptidase that was for long time erroneously categorized in the BMP 
family, a group of bone modifier enzymes that belong to the TGF-β growth factor 
superfamily173,174. Its structure is characterized by a conserved metalloprotease catalytic domain 
followed by a Ca2+-binding EGF domain and up to five CUB (complement component 
C1r/C1s, urinary EFG, BMP-1) domains173,174. Only three proteins, besides BMP-1, belong to 
this family in humans and all of them have been catalogued as orthologues of Drosophila 
tolloid, a protein involved in the dorso-ventral patterning during development174. During ECM 
assembly they cleave the C-termini of procollagen I and II, enabling fibril formation173,174. Also, 
by cleavage of the Latent TGF-β Binding Protein (LBTP-1) and release of active TGF-β, 
tolloids regulate the cellular response to inflammation and fibrosis174. 
Meprin-a is among the largest secreted proteins found in nature given its capacity to build 
complexes up to 6MDa168,171,172. The main difference between the a and b subunits of meprin 
is that meprin-a is secreted due to its “I-domain”, a protein sequence that is recognized by 
Furin at the ER-to-Golgi compartment and cleaved in order to release the N-terminus of the a 
subunit to the secretory pathway, while the C-terminal transmembrane fraction remains bound 
to the membrane172.  
Meprin-b in turn is the only membrane bound member of the astacin family, although it can 
be shed at the cell surface by ADAM-10 or ADAM-17172. Meprins are highly glycosylated and 
promote the fibril formation of collagen I + III in vivo by cleaving their globular pro-
peptides168,172. Studies with knock-out (KO) mice have shown that meprins are required for 
collagen maturation together with BMP-1172. Therefore, in chronic pathologies involving 
fibrinogenesis and tumor invasion, such as breast cancer and colon carcinoma, meprins are 
found to be upregulated171,172.  
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4.2.4.2 A Disintegrin And Metalloprotease with Thrombospondin type-1 repeat 
(ADAMTS) family 
ADAMTS are secreted proteases characterized by a variable thrombospondin type-1 repeat 
region (TSR)175,176. Structurally, ADAMTS highly resemble the ADAM family of proteins, 
however, the 2 main differences between them are that all ADAMTs have protease activity and 
that they are highly glycosylated175,176.  
The basic structure of ADAMTS proteases consists of a signal peptide, followed by a pro-
peptide domain, a metalloprotease catalytic domain, a characteristic disintegrin-like domain, 
and the ancillary domain, comprised by a central TSR domain, a cysteine rich region and a 
spacer domain (Figure 25)167,177,178.  
 
Figure 25. Schematic representation of ADAMTs structure and comparison with ADAMs and 
MMPs. (A) depicts the characteristic domain for each group of proteins whereas (B) illustrates 
their topography. Taken from Yang et al. (2017)179. 
The association between the ADAMTS disintegrin-like domain and the substrate-binding 
pocket provides great variability and therefore, high substrate specificity for each ADAMTS 
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protein, making them excellent therapeutic targets to treat diseases such as Ehlers-Danos 
syndrome, thrombotic thrombocytopenic purpura and Weill-Marchesani syndrome167,178,180. 
Physiologically, ADAMTS participate in several cellular processes but depending on the 
species, cell type and environmental conditions, they can be expressed either constitutively or 
in an induced manner178. Overall, ADAMTS are involved in homeostatic processes such as 
tissue regression during development181, cleavage of cartilage and tendon in bone maturation178 
and fertility169,178, as well as in pathological ones, as is the case for cancer angiogenesis178,180. 
4.3 Matrix metalloproteases (MMPs) 
MMPs are amongst the most thoroughly studied members of metzincins182. Since their 
discovery in 1962 by Gross and Lapiere183, they have been the focus of research on therapeutic 
targets for inflammation, cancer and tissue remodeling127,182,184,185. MMPs have a highly 
conserved structure (Figure 26) consisting in a signal sequence, followed by a ~80 amino acids 
propeptide, a metalloprotease catalytic domain (~170 amino acids), a linker region and a 
hemopexin domain (~200 amino acids)186,187.  
MMPs have been traditionally classified according to homology with MMP1 (with exception of 
MMP7, -23 and -26 lacking the linker region and hemopexin domain)167. They share the 
cysteine switch motif in the propeptide region (PRCGXPD) that controls MMP activation, and 
a motif in the catalytic domain (HExxHxxGxxH), where the three histidines bind the Zn2+ ion 
necessary for their catalytic activity127,160,186,188–190.  
Although the cleavage of the propeptide is not absolutely necessary for their activation, most 
MMPs reach the active state after its removal188,191,192. The propeptide can be removed either by 
cleavage (mostly by another active MMP, but also peptidases such as trypsin or plasmin), by 
chemical agents, such as mercurial and disulfide compounds, chaotropic agents, oxidants and 
alkylating agents188, or by conformational changes triggered by nitric oxygen (NO), reactive 
oxygen species (ROS) and hypoxia processes193. 
The regulation of MMPs takes place also at the transcriptional level via control of gene 
expression, transcript stability, epigenetic variations and promotor polymorphisms182. In this 
regard, some aspects are common to all MMPs: they possess a TATA box, an AP-1 binding 
site and a PEA3182. MMPs can also be regulated post-transcriptionally by miRNAs, as has been 
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shown for MMP2 and -9, which expression levels can be controlled by miRNA-29 in breast 
cancer, whereas miRNA-9 can modulate metastasis, invasion and angiogenesis in 
neuroblastoma by regulating MT1-MMP activity127,194. 
 
Figure 26. Diversity of MMPs. Schematic representation of known human MMPs and their 
characteristic domains. Adapted from Khokha et al. (2013)167. 
Although ubiquitously located, the expression of MMPs is tissue and cell dependent186,190. 
Fibroblast and leukocytes, though, are main sources of MMPs, in particular of MMP2186. Also, 
platelets highly express MMP1, -2, -3 and MT1-MMP186. Given their role in ECM remodeling 
and the high turnover rate of the vascular tissue, MMPs are highly expressed in endothelial and 
vascular smooth muscles cells186.   
MMPs can be both soluble or membrane-anchored, and proteins belonging to this latter group 
have, in addition to the described domains, a transmembrane domain of variable length, and a 
short cytoplasmic domain important for intracellular trafficking, activity regulation and 
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recycling187. Besides MMP-23, which is a type-II membrane protein with an immunoglobulin-
like domain and a cysteine (Cys)/proline (Pro) rich region at the C-terminus, trans-membrane 
(TM) MMPs are further classified in two classes: type-1 transmembrane MMPs (also known as 
MT-MMPs, including MMP-14, -15, -16 and -24) and GPI-anchored MMPs (MMP-17 and -
25)182,186,195.  
All the MT-MMPs possess a Rx[R/K]R motif at the end of their propeptide domain that is 
recognized and cleaved by proconvertases such as Furin, and leads to the intracellular 
activation of membrane bound MMPs (Figure 27)189,195. In addition, type-1 MT-MMPs have a 
unique feature in their catalytic domain: an 8-9 amino acid insertion named the MT-loop that 
has been described to be relevant for proper localization and is not found in any other member 
of the MMP family195–197. 
 
Figure 27. MMPs containing Furin cleavage sites. Figure taken from Cui et al. (2017)186. 
Altogether, twenty eight MMPs have been identified in vertebrates and twenty three are 
expressed in humans, among which fourteen are expressed in the vascular system186. 
Structurally, soluble MMPs can also have additional domains relevant for their proteolytic 
activity, for example, MMP2 and -9, the so-called gelatinases, possess three repeats of a 
fibronectin-like motif that enhances the interaction between the MMP and collagen186.  
4.3.1 Classification of soluble MMPs 
MMPs have been initially classified according to their substrate, however, research from the 
last 20 years has shown that their broad spectrum of substrates is not limited to ECM 
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components198. Cytokines, chemokines, cell surface ligands, receptors and antimicrobial 
peptides constitute also critical substrates for cell signaling and transcriptional regulation of the 
expression of other MMPs167,182,187,188,190. Although MMPs can also degrade intracellular 
substrates167,187,198, the following description focus on their extracellular roles.  
4.3.1.1 Collagenases 
This was the first group of MMPs identified and is represented by MMP1, -8, -13 and -18, 
which hydrolyze collagen type I, II and III (interstitial collagens) in their native triple helical 
structure182,187,188,199,200. Their function has been directly associated with fibrosis resolution, 
wound healing and restoration of the ECM after injuries187. MMP1, known as the interstitial 
collagenase and the first MMP that had been described, can degrade both collagen and gelatin, 
and activate MMP9 by proteolytical cleavage186. It has been reported to be upregulated in 
inflammatory conditions and autoimmune disorders as well as during osteoarthritis186.  
Meanwhile, MMP-8, also known as the neutrophil collagenase, also cleaves interstitial collagens 
and is recognized as the first collagenase appearing in wound healing processes167,186. It is 
secreted in a “free” form, meaning it traffics intracellularly in an inactive form and is only 
activated in the extracellular space by MMP3 and -10186. The other collagenases, MMP13 and -
18 (the latter only expressed in Xenopus laevis), are mainly involved in bone resorption by 
cleavage of collagen and aggrecan (MMP13)186,201, and  control of axonal growth (MMP-18). 
Notably, both MMP13 and -18 are also highly expressed in migrating cells, either cancerogenic 
(MMP13)186 or macrophages during Xenopus embryonic development (MMP18)202. 
4.3.1.2 Stromelysins 
Although MMPs belonging to this group are structurally similar to the collagenases, 
stromelysins cannot degrade interstitial collagen186,199. Stromelysins bind to a varied set of 
substrates, such as collagen IV and IX, laminin, fibronectin, elastin and proteoglycans, with 
different affinities corresponding to the tissue where the protein is expressed187. Three MMPs 
belong to this group (MMP3, -10 and -11) although only the first two are soluble and secreted, 
extracellularly activated by other MMPs and actively degrade ECM components186,189,199. 
MMP11 differs from MMP3 and -10 in that it is activated by Furin and its capacity to degrade 
ECM is limited186. Particularly, MMP3 can activate other MMPs (such as MMP9) and has a 
catalytic pocket that can degrade substrate using cobalt, manganese, cadmium and/or nickel 
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instead of Zn2+186,203. As mentioned, MMP11 is distantly related and its role in migration is 
controversial, having both promoting and inhibiting roles in cancer metastasis depending on 
the cancer type and the stage186,204.  
4.3.1.3 Matrilysins 
Matrilysins are characterized by the lack of hemopexin domain186,205. Only two MMPs belong 
to this group: MMP7 and -26. MMP7 has been shown to be key in ECM remodeling and 
immune system modulation187. It cleaves the FAS-ligand, controls programmed cell death and, 
by upregulation of TNFα, initiates the apoptotic response189,190,206. Moreover, MMP7 can also 
cleave E-cadherin, elastin, Pro-α defensins and syndecan-1 modulating cell-to-cell interactions 
and plays an important role in wound healing190,199. On the other hand, MMP26 has only been 
reported in human and some primates’ genomes199. It has been associated with remodeling of 
embryonic tissue during development and promotion of angiogenesis and cancer metastasis 
under stimulation of granulocyte-macrophage colony-stimulating factor (GM-CSF)186.  
4.3.1.4 Elastases 
MMP12 is the main elastin degrading MMP186. It is highly expressed in macrophages and, 
contrasting with most of the members of the family, exerts a protective function on the tissue 
by translocating to the nucleus, binding IkBα and promoting INFα secretion from host cells in 
virus infection events186,199,207. Additionally, Marchant et al. (2014) suggested that MMP12 can 
attenuate the subsequent inflammatory response by clearing systemic INFα: after infection, 
extracellular MMP12 can cleave the plasma INFα, avoiding long term toxicity  by negative 
feedback207. 
4.3.1.5 Enamelysin 
MMP20 is found in teeth and its expression is upregulated in the process of new enamel 
formation, cleaving matrix enamel proteins such as ameloblastin, amelogenin and enamelin186. 
4.3.1.6 Gelatinases 
Gelatin is denatured type I collagen and gelatinases bind it via their fibronectin-like III-repeat 
motif on the catalytic domain160,167,182,186,188,189,199,208. Two MMPs possess such a motif: MMP2  
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and MMP9, and their roles in inflammation209–211, cancer212–214 and endothelial transmigration 
have been thoroughly studied167.  
As with most MMPs, knockout mice have been generated for gelatinases although no 
remarkable phenotype has been observed in steady state167. Nevertheless, alterations in the 
mice response to inflammation denote a phenotype that is only evidenced upon challenging215. 
In this regard, Song et al. (2015) showed in a murine double knock out model (MMP2-/- +  
MMP9-/-) that MMP2 and MMP9 are required to modulate the chemotactic signals of 
astrocytes at the blood-brain-barrier and that such activity is restored only when either MMP2 
or MMP9 were re-expressed210.  
 
Figure 28. Structure of the complex formed between MMP2 and its inhibitor TIMP2. Figure 
taken from Morgunova et al. (2002)192. 
MMP2, which is the focus of this study, is constitutively expressed in monocytes, fibroblasts, 
keratinocytes, endothelial cells, and chondrocytes199. In general, MMP2 has been strongly 
associated with processes involving cell migration212–214,216. In particular, several studies have 
documented upregulation of MMP2 in cancer invading cells, where upregulation of MMP2 
activation promotes cell invasion192,212.  
In this regard, Packard et al. (2009) showed that MMP2 and MMP9 localized at the leading 
edge of migrating tumors217. Also Shaverdashvili et al. (2014) showed that MT1-MMP induced 
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cell migration of melanoma cells by upregulating MMP2 activity213. Moreover, Jacob et al 
(2016) evidenced that Tks5-mediated active delivering of MMP2 and MMP9 in Rab40b 
vesicles to the invadosome enabled focal ECM degradation and cancer cell invasion216. 
Interestingly, Matsumura et al. (2005) have demonstrated that MMP2 inhibition can be 
beneficial for the survival rate of myocardial infarction by protecting the tissue against cardiac 
rupture218. In this scenario, a reduction in the cleavage of fibronectin and laminin delays 
macrophage migration and tissue proteolysis without affecting scar formation and 
agiogenesis218. 
MMP2 is also a key regulator of inflammation185,211,219. T-cells, Th1 in particular, secrete MMP2 
in order to further stimulate MMP2 secretion in macrophages167. In dendritic and Langerhans 
cells, MMP2 and MMP9 aid in cell transmigration and the presentation of antigens131. MMP2 
can also induce the production of CXCR3 receptor antagonists, such as CCL7, as well as 
inactivate chemokines such as CXCL12130. 
 
Figure 29. MT1-MMP-mediated activation of MMP2. Figure taken from Itoh (2015)195. 
Given its multiple roles in cancer and inflammation, MMP2 is tightly regulated214. In this 
context, it can be regulated in 5 different ways: (1) by transcriptional control199, (2) by 
extracellular cleavage after secretion, (3) by MT-MMPs195,213,214,220, (4) by internalization from 
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the cell surface (i.e. by indirect binding to LRP-1 via trombospondin-1 or TIMP1 or -3) or (5) 
by tissue inhibitors of matrix metalloproteases (TIMPs)214. 
Among these, the best described mechanism is the one activating MMP2 at the cell surface by 
MT-MMPs192,221. In principle any MT-MMP can cleave MMP2 propeptide, but it has been 
shown that MT1-MMP does it with higher efficiency –MT4-MMP does not interact with 
MMP2 and, MT2- and MT3-MMP do it with lower affinity, whereas MT5-MMP binding to 
MMP2 has not yet been confirmed in vivo195,214. MMP2 activation initiates with the 
homodimerization of MT1-MMP via the hemopexin domain195,221. Then one of the MT1-MMP 
units in the homodimer is inhibited by binding of the MMP2-TIMP2 complex (Figure 28) via 
TIMP2 N-terminus, while the other free MT1-MMP is able to cleave MMP2 propeptide 
(Figure 29)195,214,221. Although any of the 4 identified TIMPs can inhibit MMP2, only TIMP2 
mediates its activation at the plasma membrane214. 
4.3.1.7 Other MMPs 
Some MMPs share the characteristic structure features common to their counterparts, but 
because of differences in substrate degradation or lack of characteristic features common to a 
group, are not classified in any of the mentioned groups190,222. 
One of the most relevant MMPs in this group is MMP19, which structurally resembles the 
stromelysins (has been named by some authors as stromelysin-4) but unlike members of this 
group, it can degrade collagen IV186,223. Its catalytic activity is not limited to collagen, instead, 
MMP19 can degrade a wide variety of ECM substrates such as laminin, nidogen, fibronectin 
and type I gelatin (in vitro)186,223. 
4.3.2 Transmembrane MMPs  
As mentioned before, MT-MMPs are classified in 2 groups, the TM-MMPs, containing a 
transmembrane domain, and the GPI-anchored type, without it (Figure 30)195. Although all 
MT-MMPs intervene in cell migration and matrix invasion processes, TM-MMPs anchor to the 
membrane after being transported in vesicles from the TGN195. The GPI-anchored-MMPs, 
instead, are directly associated with GPI moieties containing 2-3 fatty acids directly at the ER 
lumen195.  
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Up to date, MT1-MMP is the only TM-MMP that promotes migration in collagen 
matrices195,224. Such a role explains the enriched localization of MT1-MMP at the leading edges 
of cells in structures such as lamellipodia, filopodia and invadopodia195,225,226.  
MT1-MMP is one of the most studied MMPs195,225. It has been associated mainly with tumor 
invasion, although it plays also roles in inflammation (by cleavage of TNF-α) and cell migration 
(by cleavage of syndecan)186,227. MT1-MMP is mainly localized in fibroblasts, vascular smooth 
muscle cells, brain, uterus and plays an important role in angiogenesis186. Although MT1-MMP 
is mostly activated by Furin at the TGN, a small portion can be transported in its inactivated 
form147.  
 
Figure 30. Structural differences between TM and GPI anchored MT-MMPs. Figure taken from 
Itoh (2015)195 
Deryugina et al (2004) found that MT1-MMP can act as an integrin convertase by cleavage of 
pro-αv when associated with αvβ3 integrin; this enhances FAK phosphorylation and 
subsequent cell migration147. Furthermore, Takino et al (2010) demonstrated that MT1-MMP 
induces ERK pathway activation and subsequent cancer cell proliferation in 3D collagen 
matrices224. 
It has been shown that MT1-MMP accumulation is necessary to initiate invadosome 
formation, defining a “pre-invadosome” stage228. In order to maintain a pool of MT1-MMP 
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that is easily and rapidly available upon stimulation, and also that copes with the formation and 
maintenance of new invadopodia, MT1-MMP is kept in an intermedial endosomal 
compartment after its synthesis and trafficking through the secretory pathway225,228,229. From 
there is transported in Rab8 vesicles to the plasma membrane and from there can be recycled 
both via clathrin-dependent or -independent mechanisms (Figure 31)228.  
 
Figure 31. Membrane trafficking of MT1-MMP and its delivery to invadopodia. Upon Furin 
activation at the Golgi, MT1-MMP is transported to the plasma membrane. Black arrows indicate 
directed polarized secretion of MT1-MMP from Golgi or exosomes guarantees the confined 
activation of MT1-MMP. Recycling occurs via clathrin- or caveola-mediated endocytosis to the 
recycling endosome, from where a small fraction undergo degradation upon transportation to the 
lysosomes. The red lines represent routes for the confined delivery of MT1-MMP “in response to 
motogenic stimuli”. Figure taken from Frittoli et al. (2011)228. 
 
4.3.3 MMPs and cancer 
Almost all MMPs participate in tumor angiogenesis by degrading capillary basal membrane 
(Figure 32)182. In particular, MMP9 has been shown to modulate angiogenesis by stimulation of 
CXCL5, 6 and 8 release and of fibroblast growth factor (FGF) and vascular endothelial growth 
factor (VEGF)182. Indeed, the increased expression of VEGF can also be triggered by MMP2 
and MT1-MMP and VEGF cleavage is promoted by MMP1, -3, -7, -16 and -19, increasing the 
angiogenic potential of tumor cells182. 
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Tumor invasion occurs either by mobilization of a group of cells or by cell migration, where 
the migrating cell moves in an amoeboid or mesenchymal manner and mimics the epithelial-to-
mesenchymal transition (EMT) characteristic of embryonic development and invasive 
cancer206,230. In this regard, MMP2, -9 and MT1-MMP have been involved in tumor cell 
extravasation206. Afterwards, MMPs create the metastatic niche for tumor cells to grow by 
promoting angiogenesis, modulating apoptosis and preventing inflammatory cell chemotaxis 
by cleavage of chemokines such as CXCL12 and IL-1β130,206.  
 
Figure 32. MMPs in cancer. Differential expression of MMPs in tumor growth, proliferation, 
invasion, intravasation, extravasation and angiogenesis. Figure taken from Winer et al. (2018)206.  
Angiogenesis is mainly regulated by MMP1, -2, -7, -9 and MT1-MMP, whereas apoptosis is 
reduced in tumor cells by MMP7-mediated cleavage of the Fas ligand at the cell surface of 
tumor cells, restricting Fas death receptor stimulation206. In terms of inflammatory response 
caused by chemotaxis inhibition, MMP1, -2 and -9 can downregulate interleukin receptor 
availability on the cell surface and promote tolerance to cancer130,206.  
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Given their multiple roles in promoting cancer progression, MMPs were initially used as a 
therapeutic target for cancer treatment206,231. The design of several inhibitors initiated in the late 
1980s with Batimastat, however, due to its high toxicity was not further developed206. Some 
other inhibitors targeted to several MMPs moved to phase III clinical trials but were cancelled 
without successful results, probably due to the fact that MMPs are very similar, particularly in 
the area close to the active site, therefore, targeting only a specific group of MMPs results 
challenging206,231. Nowadays, a strategy addressing selective MMPs with inhibitors targeting 
MMP1, -2, -3, -9 and MT1-MMP is ongoing and several of these inhibitors are being tested in 
preliminary phases of clinical trials206. 
4.3.4 MMPs and cell migration 
As mentioned before, MMPs actively participate in cell migration158,185,202. Cell migration occurs 
as a cyclic process where cells polarize at one end, extend protrusions in that direction and 
stabilize by forming adhesions with the ECM232. The extension of such protrusions requires 
actin polymerization and depending on the type of protrusion, such extensions could be 
branching-like (as in lamellipodia), parallel organized bundles (in filopodia)232 or punctual cores 
(in podosomes and invadopodia)233. 
 
Figure 33. Migration in 2D (A) and 3D (B) environments. Figure taken from Wiesner et al. 
(2014)234. 
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Migration can happen in 2 dimensions: in 2D cells slide along the matrix, whereas in 3D cells 
can penetrate it (Figure 33)165,234,235. Although the ECM represents a 3D environment, some 
cells, like leukocytes, could be exposed to 2D environments when, for example, they need to 
crawl on top of endothelial layer, preceding transmigration of blood vessels236.  
In 3D environments, cells can move either in an amoeboid manner, where cells maintain a 
spherical shape, generate short protrusions and migrate with higher velocity; or in a 
mesenchymal manner, where they acquire a more extended shape and generate longer 
protrusions at the cost of reduced velocity234. Both migration modes happen in parallel and 
depend mainly on the ECM network surrounding the cells128,129. 
Two structures are crucial for MMP secretion to ECM degradation areas: podosomes, in cells 
of the hematopoietic system, and invadopodia in cancer cells237. Their structures are described 
in more detail below. 
4.3.4.1 Podosomes and invadopodia 
The structure defining both podosomes and invadopodia constitutes an F-actin core 
surrounded by a “ring” of actin regulators –such as cortactin, N-WASP, Tsk5 and Arp2/3– 
that are recruited to the ECM via integrins, and plaque proteins –such as paxillin, vinculin and 
talin158,216,237,238. Although initially thought as a surrounding structure, nowadays it is known that 
the plaque ring is formed by discontinuous clusters of plaque proteins239.  
Both podosomes and invadopodia localize on the contact site between the cell membrane and 
the substrate in a perpendicular way and display a characteristic dot-like structure (Figure 
34)158,162,234,239. Although structurally similar, podosomes are associated with migrating albeit 
non-malignant cells, such as macrophages, whereas invadopodia is mainly associated with 
cancer cells163,165.  
The main differences between both structures lie in their number (podosomes are more 
numerous, 20-100/cell vs. 1-10/cell), their size (invadopodia are bigger, 8x5 µm2 vs. 1x0.4 
µm2), their life time, (podosomes have a high turnover rate) and their ability to degrade matrix 
(higher in invadopodia)240. In this regard, one of the main characteristics of invadosomes is 
their degrading capacity237. Contrary to FAs, where their presence is mostly associated with 
matrix reorganization and fibrillogenesis, invadosomes actively secrete matrix metalloproteases 
and ADAMs in order to degrade underlying ECM and move throughout the tissue237.  
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Figure 34. Podosome structure. (A) Scheme depicting podosome organization in clusters. (B) 
Confocal microscopy image of a primary human macrophage stained for F-actin (red, Phalloidin-
Alexa564) and talin (green, primary antibody + Alexa 488). (C) Scheme of podosome substructure 
with the connecting filaments in orange, the cap in green, the lateral filaments in pink, the F-actin 
core in red, the Arp2/3 complex in yellow and integrins in dark blue color.  Figure taken from van 
den Dries et al. (2019)239. 
Although invadopodia has a higher degrading capacity, probably due to a longer lifetime, 
podosomes numbers allow leukocytes to degrade a larger area165. In particular, podosomes in 
monocyte cells recruit membrane-bound type I matrix metalloprotease (MT1-MMP, see 
section 4.3.2) to the plasma membrane in a microtubule-dependent manner mediated by the 
motor proteins kinesin-1 and -2 and RabGTPases such as Rab8226,241. Noticeably, such 
recruitment is not relevant for the podosomes assembly, but for its proteolytic activity165,226. 
4.4 Intracellular transport of MMPs 
MT1-MMP has been described as the major proteolytic enzyme in invadopodia225,226,228,229, 
although it has also been observed in podosomes on human macrophages241,242. Monteiro et al. 
(2013) showed that WASH and Arp2/3 were required for the formation of invadopodia 
extensions and, together with the exocyst complex,  for the docking of MT1-MMP positive 
endosomes to the plasma membrane229. This in turn recruited MT1-MMP and promoted basal 
membrane rupture and the subsequent invasion of tissue229.  
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Vesicle transport is essential for MT1-MMP secretion195; therefore, research efforts have 
focused on elucidating the machinery that brings MT1-MMP to the plasma membrane. In this 
regard, Bravo-Cordero et al. (2007) demonstrated that MT1-MMP transport to the invasive 
structures was mainly dictated by regulated exocytosis243. Moreover, they identified 
colocalization between Rab8 and MT1-MMP, strongly indicated that the GTPase activity is 
necessary for MT1-MMP exocytic transport243. Altogether, they propose the existence of a 
permanent pool of intracellular MT1-MMP that can rapidly distribute this MMP to the plasma 
membrane upon stimulus243. 
Further studies from the Linder and Scita groups elucidated a network of at least 4 different 
GTPases controlling the delivery of MT1-MMP to podosomes in macrophages, with Rab8a 
regulating MT1-MMP delivery from Golgi to plasma membrane, and Rab5, Rab22a and Rab14 
involved in its endosomal recycling226,228,242,244. In cancer cells, MT1-MMP trafficking is rather 
regulated by Rab2a, Rab4 and Rab5, which control its availability from the endosomes to the 
plasma membrane226,245. 
Although MT1-MMP trafficking has been intensively studied in the last years, the trafficking of 
soluble MMPs requires more investigation. Initially, studies on neurons from Sbai et al. (2008) 
evidenced for the first time that MMP2, MMP9 and TIMP1 were trafficking in vesicles from 
the secretory pathway, based on observations of a secretion impairment in BFA treated cells246. 
Later on, the same group demonstrated that MMP2 and MMP9 were delivered in different 
vesicles that were distributed along microtubules and transported by kinesin and myosin V247. 
In parallel, Kean et al. (2009) showed in cancer cells, that MT1-MMP, but not MMP2 and 
MMP9, required syntaxin-13 for proper delivery to the cells surface248. Furthermore, they 
revealed that SNAP23 and VAMP3 are required for MMP2 and MMP9 secretion248.   
Recently, Jacob et al. (2013) identified the requirement of Rab40b for proper delivery of 
MMP2/9 to invadopodia. Moreover, they observed that Rab40b silencing reduced matrix 
degradation down to 50%, suggesting that MT1-MMP, which was already shown to be 
transported in different vesicle carriers, may compensate for the impaired delivery of 
MMP2/9212.  
In conclusion, the transport of MMPs to either podosomes or invadopodia is mediated by 
vesicular carriers, which seem to be different among MMPs246. These carriers are transported 
from the TGN –or intermediate endosomal compartments in the case of MT1-MMP– via 
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motor proteins towards the plasma membrane241,249. Although new investigations are 
contributing to the elucidation of MMP trafficking pathways, the intracellular mechanism 
driving their transport through the secretory pathway remains unknown. And this question is 
the core of the present thesis. 
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5. Aims and scope 
MMPs play a crucial role in tissue homeostasis129,160,185,211,234. During the last 20 years these 
proteins were the focus of many researchers looking for a mechanism that could control their 
function and, in this way, develop therapies against cancer185,250,251. However, the moonlighting 
functions of MMPs, as well as their highly conserved catalytic domain, contributed to the 
failure of many of these efforts206. 
Although the literature covering MMPs function is abundant, the intracellular trafficking of 
these proteins remains poorly understood. Some studies have made an effort to describe their 
trafficking in neurons246,247, cancer212,216, and olfactory cells249, however, the machinery involved 
has not been yet elucidated. Therefore, the principal aim of this thesis was to identify the 
molecular mechanism of intracellular trafficking of MMPs, with particular focus on MMP2. 
For this purpose, this thesis addressed the following goals: 
 
I. To identify MMP2 potential interacting candidates that could influence its intracellular 
trafficking. 
II. To evaluate their impact in MMP2 intracellular trafficking using single-cell cargo sorting 
assays. 
III. To examine the physiological relevance of MMP2 trafficking in the absence of identified 
candidate(s). 
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6. Materials and methods 
All the methods marked with an asterisk (*) are included on the paper Nucleobindin-1 regulates 
ECM degradation by promoting intra-Golgi trafficking of MMPs, at the moment under revision for 
publication on the Journal of Cell Biology (JCB). Specific methods from other labs are also 
indicated in brackets. 
6.1 Molecular biology methods 
Expression vectors were generated using either a general cloning approach (as follows) or the 
Gibson assembly method252. Unless otherwise indicated, all the restriction enzymes were 
purchased from New England biologicals (NEB, Ipswich, USA) and used according to 
manufacturer’s recommendation. For the PCR reactions, a Mastercycler Nexus Gradient 
(Eppendorf, Hamburg, Germany) was used.  
6.1.1 Polymerase Chain Reaction (PCR) 
Plasmid DNA was amplified using 20 ng of template vector, 200 µM dNTPs, 0.5uM of 
primers (reverse and forward, see Table XX) and 0.01 units of Phusion High Fidelity DNA 
Polymerase (Thermo Fischer, Waltham, USA) in the provided 1X HF buffer and completed 
with Gibco™ sterile distilled water (Thermo Fischer, Waltham, USA) up to a final volume of 
50 µL.  
Samples were then incubated for 5 min at 95˚C to denature DNA strands, then incubated in 35 
cycles of 30 sec at 95˚C and incubated for annealing 30 sec at temperatures ranging from 52 to 
67˚C according to the annealing primer pair. Finally, elongations cycles of 30 sec/500 bp at 
72˚C were performed with a final elongation cycle of 10 min at 70˚C before cooling at 4˚C. 
6.1.2 sgRNA annealing and insertion into pX vectors for CRISPR cell line 
generation 
The annealing of sgRNAs was performed using 100 µM top and bottom oligo nucleotides. 
These were mixed with 10 units of polynucleotide kinase in 1X T4 ligase provided buffer and 
incubated as follows: 30 min at 37˚C + 5 min at 96˚C + 1 min incubation at 95˚C + 5 min at 
85˚C + 1 min at 80˚C + 0.1 C/sec until reaching 70˚C. The annealed oligo nucleotides were 
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then stored at 4˚C and posteriorly digested with BbsI to create compatible ends for cloning in 
pX vector. 
6.1.3 Agarose gel analysis and DNA purification 
DNA amplification was analyzed using 1% agarose gels stained with SYBR Safe (Thermo 
Fischer, Waltham, USA) in 1% TAE buffer. Samples were mixed with 10X DNA loading dye 
and ran for 30 min at 100V. Confirmation of PCR products was performed evaluating 
correspondence to the expected molecular weight using a marker (8 µL) from Thermo 
Scientific (Waltham, USA). Correct bands were cut and digested with mi-Gel extraction Kit 
(Metabion, Martinsried, Germany), according to the provider instructions.  
6.1.4 Restriction digest 
After PCR purification, products and vectors were digested overnight (ON) at 37˚C with the 
enzymes indicated in Table XX. Then the enzymatic components were removed using the mi-
PCR purification Kit from Metabion (Martinsried, Germany) and ligated into backbone 
vectors. 
6.1.5 Ligation 
The DNA amounts used for digestion were calculated using the NEBBioCalculator webtool 
(nebiocalculator.neb.com/#!/ligation) or keeping a ratio fragment to vector of 3:1 or 7:1 
depending on the length of the fragment. For all reactions, 100 ng of vector was used. The 
reaction was carried out for at least 1h at room temperature (RT) with 10 units of T4 ligase in 
the corresponding buffer (CutSmart, 2.1 or 3.1) and completed with water to a final volume of 
20 µL. 
6.1.6 Gibson assembly 
This cloning and ligation strategy was performed as previously published252 using the Gibson 
Assembly master mix provided by the Core Facility of the Max Planck Institute of 
Biochemistry. Primers are listed in Table XX. The mixture of fragments was done keeping a 
fragment to plasmid ratio 3:1 and using at least 25 nmol plasmid per reaction. DNA amount 
for each reaction was calculated using the Promega webtool 
(https://www.promega.de/resources/tools/biomath/). 
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6.1.7 Transformation into E. coli bacterial cells 
10 – 20 µL of ligated DNA were transformed into at least 30 µL of E. coli chemically 
competent OmniMAX 2Tl cells by incubation for 30 min on ice, followed by a heat shock of 
90 sec at 42˚C and recovery for at least 1h at 37˚C with constant shaking. After this time, cells 
were plated in agar LB plates containing ampicillin or kanamycin (100 µg/mL) and incubated 
ON at 37˚C. 
6.1.8 Single clone isolation and sequencing validation 
After ON incubation, colonies were picked and cultured in 4 mL LB medium containing 
ampicillin / kanamycin (100 µg/mL) and incubated again ON at 37˚C with constant shaking. 
Then, plasmid DNA was purified using the NucleoSpin Plasmid EasyPure Kit (Macherey-
Nagel, Düren, Germany) and DNA concentration was determined with a Nanodrop ND-1000 
Spectrophotometer (PEQLAB Biotechnologie GmbH, Erlangen, Germany). To confirm the 
correct insertion, DNA was evaluated by sequencing using the SmartSeq Kits from Eurofins 
Genomics (Ebersberg, Germany). 
6.1.9 Mutagenesis for introduction of single point mutations 
This methodology was developed and performed by Birgit Blank as previously documented253. 
Briefly, PCRs were performed as described above with the following modifications: 400 µM 
dNTPs and 0.6 µM primers were used. The number of cycles was reduced to 16 and after 
confirmation of correct PCR product by agarose gel electrophoresis, the DNA was digested 
with DpnI for 1h at 37˚C to destroy the template DNA. Finally, 2.5 µL of the treated DNA 
were transformed into 50 µL competent E. coli cells. 
6.1.10 Generation of chemically competent E. coli 
E. coli Omnimax 2Tl culture (2 mL) were incubated ON in 100 mL LB growth medium at 
37˚C with permanent shaking until they reached OD 0.5. Cells were then collected to 4˚C and 
centrifuged 15 min at 3000 rpm (4˚C). After discarding the SN, the pellet was resuspended in 
10 mL TSS buffer with 2.5mL of 87% glycerol and aliquots were snap frozen and stored at -
80˚C. 
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6.1.11 Plasmids, primers and restriction enzymes 
All restriction enzymes used in this study were purchased from New England Biolabs Inc. 
(Ipswich, MA, USA). Primers were purchased to Metabion International AG (Planegg, 
Germany).  
Table 1. List of plasmids used in this work.  
Backbone 
plasmid Insert Publication 
Cloning 
method 
Restriction 
enzymes 
Primer Forward 
5' - 3' 
Primer Reverse 
5' - 3' 
pLPCX ssHRP-Flag 
von Blume 
2012107 N/A       
pLPCX 
LyzC-
Flag-
EGFP 
This work RC 
EcoRI / 
BamHI 
CCGGAATTCCGG
ATGAAGGCTCTC
ATTGTTCTGGGG
C 
CGCGGATCCGC
GCTTGTCATCG
TCATCCTTGTAA
TCGATGTCATG
ATCTTTATAATC
ACCGTCATGGT
CTTTGTAGTCC
ACTCCACAACCT
TGAACATACTG
ACGG 
BamHI / 
NotI 
CGCGGATCCGTG
AGCAAGGGCGA
GGAG 
TTTTCCTTTTGC
GGCCGCTTACT
TGTACAGCTCG
TCCATGC 
pIRESneo
3 
Str-
KDEL-
LyzC-
FLAG-
SBP-
EGFP 
Deng et al., 
201896 N/A       
pLPCX 
hsMT1M
MP-
pHluorin-
HA 
This work RC EcoRI / Not1 
CCGGAATTCATG
TCTCCCGCCCCA
AGAC 
TTTTCCTTTTGC
GGCCGCTCAAG
CGTAATCTGGA
ACATCGTATGG
GTAGACCTTGT
CCAGCAGGGAA
CG 
pIRESneo
2 
Str-
KDEL-
SS-SBP-
EGFP 
This work RC AscI / EcoRI 
TTGGCGCGCCAT
GGCTACAGGCTC
CCGGAC 
CCGGAATTCCC
GGATAAGGGA
ATGGTTGGGAA
GG 
pIRESneo
3 
Str-
KDEL_SS
-SBP-
EGFP-
HA-
Cathepsin
D 
Deng et al., 
201896 N/A       
pIRESneo Str- This work RC AscI / TTGGCGCGCCATGGCTACAGGCTC
CTTATCGTCGT
CATCCTTGTAAT
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4 KDEL_SS
-SBP-
EGFP-
HA-
MMP2nSS 
EcoRI CCGGAC CGGATAAGGG
AATGGTTGGGA
AGGC 
GCCTTCCCAACC
ATTCCCTTATCC
GATTACAAGGAT
GACGACGATAA
G 
CCGGAATTCCC
CAGCGTAATCT
GGAACATCGTA
TG 
pIRESneo
3 
Str-
KDEL-
SBP-
MT1MMP
-mCherry 
This work, 
kind gift 
from Franck 
Perez Lab 
RC 
AscI / 
EcoRI 
AAGTGGCGCGC
CATGTCTCCCGC
CCCAAGA 
GCGCGAATTCG
CTCCGCCCTCCT
CGTCCA 
FseI / SfiI 
AGATGGCCGGC
CATTAGGCGGG
GCGGTGAGCG 
AATCGGCCCTC
GAGGCCTCAGA
CCTTGTCCAGC
AGGG 
BsrGI / SbfI 
MCHERRY CODING SEQUENCE 
WITH THE MENTIONED 
RESTRICTION SITES 
pLPCX SS-EGFP This work RC EcoRI / XhoI 
CTGGGCCCATAA
AGCTTATACGAA
TTCATGGCTACA
GGCTCCCGGAC 
CTCCTCGCCTTT
GCTCACCATGG
AATTCCCGGAT
AAGGGAATGG 
pLPCX GFP-HA This work RC BamHI / EcoRI 
CGTGGATCCATG
GTGAGCAAGGG
CGC 
GCAGAATTCTT
AAGCGTAGTCT
GGGACGTCGTA
TGGGTACTTGT
ACAGCTCATCC
ATGCCG 
pLPCX 
SS-Flag-
MMP2-
HA-eGFP 
This work GA EcoRI / XhoI 
GGGCCCATAAAG
CTTATACGAATT
CCATGGCTACAG
GCTCCCGGAC 
TCCTCGCCTTTG
CTCACCATAGC
GTAATCTGGAA
CATCGTATGGG
TA 
TACCCATACGAT
GTTCCAGATTAC
GCTATGGTGAGC
AAAGGCGAGGA 
GCGGCCGCTTG
TCGACACTCGA
GTTAAGGCCGG
CCCTTGTACAG 
pLPCX GoD1cpv Deng et al., 201896 N/A       
pLPCX NUCB1 tagless This work RC 
EcoRI / 
Not1 
INSERT FROM PCMV6-AC-NUCB1-
TURBOGFP (ORIGENE: RG201786) 
pLPCX NUCB1-myc This work GA 
HindIII / 
BamHI 
GATCTGGGCCCA
TAAAGCTTCCAT
GCCTCCCTCTGG
GC 
CGACACTCGAG
TATGGATCCTC
ACAAGTCTTCTT
CAGAGATGAGT
TTCTGCTCCAG
ATGCTGGGGCA
CCTCAAC 
pBT-PAF NUCB1-myc This work RC 
HindIII / 
NotI 
INSERT FROM PLPC-NUCB1-
TAGLESS 
pLPCX NUCB1-EQ1-myc This work SDM 
HindIII / 
NotI 
CGGACTCAGATC
TGGGCCCATAAA
GCTTCCATGCCT
CCCTCTGG 
GTGCCTCCAGC
TGCTGCTCATC
C 
GGATGAGCAGC
AGCTGGAGGCA
CCCCTTTTTCTG
GAGACTAAATA
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C AAATCTTTTATT
TTATCGATGTA
TATGCTCACAA
GTCTTCTTCAG
AGATGAGTTTC
TGCTCC 
pLPCX NUCB1-EQ2-myc This work SDM 
HindIII / 
NotI 
CGGACTCAGATC
TGGGCCCATAAA
GCTTCCATGCCT
CCCTCTGG 
GCGAGGAACTG
CTCCAGGGTC 
GACCCTGGAGCA
GTTCCTCGC 
CCCCTTTTTCTG
GAGACTAAATA
AAATCTTTTATT
TTATCGATGTA
TATGCTCACAA
GTCTTCTTCAG
AGATGAGTTTC
TGCTCC 
pLPCX 
NUCB1-
EQ1+2-
myc 
This work RC BamHI / SphI 
INSERT FROM PLASMID PLPCX-
NUCB1-EQ1-MYC REPLACED IN 
PLPCX-NUCB1-EQ2-MYC 
pLPCX 
dPro-
peptide-
Flag-
MMP2-
eGFP 
This work GA EcoRI / XhoI 
GCCCATATATGG
AGTTCCGCGTTA
C 
GGGCTTGCGAG
GGAAGAAGTTG
TAGCTACCGCC
TCCACCCTTATC
G 
CGATAAGGGTG
GAGGCGGTAGC
TACAACTTCTTCC
CTCGCAAGCCC 
CCTCGCCTTTG
CTCACCATGCA
GCCTAGCCAGT
CGGATTTG 
CAAATCCGACTG
GCTAGGCTGCAT
GGTGAGCAAAG
GCGAGG 
GCGGCCGCTTG
TCGACACTCGA
GTTAAGGCCGG
CCCTTGTACAG 
pLPCX 
dCatalytic 
Domain_
Flag-
MMP2-
eGFP 
This work GA EcoRI / XhoI 
GGGCCCATAAAG
CTTATACGAATT
CCATGGCTACAG
GCTCCCGGAC 
CAGCTCCTCGC
CTTTGCTCACCA
TGAGCTCCTGA
ATGCCCTTGAT
GTC 
GACATCAAGGGC
ATTCAGGAGCTC
ATGGTGAGCAAA
GGCGAGGAGCT
G 
GCGGCCGCTTG
TCGACACTCGA
GTTAAGGCCGG
CCCTTGTACAG 
pLPCX 
dHpex-
Flag-
MMP2-
eGFP 
This work GA EcoRI / XhoI 
GGGCCCATAAAG
CTTATACGAATT
CCATGGCTACAG
GCTCCCGGAC 
CAATGTCAGGA
GAGGCCCCATA
GTTGGCCACAT
CTGGGTTGCC 
GGCAACCCAGAT
GTGGCCAACTAT
GGGGCCTCTCCT
GACATTG 
CCTCGCCTTTG
CTCACCATGCA
GCCTAGCCAGT
CGGATTTG 
CAAATCCGACTG
GCTAGGCTGCAT
GGTGAGCAAAG
GCGAGG 
GCGGCCGCTTG
TCGACACTCGA
GTTAAGGCCGG
CCCTTGTACAG 
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pLPCX 
MMP2-
Prop-
CtoA 
eGFP 
This work SDM  
SINGLE MUTAGENIC PRIMER: 
GGCCACATCTGGGTTGCCGGCGCG
TGGCTTCCG 
pLPCX 
nSS-Flag-
MMP2-
Propeptid
e-
truncation
-HA-
eGFP 
This work GA EcoRI / XhoI 
AGCGTAATCTGG
AACATCGTATGG
GTAGTTGGCCAC
ATCTGGGTTGC 
GGGCCCATAAA
GCTTATACGAA
TTCCATGGCTA
CAGGCTCCCGG
AC 
GCAACCCAGATG
TGGCCAACTACC
CATACGATGTTC
CAGATTACGCT 
GCGGCCGCTTG
TCGACACTCGA
GTTAAGGCCGG
CCCTTGTACAG 
pLPCX GPP130-Twitch5 This work RC 
MluI / NotI 
CACACGCGTGTG
AGCAAGGGCGA
GGAG 
CACGCGGCCGC
TCAATCCTCAAT
GTTGTGACGG 
HindIII 
CCCAAGCTTATA
CGAATTCATGGG
AAACGGGATGT
GCTC 
CCCAAGCTTAG
AATCTTGCCTTC
CTTTGTTCAGT
G 
pBT-PAF NUCB1-His This work RC NheI / NotI 
GGCGGCCATCAC
AAGTTTGTACAG
CTAGCCATGCCT
CCCTCTGGGC 
GCGGCCGCTTG
TCAGTGATGAT
GATGGTGATGA
CCGCCTCCACCC
AGATGCTGGG
GCACCTCAAC 
pBT-PAF 
His-
Sumo-
MMP2 
This work GA HindIII / NotI 
CATTCCCTTATCC
TCGGGAACAAA
GCTTCATCACCA
TCATCATCACGG
GTCC 
CTTATCGTCGT
CATCCTTGTAAT
CGCATTCACCTC
CAATCTGTTC 
GAACAGATTGGA
GGTGAATGCGA
TTACAAGGATGA
CGACGATAAG 
GATCAGTTATC
TATGCGGCCGC
TCAGCAGCCTA
GCCAGTCGGAT
TTG 
pBT-PAF 
NUCB1_
EQ1+2-
His 
This work RC NheI / NotI 
GGCGGCCATCAC
AAGTTTGTACAG
CTAGCCATGCCT
CCCTCTGGGC 
GCGGCCGCTTG
TCAGTGATGAT
GATGGTGATGA
CCGCCTCCACCC
AGATGCTGGG
GCACCTCAAC 
pLPCX NUCB1-cyto This work RC 
HindIII / 
NotI 
CCATAAAGCTTA
TACATGGTCCCC
CTGGAGCGAGG
G 
TTATCGATGTA
TATGCGGCCGC
G 
RC: recombinant cloning; GA: Gibson assembly; SDM: site directed mutagenesis. 
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6.2 Cell culture methods 
6.2.1 General culture conditions 
HeLa and HEK293T cells were cultured in Dulbecco’s Modified Eagle Medium (DMEM), 
high glucose, GlutaMAX supplemented with 1% Penicillin/Streptomycin and 10% fetal 
bovine serum (FBS). MDA-MB-231-MT1-MMP-mCherry were a kind gift from Dr. Angelika 
Haußer and were cultured in Leibowitz 15 medium supplemented with 15% FCS and 0.5 
mg/mL gentamycin (G418). Unless indicated otherwise, all cell culture reagents, including 
DNA/RNAse free water were from Gibco (ThermoScientific, Waltham, USA). Plasticware 
(well plates and petri dishes) were purchased from Corning Inc. (Corning, USA). 
HeLa and HEK293T cells were kept at 37˚C and 5% CO2, whereas MDA-MB-231-MT1-
MMP-mCherry cells were maintained at the same temperature but with only 1% CO2. To 
passage the cells, first they were washed with DPBS, then incubated for 2-5 min with 1X 
trypsin/EDTA and resuspended in cell culture media. Then cells were centrifuged for 5 min at 
1000 rpm, supernatant was discarded, and cells were resuspended in growth medium. 
Afterwards, cells were count (only for seeding) or directly transferred to a new dish with 
growth medium (amount adjusted according to the desired cell density).  
6.2.2 Freezing and thawing 
Cells destined to be kept for long term were detached as mentioned before for passaging and 
after centrifugation and discarding supernatant, resuspended in a solution of FCS with 1% 
DMSO, transferred to cryo-freezing units and frozen at -80˚C. After freezing was complete, 
they were transferred to a liquid nitrogen tank at -196˚C. For thawing, cells were briefly 
incubated at 37˚C in a water bath and then resuspended in growth media (twice their volume). 
After 5 min centrifugation at 1000 rpm, supernatant was discarded, cells were resuspended in 5 
mL growth medium, mixed with additional 15 mL fresh medium and transferred to a 15 cm 
petri dish. Once 70-80% confluence was reached, cells were used for experiments. 
6.2.3 siRNA tranfection 
Cells were silenced using 1.5 µL of 20 µM siRNA with 12 µL HiPerfect® (Quiagen, Venlo, 
The Netherlands) diluted in 100 µL OptiMEM. After vortexing and RT incubation, the 
mixture was added dropwise to cells seeded in 6-well plates. For MDA-MB-231-MT1-MMP-
mCherry cells the amount was escalated to silence 10 cm dishes.  
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The oligonucleotides used for silencing were purchased from Life Technologies, with the 
following epitopes:  
siNUCB1-1:  5’-UCAUGCAGUAUGAAGAAGGUCUUGG-3  
siNUB1-2:  5’-GAGCUGGAGAAAGUGUACGACCCAA-3 
siMMP2-1:  5’-AGUAGAUCCAGUAUUCAUUCCCUGC-3  
siMMP2-2:  5’-CCAGAUGUGGCCAACUACAACUUCU-3  
6.2.4 Plasmid transfection 
HeLa and HEK293 transfections were done using polyethylenimine (PEI) in growth medium. 
Once HeLa cells reached around 50-60% confluence, a mixture of 2 µg DNA and 1.25mg/mL 
Polyethylenimine (PEI, Alfa Aesar Chemicals, Shanghai, China) in OptiMEM® was added 
dropwise to cells in culture and incubated for 24 h. For MT1-MMP-mCherry RUSH 
transfection, the same concentration of Lipofectamine LTX was used instead of PEI.  
6.2.5 Single clone isolation 
Cells were trypsinized as described above, counted by the Countess II system (Thermo Fisher 
Scientific, USA), diluted and seeded in a concentration of 100 cells in 15mL. Cells were 
incubated in 15 cm dishes until they were big enough to be distinguishable by naked eye. Then 
cells were manually scratched off with a pipette tip and transferred to a 96 well plate. Cells 
were incubated again until reaching at least 70% confluence. 
6.2.6 Generation of stable cell lines 
HeLa cells stably expressing MMP2-eGFP or any of its variants were transfected by VSV-G 
pseudotyped retroviral particles produced in transiently transfected HEK293T cells, as 
described by Pfeifer et al. (2000)254. Viral particles were concentrated from cell culture 
supernatants and used for infection. The next day, HeLa cells were selected in 2 µg/ml 
puromycin (Sigma-Aldrich, Munich, Germany) for 24 h and frozen or used for experiments. 
6.2.7 Generation of CRISPR cell lines 
HeLa cells were transfected with pSpCas9 vectors encoding at least 3 designed gRNAs and 
using PEI as a transfection reagent. Selection was performed using puromycin (2 µg/ml) for at 
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least 24 h. Then single clones were isolated (see above), expanded and analyzed by western 
blotting and immunofluorescence microscopy. For sequencing, genomic DNA was isolated by 
GenElute Mammalian Genomic DNA Miniprep Kit according to manufacturer’s protocol 
(Sigma-Aldrich, Munich, Germany). More details are given in section 7.3. 
6.2.8 qRT-PCR (Haußer Lab)* 
RNA isolation from cells was performed using the NucleoSpin® RNA kit (Macherey-Nagel) 
according to the manufacturers’ instructions. The real-time PCR reaction was performed using 
the QuantiTect SYBR Green RT-PCR Kit (Qiagen) and 100 ng of RNA. qRT-PCR was 
performed with a Cfx96 device (Bio-Rad) using a Power SYBR Green RNA-to-Ct 1-Step kit 
(Applied Biosystems). To amplify MMP2 (Hs_MMP2_1_SG) and Peptidylprolyl Isomerase 
(PPIA; Hs_PPIA_4_SG), QuantiTect Primer assays (Qiagen) were used, and changes in the 
relative expression levels were determined using the 2–ΔΔCt method (Bio-Rad CFX Manager 
software 3.1). 
6.3 Biochemical methods 
6.3.1 SDS PAGE and Western blotting 
10% homemade acrylamide gels or NuPAGE 4%–12% gradient gels were used for SDS-
PAGE. For Western blotting, transfer of samples to nitrocellulose membranes was performed 
for 75 min. Then membranes were blocked in 5% BSA in Tris-buffered saline (TBS) for at 
least 1 h at room temperature. After this time, membranes were incubated overnight with 
primary antibody in a shaker at 4 ˚C, washed for 1 h with TBS + 0.1% Tween-20 (TBS-T) and 
incubated with secondary antibody for 2 h at 4 ˚C. Previous to documentation in ChemiDoc 
Imaging System (Bio-Rad®), ImageQuant LAS 4000 series (GE Healthcare Life Sciences, 
Pittsburgh, PA, USA) or Amersham Imager 600 (GE Healthcare Life Sciences, Pittsburgh, PA, 
USA), membranes were washed for half an hour with TBS-T.  
6.3.2 Protein expression and purification* 
Stable HEK293 cells lines expressing His-SUMO-MMP2, rNUCB1-His or rNUCB1-
mEF1+2-His were generated by transfecting of 1.2 µg of the pBT-PAF vector encoding the 
correspondent sequence of interest (see Table 1), 0.8 µg pB-RN vector and 0.8 µg pBase 
vector with PEI (see section 6.2.4). After selection, 2 pools of positively transfected cells were 
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frozen. HEK293T cells were incubated with DMEM serum-free media supplemented with 1 
µg/mL doxycycline and 1 µg/mL aprotinin for at least 20 h to induce protein production. 
Upon this time, cell supernatants were collected and purification initiated.  
For His-SUMO-MMP2 and rNUCB1-His a purification column packed with cOmplete His-
tag purification resin from Roche (Mannheim, Germany) was used, as described by Crevenna 
et al., (2016) was used95. For the purification of rNUCB1-mEFh1+2- cell supernatants were 
collected, concentrated 100X using centrifugal filter units (Amicon Ultra, Ultracel 10K), 
transferred to an Eppendorf tube containing previously equilibrated Protino® Ni-NTA 
agarose beads (His-binding buffer) and incubated for 2 h at 4ºC with rotation. Afterwards, the 
protein-bound-beads were washed by centrifugation cycles (3400 xg, 5 min each), incubated 
with His-elution buffer and finally, eluted samples were dialyzed overnight in His-
reconstitution buffer at 4˚C. 
6.3.3 Maleimide protein labelling* 
Recombinant His-SUMO-MMP2 was labeled with Cy®3-NHS-Ester according to the 
manufacturer instructions (Sigma-Aldrich, St. Louis, MO, USA). After labeling, the protein was 
dialyzed in 20 mM Tris + 100mM NaCl, pH7.0 to remove excess of free dye. 
6.3.4 Visualization of NUCB1 EF-hand motifs* 
The nuclear magnetic resonance structure of NUCB1 [1SNL, Research Collaboratory for 
Structural Bioinformatics Protein Data Bank (RCSB PDB)] were visualized using the UCSF 
Chimera software [developed by the Resource for Biocomputing, Visualization, and 
Informatics at the University of California, San Francisco, with support from NIH P41-
GM103311]255. The rotamer that is shown was selected according to the highest probable 
candidate from the Dunbrack backbone-dependent rotamer library Shapovalov and Dunbrack 
(2011), and the pictures were adapted from the available model 1SNL de Alba and Tjandra 
(2004) in RCSB PDB using the UCSF Chimera software108,255,256. 
6.3.5 Immunoprecipitation assays* 
HeLa cells (3 × 105 cells/mL) were seeded in 15-cm plastic dishes (2 per sample), incubated 
overnight, transfected with 15 g DNA per dish using PEI (ratio: 2 µg DNA / 7.5 µL PEI) and 
incubated for 20 h. Thereafter, the cells were washed twice with 1X PBS, scraped, and 
centrifuged for 3 min at 3400 rpm. Supernatants were removed and pellets were washed two 
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more times. After washing, 300 µL lysis IP buffer were added to the samples and these were 
incubated for 30 min on ice. After this time, samples were filtered through a 27G needle and 
centrifuged at >13,000 rpm, 4˚C for 5 min. Then, supernatants were placed in a new 
Eppendorf tube and centrifuged once more for at least another 20 min, >13,000 rpm, 4˚C. 
Afterwards, total protein was estimated using Bradford assay and normalized to the lowest 
protein concentration. To incubate with the beads, a volume of 27 µL per sample was taken, 
mixed with 9 µL 4× Laemmli buffer and labeled as input sample (10% input). Samples were 
then mixed with 35 µL GFP beads, previously equilibrated with the lysis IP buffer, and 
incubated in an end-to-end rotator at 4˚C for 1 h. After incubation, samples were centrifuged 
at 3400 rpm, 4˚C for 3 min, supernatants were discarded, and pellets washed with 1 mL lysis 
IP buffer. This step was repeated twice, and after the last removal of supernatant, 35 µL oh 4X 
Laemmli buffer was added to the samples, incubated at 95˚C for 10 min and centrifuged at 
maximal speed (room temperature –RT˚–). Finally, supernatants were collected and labeled as 
IP sample for loading in 10% SDS gel. 
For the immunoprecipitation experiments using rNUCB1-His, approximately 100 µL of the 
recombinant protein were dialyzed overnight using the Pur-A-Lyzer™ mini dialysis Kit 
(Sigma-Aldrich, St. Louis, MO, USA) was used to dialyze approximately 100 µL of the 
recombinant protein in 500 mL IP buffer without protease inhibitor. After overnight dialysis, 
protein concentration was determined via absorbance measurement at 280 nm using a 
Nanodrop ND-1000 Spectrophotometer (PEQLAB Biotechnologie GmbH, Erlangen, 
Germany) was used to determine protein concentration via absorbance measurement at 280 
nm. Then, protein concentrations were normalized and samples were incubated for 2 h (on 
rotator at 4ºC) with previously equilibrated Protino® Ni-NTA agarose beads (Macherey-Nagel, 
Duren, Germany; equilibration buffer: IP buffer without protease inhibitor). During the 
incubation time, Golgi preps (see section 3.4.1) were lysed by incubation with 50 µL lysis IP 
buffer for 15 min on ice and centrifuged at 13200 rpm for 10 min to remove lipid membranes. 
Upon incubation, beads were washed 5X with lysis IP buffer and centrifuged at 3400 rpm, 4ºC 
for 3 min each time. The lysed Golgi preps were added to the beads and incubated for 2 h with 
rotation at 4ºC. After incubation, samples were centrifuged at 3400 rpm at 4ºC for 3 min. The 
beads were transferred to a new tube in the last step. Then, 35 µL Laemmli buffer 4× was 
added to the samples and they were incubated at 95˚C for 10 min. Samples were centrifuged at 
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maximal speed (room temperature), the supernatants were collected, labeled as IP sample and 
loaded in a NuPAGE™ 4–12% Bis-Tris protein gel. 
6.4 Cell Biological methods 
6.4.1 Isolation of Golgi membranes (Golgi preps) 
The following procedure was adapted from the one described by von Blume et al. (2012)107. At 
least 15 x 15 cm plastic dishes containing HeLa control cells (3 x 105 cells/mL) were seeded 
and incubated overnight. Then they were washed 2x with PBS, cells were trypsinized (see cell 
culture section) and pooled in a falcon plus 10mL 1X PBS. Samples were centrifuged at 1000 
rpm for 5 min, supernatant was discarded and pellets were placed on ice. From here on, all the 
procedure is made on ice. Cells were resuspended in 1 mL breaking buffer and centrifuged at 
900 rpm, 4˚C for 10 min. Supernatants were then discarded and pellet was resuspended in 
homogenization buffer (1:5 sample:buffer ratio). Samples were then transferred to an EMBO 
homogenizer with a 0.8 cm sphere and pushed 10-15 times through, caring about not 
introducing bubbles during the procedure. Afterwards, few µL of the sample were stained with 
trypan blue and evaluated by light microscopy to check for cell plasma membrane disruption.  
When >80% of the cells were disrupted, homogenization buffer was added to the samples up 
to a final volume of 7.5 mL. Then the homogenate for the sucrose gradient was prepared by 
adding 7mL of 62% sucrose buffer and 150 µL of 100 mM EDTA pH 7.4. Refracted indexed 
was checked and, if necessary, adjusted to ~37% (+/- 0.5%). To prepare the gradient, 11.6 mL 
of 29% sucrose buffer were added at the bottom of a 30mL ultracentrifugation tube. Then, 
using a long needle, 15 mL of 35% sucrose buffer were poured very slowly on the bottom of 
the tube, caring about not mixing both sucrose solutions.  
Finally, the homogenate sample was poured with a long needle in the bottom of the tube, 
keeping the gradient. Samples were then centrifuged at 28000 rpm for 2.5 h and 4˚C 
(acceleration: 7/10). Afterwards, a 20G or 21G needle was used to take the cloudy fraction 
located in the upper part of the tube below the meniscus. This sample was transferred to a new 
ultracentrifugation tube, filled up to ¾ with breaking buffer and centrifuged again for 30 min, 
28000 rpm at 4˚C with maximal acceleration. Finally, supernatant was discarded, pellet 
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resuspended in ~150 µL and samples snap frozen in liquid nitrogen. These samples were 
stored at -80˚C. 
6.4.2 Secretion assays* 
The Retention Using Selective Hooks (RUSH) secretion assay was performed according to the 
protocol described by Deng et al. (2018)96. Briefly, HeLa and NUCB1-KO cells (1 × 103 
cells/mL) were seeded in 6-well plates, incubated overnight and transfected with SS-Flag-
MMP2-SBP-eGFP or LyzC-Flag-SBP-eGFP using PEI. After 24h incubation, the cells were 
washed 3 times with 1X PBS and incubated in DMEM serum-free media for 45 or 60 min. 
After this time supernatants were collected and concentrated 20X using Centrifugal Filters 
(Amicon Ultra, Ultracel 10K). The cells were then lysed using 1× PBS + 0.05% Triton A-100, 
and the total protein was quantified. All samples were normalized to the corresponding lysate 
protein concentrations and Laemmli buffer was added to a final concentration of 1× for 
subsequent evaluation via SDS–PAGE and Western blotting.  
The HRP transport and secretion assay was performed according to a previously described 
protocol93,94,107. Twelve-well plates were seeded with 125,000 HeLa or NUCB1-KO cells stably 
expressing SS-HRP-FLAG and incubated for 24 h. HeLa Brefeldin A (BFA) samples were pre-
incubated with 10 µg/µL BFA in medium for 1 h previous to start the HRP secretion. Cells 
were then washed 5× with PBS and incubated in medium with or without BFA for 4 h. Cell 
culture supernatants were harvested and filtered. Cells were lysed in 0.5% Triton X-100 in 
PBS. The HRP activity was assessed by mixing 50 µL of medium or whole cell lysis with 50 µL 
Liquid Substrate System solution (2,2’-Azino-bis (3-ethylbenzothiazoline-6-sulfonic acid), 
Sigma-Aldrich, A3219) and absorbance measurements on a Magellan™ plate reader (Tecan 
Group Ltd., Switzerland) at 405 nm. The ratio of absorbance between secreted HRP and 
cellular HRP was then normalized to HeLa control samples, set to 100% and the normalized 
data from three independent experiments were plotted as mean ± SD. Significant differences 
with p-values < 0.05 were analyzed using the non-parametric Kruskal–Wallis test with Dunn’s 
multiple comparison test.  
Endogenous MMP2 secretion assays were performed using MDA-MB-231 cells stably 
expressing MT1-MMP-mCherry. Here cells were seeded into 6-well plates, incubated overnight 
and silenced afterwards using the described siNUCB1-1 (see section 6.2.3). Cells were 
incubated until 80% confluence was reached, washed with 1X PBS and incubated in 2 mL 
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Leibowitz L15 serum-free media for 16–20 h. After this time, supernatants were collected and 
concentrated 20× using centrifugal filter units (Amicon Ultra, Ultracel 10K). Cells were then 
lysed using 1× PBS + 0.05% Triton X-100, and total protein was quantified and normalized by 
the corresponding cell lysate protein concentration. Samples were then analyzed via SDS–
PAGE and Western blotting. 
Following the protocol described by Deng et al. (2018)96, a semi-quantitative analysis of band 
intensities was performed using Fiji (ImageJ), and normalized data from at least two 
independent experiments were plotted as the mean ± SD. Significant differences were analyzed 
using the non-parametric Kruskal–Wallis test with Dunn’s multiple comparison test (p-values 
< 0.05). 
6.4.3 Zymography* 
Gel Zymography experiments were performed as described by Toth et al. (2012)257. For this 
purpose, HeLa or NUCB1-KO cells (1.5 × 105 cells/mL) were seeded in 10-cm petri dishes, 
incubated overnight and thereafter transfected with either SS-Flag-MMP2-SBP-eGFP or LyzC-
Flag-SBP-eGFP using PEI. After 24 h incubation, cells were washed carefully and starved by 
incubating in serum-free medium containing 40 µM biotin for 45 or 60 min, accordingly. 
Supernatants were collected and concentrated 20× using centrifugal filter units (Amicon Ultra, 
Ultracel 10K), whereas cell lysates were incubated with 300 µL Zymography lysis buffer on ice 
for 15 min and centrifuged at maximal speed for 20 min.  
Samples were prepared by adding 1× Zymography sample buffer and evaluated using a 
Novex™ 10% Zymogram Plus (Gelatin) gel. For electrophoresis, zymography running buffer 
was used and samples ran at 150 V for 80 min. After this time, gels were briefly washed with 
distilled water and incubated with 100 mL 1X renaturing solution for at least 3 h. Then, gels 
were washed 3× with distilled water, incubating each time with at least 100 mL distilled water 
for 10 min. After the last washing step, water was replaced with 100 mL 1X developing 
solution and incubated for 30 min at room temperature. Upon this time, buffer was replaced 
with new 1X developing solution and incubated for at least 20 h at 37ºC on a shaker. Finally, 
the gels were briefly washed with water and stained with zymography staining solution until 
completely dark blue. Bands appeared as sharp clear areas. If necessary, gels were briefly (< 5 
min) de-stained in zymography destaining solution. Semi-quantitative analysis was performed 
with Fiji (ImageJ). 
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6.4.4 Invasion assay (Haußer Lab)* 
50 µL growth factor-reduced Matrigel (BD Biosciences, Bedford, MA, USA) diluted 1:20 in L-
15 medium containing 0.5% FCS was used to coat Transwells (pore size 8 µm; Costar®; 
Corning Inc., Corning, NY, USA) on the upper side and then allowed to polymerize for 1 h at 
37°C. Transfected cells (5×104 cells/mL) were seeded in Transwells in 100 µL of L-15 
medium containing 0.5% FCS. L-15 medium supplemented with 10% FCS was placed in the 
bottom chamber of the Transwell. After 24 h of invasion, cells on the bottom of the 
membrane were fixed and stained with crystal violet. Quantification of six independent fields 
at a 10× magnification was performed using Image J (v1.49s). 
6.4.5 Matrix degradation of MDA-MB-231 cells (Haußer Lab)* 
Using Oregon488-conjugated gelatin (1 mg/mL; Invitrogen), coverslips were coated and 
crosslinked with 0.5% glutaraldehyde (Carl Roth GmbH, Karlsruhe, Germany). Transfected 
cells (5 × 104 cells/mL) were seeded on these coverslips and incubated for 5 h at 37C. At this 
time, cells were fixed and nuclei counterstained with 4,6-diamidino-2-phenylindole (DAPI). 
A confocal laser scanning microscope LSM 710 (Carl Zeiss GmbH) equipped with a Plan-
Apochromat 20/0.8 was used for imaging and 40 confocal images per condition were 
acquired using identical settings for 488 and DAPI channels. Quantification of gelatin 
degradation was performed using the CellProfiler software version 3.0.0. Relative degraded 
area was defined as the measured area normalized by the average area of siControl in each 
experiment. 
6.4.6 2D gelatin degradation assay of human primary macrophages (Linder Lab)* 
NHS Rhodamine (Thermo Fisher Scientific) fluorescent gelatin (from swine; Carl Roth 
GmbH) was prepared according to the method described by Chen and Ko (1994). Rhodamin-
labelled gelatin was then used to coat coverslips by fixation in 0.5% glutaraldehyde (Carl Roth 
GmbH), and washing in RPMI and culture medium. Seventy-two hours after siRNA 
transfection, cells were reseeded on coated coverslips (5 x 104 cells), fixed and permeabilized at 
4, 6, and 8 h after seeding. Later on, fixed cells were stained with Alexa Fluor-488–phalloidin 
and coverslips were mounted on Mowiol (Calbiochem) containing 1,4-
diazabicyclo[2.2.2]octane (25 mg/mL; Sigma-Aldrich). Quantification of matrix degradation 
was determined by counting the degradation sites/cells of different conditions using ImageJ 
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software. For comparison, laser intensity was not changed between measurements. Two 
donors of independent experiments were analyzed, with at least eight fields of view (400–1000 
cells) per condition. 
Images were acquired using confocal laser scanning microscopes (Leica DMi8 confocal point 
scanner equipped with a 20× HC PL APO IMM/CORR CS2 and oil immersion 63× HC PL 
APO Oil CS2 objective and 3× HyD, 2× PMT, 1× Trans-PMT detector). Acquisition and 
processing were performed using the Leica LAS X SP8 confocal software (Leica Camera AG, 
Wetzlar, Germany) and/or Volocity 6.1.1 software (Perkin-Elmer, Waltham, MA, USA) and 
ImageJ software. 
6.5 Physical methods 
6.5.1 Mass spectrometry (MS)* 
Samples were processed at the core facility of the Max Planck Institute of Biochemistry 
(Martinsried, Germany). SDS gel lanes were digested with trypsin using in-gel digestion 
protocol, and peptides were extracted and purified via C18 StageTips. Afterwards, they were 
analyzed in a Q Exactive HF machine with a data-dependent acquisition scheme using higher-
energy collisional dissociation fragmentation. Raw data were processed using the MaxQuant 
computational platform, and the peak lists were searched against a human reference proteome 
database from Uniprot. All identifications were filtered at 1% false discovery rate and label-free 
quantitation. Proteomic data were analyzed with the Perseus 1.5.5.3 software Tyanova et al., 
(2016), and results from a t-test using Perseus were plotted as logarithmic ratios against 
logarithmic p-values258. The final selection of positive hits was done by filtering out potential 
contaminants, reverse sequences, and hits identified only by site. 
6.5.2 Circular Dichroism (CD)* 
CD measurements were performed as described previously95 with the following modifications: 
measurements were performed at 4ºC using a His-reconstitution buffer. The mean of four 
independent spectra (from 198 to 250 nm with 0.1 nm spacing) was recorded and used for 
CONTIN analysis, which was performed with CDPro. CONTIN decomposes the CD signal 
into six secondary structural elements: regular α-helical, distorted α-helical, regular β sheet, 
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distorted β sheet, turn, and unordered259. Reported values in the main text for the α-helical and 
β sheet content were the sum of regular and distorted fractions for each secondary element. 
6.5.3 Analytical Ultracentrifugation (AUC)* 
Sedimentation velocity experiments were performed on an Optima XL-I analytical 
ultracentrifuge (Beckman Inc., Palo Alto, CA, USA.) using an An 60 Ti rotor and double-
sector epon center pieces. The proteins were added to a 20 mM Tris + 100 mM NaCl buffer at 
0.6 mg/mL and 1.6 mg/mL for His-SUMO-MMP2 and NUCB1-His, respectively. Buffer 
density and viscosity was measured using a DMA 5000 densitometer and an AMVn 
viscosimeter, respectively (both by Anton Paar, Graz, Austria). Fluorescently labeled protein 
concentration distribution was monitored at 544 nm at 50,000 rpm and 20°C. Time-derivative 
analysis was computed using the SEDFIT software package, version 12.1b (Schuck, 2000), 
resulting in a c(s) distribution and an estimate of the molecular weight Mf (from the 
sedimentation coefficient and the diffusion coefficient, as inferred from the broadening of the 
sedimentation boundary, assuming all observed species share the same frictional coefficient 
f/f0). 
6.6 Microscopy methods 
6.6.1 Immunofluorescence and confocal microscopy* 
Samples were prepared by seeding HeLa cells (3 × 104 cells/mL) into six-well plates with two 
glass slides per well. Cells were incubated for 24 h, transfected (see section 6.2.4) and incubated 
for no more than 24 h. Then, cells were washed 3 times with 1X PBS, fixed with 4% PFA for 
10 min and permeabilized with 0.2% Triton X-100 and 0.5% SDS in PBS for 5 min (if no co-
staining was needed, cells were directly mounted after fixation). In between fixation and 
permeabilization, cells were washed 3–5 times with PBS. For co-staining, cells were incubated 
with 5% BSA in PBS overnight at 4˚C. After this time, primary antibody was added, incubated 
either overnight at 4˚C or 1 h at RT˚, washed 3–5 times with 1X PBS and secondary antibody 
was added. After 1 h incubation at RT˚, cells were mounted in glass slides using ProLong™ 
Gold antifade reagent (Invitrogen) and evaluated using confocal microscopy. 
Images acquisition was performed at 22˚C on a Zeiss laser scanning LSM780 confocal 
microscope (Carl Zeiss GmbH, Jena, Germany) equipped with a 100× (NA, 1.46 oil) objective. 
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To detect AlexaFluor, the 488-nm laser line was used. Pictures were acquired using Leica 
software (ZEN 2010) and processed, merged, and gamma adjusted in ImageJ (version 1.37). 
6.6.2 RUSH assays* 
RUSH cargo sorting assays were performed as previously described Deng et al. (2018)96. 
Briefly, HeLa or NUCB1-KO cells were cultured on sterile glass slides in 6-well dishes, 
transfected using pIRESneo3-SS-Str-KDEL-Flag-MMP2-SBP-HA-eGFP, pIRESneo3-SS-Str-
KDEL-acGFP-HA, pIRESneo3-SS-Str-KDEL-LyzC-SBP-eGFP, or pIRESneo3-SS-Str-
KDEL-MT1MMP-SBP-mCherry alone or together with NUCB1-WT, NUCB1-WT-myc, or 
its EF-hand mutants for 16 h. Afterwards, cells were washed with 1X PBS and incubated with 
DMEM complete medium supplemented with 40 µM D-biotin (SUPELCO, 47868). Time 
point 0 cells was defined as incubation with complete medium without D-biotin to confirm 
reporter retention. After biotin incubation, cells were washed 2 x in 1X PBS, fixed, mounted 
and evaluated by immunofluorescence microscopy, as described in section 6.6.1. Only cells 
showing proper reporter transport to the Golgi after biotin addition were processed, whereas 
those showing ER signal after biotin addition were discarded. To cover the whole volume of 
the cells, typically 8–16 z-stacks with a step size of 0.39 µm were acquired for each field of 
view. 
6.6.3 Vesicle quantification* 
A custom-made ImageJ macro previously described Deng et al. (2018)96 was used to evaluate 
cellular vesicle numbers. In this macro, ImageJ’s rolling ball background subtraction algorithm 
is used together with the enhance contrast function, and maximum z-projection of the RUSH 
reporter channel to cover all vesicles of the cell volume in a 2D image. After using a median 
filter, suitable cells were selected via polygon selection and a binary image was generated using 
the Threshold function, using the threshold algorithm “Yen” was used as default and adjusting 
threshold by manual correction for low-intensity images. The vesicle objects in the binary 
images were compared with the original image and controlled via visual inspection. In the 
binary image, vesicle objects with sizes 4–20 pixels were quantified using the Analyze Particles 
function. All macros used for image analysis are available at 
https://github.com/MehrshadPakdel. 
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6.6.4 RUSH live cells trafficking assay* 
Live cell dishes (µ-Dish 35 mm, high Glass Bottom from ibidi, Gräfelfing, Germany) were 
seeded with HeLa control or NUCB1-KO cells (3 x 104 cells/mL), incubated overnight and 
transfected with the SS-SBP-MMP2-eGFP RUSH construct for 24 h. Upon incubation, cells 
were washed with 1X PBS and incubated in DMEM, high glucose, HEPES, no phenol red 
(GibcoTM, Thermo Fischer, Waltham, USA). Image acquisition was performed using GE 
DeltaVision Elite microscope at intervals of 1 min per frame. DMEM + 40 µM Biotin was 
added to the cells at t = 0 min. Images were acquired using softWoRx 5.5 software (GE 
Healthcare). 
6.6.5 Live-cell vesicle image analysis* 
The quantification of cytoplasmic vesicles per frame was performed using a custom-made 
ImageJ macro based on RUSH vesicle analysis, as formerly described by Deng et al. (2018)96. 
In this macro, ImageJ’s rolling ball background subtraction algorithm is used, followed by a 
mean filter to smooth edges of the objects. A binary image was generated by the Auto 
Threshold function using the “Minimum” algorithm for frames 1–25, and the “Moments” 
algorithm for frames 26–45 to optimize image thresholding for ER-like objects and then for 
Golgi and vesicular structures. A comparison between vesicle objects in the binary images and 
the original image was performed and controlled via visual inspection. Lastly, the Analyze 
Particles function was used to quantify vesicle objects with sizes ranging between 4 and 40 
pixels. Seventeen HeLa and 22 NUCB1-KO cells from two independent experiments were 
evaluated and plotted as median ± interquartile range. Significant differences with p-values < 
0.05 were analyzed using the non-parametric Kruskal–Wallis test with Dunn’s multiple 
comparison test. 
6.6.6 Live-cell ER–Golgi cargo transport analysis* 
Custom-made ImageJ macros were used to quantify normalized Golgi area over time. The first 
part of the macro used a median filter to smooth the edges of objects. A binary image was 
produced for the first frame of the movie to extract the ER signal of RUSH reporter using the 
Threshold function of ImageJ and to manually extract the ER object and the ER area was 
measured using the Analyze Particles function with pixel sizes 50–Infinity. The second part of 
the macro was optimized for extracting Golgi objects for each frame and quantifying their 
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area. This macro used ImageJ’s rolling ball background subtraction algorithm followed by a 
median filter. A binary image was generated for each frame with the Auto Threshold function 
using the “Moments” algorithm and areas of binary Golgi objects were then quantified for 
each frame with the Analyze Particles function using pixel sizes 15–Infinity. The normalized 
Golgi area was calculated as the ratio of Golgi area at each frame and the ER area at the first 
frame. Normalized Golgi area for 15 control and NUCB1-KO cells were plotted for each time 
point as the median ± interquartile range. Significant differences at t = 22 min with p-value < 
0.05 were analyzed using the non-parametric Mann–Whitney test. 
6.6.7 Ca2+ influx assays* 
To measure Ca2+ entry into the TGN or cis-Golgi two fluorescent Ca2+ sensors were used: 
Go-D1-cpv, which targets the TGN, or GPP130-Twitch5, which targets the cis-Golgi, 
following the methodologies previously described by Deng et al., (2018)96 and Lissandron et 
al., (2010)49, respectively. Changes in Ca2+ concentration in the TGN by the Go-D1-cpv 
sensor were observed as changes in FRET efficiency between CFP and YFP fluorescent 
proteins linked by a modified calmodulin and calmodulin-binding domain, whereas changes in 
Ca2+ concentration in the cis-Golgi were evaluated as FRET efficiency between enhanced 
CFP and Citrine fluorescent proteins linked by a modified C-terminal domain of Opsanus tau 
troponin C260.  
Go-D1-cpv or GPP130-Twitch5 alone or together with NUCB1-WT or NUCB1-EFh1+2 
mutant were transfected to HeLa or NUCB1-KO cells. After 24 h incubation, Ca2+ entry into 
the TGN or cis-Golgi were measured upon Ca2+ depletion (cells were previously incubated 
for 1 h at 4°C in HBSS buffer supplemented with 1 µM ionomycin (Abcam, Cambridge, MS, 
USA) and 0.5 mM EGTA)93,96. Upon 2x washing steps with HBSS + 0.5 mM EGTA followed 
by 2x washing steps with HBSS only, images were acquired using the GE DeltaVision Elite 
(GE Healthcare Life Sciences) as described above. Excitation filter (430/24), dual-band Sedat 
CFP/YFP beam splitter (Chroma Technology Corp., Bellows Falls, VT, USA), and emission 
filters (535/25 for FRET and 470/24 for CFP) were rapidly changed using an external filter 
wheel controlled by a motorized unit to generate the images. 
Fluorescent signals reflecting TGN or cis-Golgi Ca2+ concentration were presented as ΔR/R0, 
where R0 is the value obtained before the addition of 2.2 mM CaCl2 to the cell’s bathing 
solution. The softWoRx 5.5 software (GE Healthcare Life Sciences) was used for image 
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acquisition and image analysis was conducted using a custom-made ImageJ macro based on 
ratiometric FRET analysis, as described before94,96,261. The macro uses ImageJ’s rolling ball 
background subtraction algorithm followed by a mean filter to smooth out the edges of the 
objects. A binary image is generated by the Auto Threshold function using the “Moments” 
algorithm. FRET and CFP channel images were multiplied by the “ImageCalculator” plugin 
with their respective binary images, resulting in images that show 0 intensities outside of the 
threshold Golgi region while retaining intensities within the Golgi. Then, a ratio image of 
FRET/CFP was generated using the “Ratio Plus” plugin. The Golgi objects were detected 
using the “Find Maxima” function and added to the region of interest (ROI) manager. Mean 
intensities of each ROI were measured in the ratio image for each frame. Ratio values of each 
frame were then subtracted with those in the first frame. These values were normalized to the 
first frame and presented as percentage ΔR/R0 to obtain the normalized ratio values before 
the addition of CaCl2. 
6.7 Statistical analysis 
Data were first evaluated for normality fit. Most of the time, the data did not follow a normal 
distribution, therefore Kruskal–Wallis test with Dunn’s comparison was used for most 
statistical significance evaluations, unless otherwise stated, using the GraphPad PRISM 
software (GraphPad Software, Inc., San Diego, CA, USA). For the evaluation of statistical 
differences in Ca2+ influx assays, the Mann–Whitney test was used. 
6.8 Other reagents 
6.8.1 Antibodies 
MMP-2 antibody was purchased from Abcam [rabbit (ab92536)] (Cambridge, MA, USA), 
NUCB1 and β-actin antibodies were obtained from Sigma-Aldrich [rabbit (HPA008176) and 
mouse (A5441), respectively], ERGIC53 was acquired from ENZO Life Sciences Inc. [mouse 
(ENZ-ABS300); Farmingdale, NY, USA], GM130 antibody was purchased from BD 
Bioscience (mouse (610822); San Jose, CA, USA] streptavidin–HRP antibody was from Cell 
Signaling [3999S; Danvers, MA, USA]; TGN46 antibody was obtained from AbD Serotec 
(sheep (AHP500G); Oxford, UK). MMP-14 (MT1-MMP) antibody was purchased from 
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Millipore (mouse (MAB3328); Burlington, MA, USA) and GFP antibody [rabbit (sc8334)] as 
well as the horseradish peroxidase (HRP)-coupled secondary antibodies [anti-rabbit IgG, anti-
mouse IgG, and anti-sheep IgG] were purchased from Santa Cruz Biotechnology Inc. (Santa 
Cruz, CA, USA). Anti-rabbit HRP antibody used with primary macrophages was purchased 
from Cell Signaling [7074; Danvers, MA, USA]. The AlexaFluor secondary antibodies used for 
immunofluorescence (alexaFluor-488, alexaFluor-594, alexaFluor-633, and Phalloidin-
alexaFluor-488) were purchased from Thermo Scientific (Carlsbad, CA, USA). 
6.9 Buffers 
Table 2. List of buffers used in this work. 
Buffer Composition 
His-binding buffer 50 mM NaP, pH 8.0, 500 mM NaCl. 
His-Elution buffer 50 mM NaP, pH 8.0, 500 mM NaCl, 250 mM Imidazole 
His-reconstitution 
buffer 20 mM Tris, 500 mM NaCl 
IP buffer 
50 mM Tris + 150 mM NaCl + cOmplete Tablets, Mini EDTA-
free, EASYpack protease inhibitor tablets (Roche Diagnostics 
GmbH, Mannheim, Germany) 
Lysis IP buffer 
50 mM Tris + 150 mM NaCl + 0.1% Triton X-100 + cOmplete 
Tablets, Mini EDTA-free, EASYpack protease inhibitor tablets (1 
per 15mL buffer; Roche Diagnostics GmbH, Mannheim, Germany) 
GolgiPrep – breaking 
buffer 250mM sucrose in 10mM Tris pH 7.4 
GolgiPrep – 
homogenization buffer 
Breaking buffer + 3 cOmplete Tablets, Mini EDTA-free, 
EASYpack protease inhibitor tablets (Roche Diagnostics GmbH, 
Mannheim, Germany) 
GolgiPrep- 62% 
sucrose buffer 62% w/w sucrose in 10mM Tris pH 7.4 
GolgiPrep - 35% 
sucrose buffer 35% w/w sucrose in 10mM Tris pH 7.4 
GolgiPrep - 29% 
sucrose buffer 29% w/w sucrose in 10mM Tris pH 7.4 
HBSS buffer 
20 mM HEPES, Ca2+/Mg2+-free HBSS (Gibco by Life 
Technologies, Grand Island, NY, USA) + 2 g/L glucose + 490 µM 
MgCl2 + 450 µM MgSO4. 300 mOsmol/L, pH 7.4. 
Coomasie solution 40 % v/v methanol, 10 % v/v acetic acid, 0.1 % w/v Coomassie Brilliant Blue R 
Destain solution 40 % v/v methanol, 10 % v/v acetic acid 
DNA-loading dye 3 % glycerol, 0.15 % OrangeG 
Laemmli buffer 200 µM Tris pH 6.8, 4 µM EDTA, 84.5 % glycerol, 8 % SDS, 4 % b- mercaptoethanol, 0.05 % bromophenol blue 
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Freezing medium 90 % FBS, 10 % DMSO 
LB growth medium 1 % w/v Trypsin-Peptone, 1 % w/v NaCl, 0.5 % w/v yeast extract 
PBS 10 mM Na2HPO4, 1.7 mM NH2PO4 pH 7.4; 2.6 mM KCl, 137 mM NaCl 
PEI solution 1.25 mg/ml PEI in sterile water; pH 7.4 
Permeabilization 
solution 0.2 % TritonX-100 and 0.5 % SDS in 4 % BSA in PBS 
Running buffer 25 mM Tris pH 7.4, 190 mM glycine, 0.1 % SDS 
Separating gel (10%) 119 mM Tris pH 8.8, 10% v/v acrylamide, 0.1 % w/v SDS, 0.01 % v/v APS, 0.0015 % v/v TEMED 
Stacking gel (5%) 125 mM Tris pH 6.8, 5 % v/v acrylamide, 0.1 % SDS, 0.01 % v/v APS, 0.001 % v/v TEMED 
Transfer buffer 25 mM Tris pH 7.4, 192 mM glycine, 20 % v/v methanol 
TAE buffer 40 mM Tris, 1 mM EDTA, pH 8.3 
TBS buffer 25 mM Tris pH 7.4, 150 mM NaCl 
Trypsinization solution 10 % Trypsin-EDTA in PBS 
TSS buffer 1 % tryptone-peptone, 0.5 % yeast extract, 100 mM NaCl, 10 % PEG (MW3000/3500), 5 % DMSO, 50 mM MgCl2, pH 6.5 
Zymography lysis 
buffer 25 mM Tris, 100 mM NaCl, 0.1% NP-40 
Zymography running 
buffer Running buffer with 5% SDS instead of 0.1% 
Zymography sample 
buffer 
Zymography running buffer, 35% Glycerol, 8% SDS, 1 mg/mL 
Bromophenol Blue 
Zymography 10× 
renaturing solution 25% v/v Triton X-100 in distilled water 
Zymography 10× 
developing buffer 
500 mM Tris-HCl (pH 7.8), 2 M NaCl, 50 mM CaCl2; and 0.2% Brij 
35 
Zymography staining 
solution 0.5% Coomassie blue R-250, 5% methanol, 10% acetic acid  
Zymography 
destaining solution 5% methanol, 10% acetic acid 
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7. Results 
The majority of the results shown in this section correspond to the paper Nucleobindin-1 regulates 
ECM degradation by promoting intra-Golgi trafficking of MMPs, at the moment under revision for 
publication on the Journal of Cell Biology (JCB). The mentioned paper was a collaborative 
effort between the von Blume group in Munich and Yale, the Haußer group in Stuttgart and 
the Linder group in Hamburg. Each section in which experiments were performed by any of 
the collaborators of this study is pointed out. 
The first aim of this thesis was to identify potential candidates involved in the trafficking of 
MMP2. Initially, an evaluation and optimization of suitable systems for the study of MMPs 
trafficking was assessed, choosing the Retention Using Selective Hooks (RUSH) system (see 
next section) to better dissect cargo transport through the secretory pathway. To enrich cargos 
specifically in the Golgi compartment, the RUSH system was combined with a mass 
spectrometry approach to identify new interacting partners involved in trafficking. The 
identified candidates were later phenotypically analyzed using the RUSH system on a single-cell 
level. As a main finding, this study identified nucleobindin-1 (NUCB1) as a crucial component 
of the intra-Golgi trafficking machinery of MMP2, opening the path for future investigations 
to elucidate new components of such machinery, as well as identify new regulatory pathways 
that modulate the intracellular trafficking of MMPs.  
7.1 MMP2 follows the secretory pathway 
To evaluate the trafficking behavior of MMP2, the RUSH system262 was used (Figure 35A). In 
this system, cells are transfected with a construct expressing two proteins at the same time: one 
is streptavidin bound to an anchor protein localizing the complex in a donor compartment, 
and the other is the protein of interest, tagged with a fluorophore and bound to a streptavidin 
binding peptide (SBP)262. The method is based on the strong affinity between streptavidin and 
biotin, therefore once biotin is added to the cell culture media, the binding of SBP to 
streptavidin is lost, and the cargo is released to the acceptor compartment262 (Figure 35A).  
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Figure 35. Schematic representation of the RUSH assay used in this study. (A) Scheme 
representing the Retention Using Selective Hooks (RUSH) system. Adapted from Boncompain et 
al. (2012)262. SS-Flag-MMP2-HA-SBP-eGFP was used as a reporter and streptavidin-KDEL as an 
endoplasmic reticulum (ER) retention hook. (B) Schematic representation of the MMP2 RUSH 
protein used as cargo in this study, illustrating the domains of MMP2. 
In this study, HeLa cells were transfected with a RUSH construct containing streptavidin 
bound to a KDEL sequence to act as a hook and keep streptavidin in the ER, and MMP2-
SBP-eGFP (Figure 35B) as cargo. Confocal imaging of fixed cells after 0, 15, 30 and 45 min of 
biotin incubation, as well as colocalization with ER and Golgi markers evidenced the 
trafficking of MMP2 through the secretory pathway (Figure 36). 
 
Figure 36. MMP2 traffics through the secretory pathway. Fluorescence images show HeLa cells 
expressing MMP2-SBP-eGFP and co-stained with a TGN46 (red) antibody. In the absence of 
biotin, MMP2-SBP-eGFP is retained in the ER (0 min). MMP2 reaches the Golgi 15 min after 
biotin addition and is sorted into vesicles (arrowheads) after 30 and 45 min of biotin incubation, 
respectively. Scale bars, 5 µm.  
A 
 
 
 
 
 
 
 
 
 
B 
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These results showed that MMP2 reaches the Golgi apparatus after 15 min of biotin 
incubation, is released in vesicles after 30 min and after 45 min of biotin incubation 
cytoplasmic vesicles are released in the extracellular space (Figure 36). It is important to note 
that in comparison with other reported cargoes analyzed using the same system (such as 
LyzC96, or E-cadherin262) only a small fraction of MMP2-eGFP remains in the Golgi at 45 min 
after biotin addition. 
7.2 Identification of potential candidates involved in the trafficking 
of MMP2 
In order to identify potential Golgi localized protein candidates involved in the intracellular 
trafficking of MMP2, a novel mass spectrometry (MS) approach was used (Figure 37A). Here, 
HeLa control cells were transfected with 2 different constructs: the described RUSH MMP2 
and, as a control, a RUSH construct containing only the signal sequence of human Growth 
Hormone (hGH, from now on SS) coupled to eGFP.  
 
Figure 37. Mass spectrometry approach to identify candidates involved in the intracellular 
trafficking of MMP2. (A) Schematic representation of the MS-RUSH protocol used to identify 
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specific MMP2 interacting partners in the Golgi complex. HeLa cells were transfected with 
MMP2-SBP-eGFP or SS-SBP-eGFP and incubated for 20 min with biotin to enrich reporter 
proteins at the Golgi. Cells were then lysed, and reporter proteins were pulled down using 
GFPtrap®. The samples were loaded on an SDS gel and analyzed using mass spectrometry for 
identification of interactors (n = 3).  (B) Volcano plot of identified candidates highlights 
significantly enriched MMP2 interactors in pink. Forty-two sorting-related candidates were found. 
Among them were tissue inhibitor of metalloproteinase 2 (TIMP2), a known inhibitor of MMP2; 
nucleobindin-1 (NUCB1), a major calcium regulator at the cis-Golgi; exocyst 5 (EXOC5) a 
component of the Exocyst complex; and synaptophysin-like protein 1 (SYPL1), predicted to be a 
transmembrane component of cytoplasmic vesicles. Significance was assessed using a two-sample 
t-test. FDR = 0.3, s0 = 0.5. X-axis represent the t-test difference in mean values between groups 
and y-axis the –Log of the p-value for the t-test. 
Biotin was added to the medium 24 h after transfection, cells were incubated for 20 min to 
accumulate cargo in the Golgi and lysed directly afterwards. Then, protein pull downs were 
performed using GFPtrap® on whole cell lysates and samples were loaded on an SDS gel. 
Finally, the bands were excised and the proteins were digested and analyzed by mass 
spectrometry. 
MS results were analyzed using the Perseus software258 and 42 MMP2 interacting candidates 
were identified (Table 3). As expected, TIMP2, an inhibitor known to bind MMP2 early on its 
trafficking to the plasma membrane, was found, validating the accuracy of the assay and 
serving as positive control for the MS experiment (Figure 37B). 
Among the other proteins found, three were considered particularly relevant for MMP2 
trafficking given their roles in cis-Golgi Ca2+ homeostasis (nucleobindin-1, NUCB1), vesicle 
tethering at the plasma membrane (exocyst complex component 5, EXOC5) and as a 
component of cytoplasmic vesicles (synaptophysin-like protein 1, SYPL1). They are described 
with more detail below. 
Table 3. List of protein interactors found with the described MS approach. 
Protein name Gene name 
72 kDa type IV collagenase;PEX MMP2 
Cystatin-B CSTB 
p53-induced death domain-containing protein 1 PIDD1 
Metalloproteinase inhibitor 2 TIMP2 
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Arginase-1 ARG1 
Bleomycin hydrolase BLMH 
Gasdermin-A GSDMA 
Exocyst complex component 5 EXOC5 
Tubulin-specific chaperone A TBCA 
Dynein heavy chain 2, axonemal DNAH2 
ATP-binding cassette sub-family A member 10 ABCA10 
Protein CASC5 CASC5 
Keratinocyte proline-rich protein KPRP 
Histidine ammonia-lyase HAL 
Integrin β-8 ITGB8 
Nicotinamide N-methyltransferase NNMT 
Small proline-rich protein 3 SPRR3 
Hemoglobin subunit β HBB;HBD 
Α-2-macroglobulin-like protein 1 A2ML1 
Protein NipSnap homolog 1 NIPSNAP1 
Protein FAM32A FAM32A 
RNA polymerase-associated protein LEO1 LEO1 
Synaptophysin-like protein 1 SYPL1 
Prefoldin subunit 1 PFDN1 
Nucleobindin-1 NUCB1 
Transmembrane protein 14C TMEM14C 
Thymidylate kinase DTYMK 
NADH dehydrogenase [ubiquinone] 1 β subcomplex subunit 9 NDUFB9 
Protrudin ZFYVE27 
ATP-dependent RNA helicase SUPV3L1, mitochondrial SUPV3L1 
Testis-specific Y-encoded-like protein 1 TSPYL1 
Epithelial splicing regulatory protein 2 ESRP2 
Dehydrogenase/reductase SDR family member 7B DHRS7B 
Neuropathy target esterase PNPLA6 
Chromodomain-helicase-DNA-binding protein 3 CHD3 
Collagen α-1(XII) chain COL12A1 
60S ribosomal protein L11 RPL11 
Armadillo repeat-containing protein 6 ARMC6 
Quinone oxidoreductase CRYZ 
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E3 ubiquitin-protein ligase RNF220 RNF220 
Mediator of RNA polymerase II transcription subunit 24 MED24 
Mediator of RNA polymerase II transcription subunit 31 MED31 
 
7.2.1 NUCB1 
NUCB1 is a 63 kDa Ca2+ binding protein mainly localized at the cis compartment of the 
Golgi104,106,112,263. NUCB1, also known as NUC or CALNUC is encoded by a gene located in 
the chromosome 19 (19q13.33) and is conserved from Drosophila to humans264. Although its 
function is not completely understood, up to date, most of the studies on NUCB1 have shown 
an effect on the activation of the α subunit of the G-protein113,116,117, the control of the 
biogenesis and folding of amyloid-β precursor in Alzheimer’s disease88,118,265 and a role in the 
regulation of endosomal trafficking of lysosomal receptors120,121.  
 
Figure 38. Protein sequence alignment of human NUCB1 (Q02818, amino acids 241–360), 
calmodulin (P0DP23), calumenin (O43852) and Cab45 (Q9BRK5). Pink boxes highlight the EF-
hand domains of NUCB1. Color scheme: CLUSTAL by group (MView 1.63, Copyright © 1997–
2018 Nigel P. Brown). 
NUCB1 belongs to the EF-hand family of proteins. Proteins in this family share a helix-loop-
helix 29 amino acid motif (the EF-hand motif) that binds Ca2+22,86,109,110. Among them, a group 
of soluble proteins, known as CREC (Cab45, Reticulocalbin, ER-55 and Calumenin), is 
mostly, although not exclusively, distributed throughout the secretory pathway22. They play a 
role as Ca2+ sensors and therefore participate in signaling cascades involving molecular 
chaperoning (calumenin, reticulocalbin-322), and cargo sorting (Cab4595,96).  
Although all the members of this family possess a conserved EF-hand domain region, the rest 
of the sequence is considerably different22,110. The alignment between NUCB1 and 3 other EF-
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hand proteins (2 of them belonging to the CREC family) shows the highly conserved E residue 
at the end of the sequence motif and the similarities between the EF-hand sequences of 
NUCB1 EF-hand motifs 1 and 2, and the calumenin motifs 4 and 5, and Cab45 motifs 3 and 
4, respectively22 (Figure 38).    
Among the CREC proteins, Cab45 is the only one residing in the Golgi103,111, although it has 
been shown that calumenin can also partially localize at the Golgi before being secreted21. 
Moreover, Cab45 has been shown to play a critical role in protein sorting by close interplay 
with SPCA1, the unique Ca2+ ATPase pump at the TGN94–96,107. Though the mechanism is not 
fully understood, it is known that after Ca2+ influx, Cab45 oligomerizes and promotes cargo 
sorting in sphingomyelin rich vesicles96. In addition, NUCB1 and Cab45 are described as the 
only soluble Ca2+-binding proteins present in the lumen of the Golgi103,104,266, suggesting that, 
as well as Cab45, NUCB1 could be playing a role in protein trafficking at an early stage in the 
Golgi. 
7.2.2 EXOC5 and SYPL1 
Exocyst component 5, previously known as Sec10, is a 81 kDa component of the exocyst 
complex that helps to stabilize the attachment of TGN derived vesicles and their tethering to 
the plasma membrane267. Together with WASH, the exocyst complex has been identified as a 
crucial component for the “polarization and tethering of MT1-MMP-positive endosomes at 
the plasma membrane”229.  
Synaptophysin-like protein-1 is a scantily studied protein that resembles the neuronal 
Synaptophysin-1268. The latter is a known transmembrane component of synaptic vesicles that 
has been proposed to regulate the formation of SNARE complexes via interaction with 
VAMP2 and VAMP3269,270. Studies on SYPL1 have identified it as a component of cytoplasmic 
vesicles in non-neuronal cells and partially associated with GLUT4 in adipocyte cytoplasmic 
vesicles269.  
Their roles in vesicle tethering and SNARE complex formation suggest that both proteins 
might be necessary for MMP2 post-Golgi transport to the plasma membrane. However, the 
scope of this study will be limited to the understanding of the early trafficking of MMP2 and 
therefore further investigation on the role of EXOC5 and SYPL1 should be the focus of 
future studies. 
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7.3 Generation of CRISPR NUCB1 KO cells  
In order to establish tools to study the role of NUCB1 in MMP2 trafficking, a commercially 
available antibody was tested by confocal microscopy and Western blotting. For this purpose, 
HeLa cells were fixed and stained with NUCB1 antibody and the Golgi markers GM130 and 
TGN46. The images showed a strong co-localization between NUCB1 and the cis-Golgi 
marker GM130 but not the TGN marker TGN46, confirming the intracellular localization 
previously documented104,106 (Figure 39A). Also, HeLa cells were transfected with either a 
commercial NUCB1 siRNA (siNUCB1) or a mock siRNA (siControl) and evaluated for 
NUCB1 expression by Western blotting, which evidenced a decreased NUCB1 expression 
after double silencing for 48 h (Figure 39B). Given the moderate knock-down efficiency in 
HeLa cells, NUCB1-KO cell lines were generated (see below). 
 
Figure 39. Immunofluorescence and Western blot evaluation of NUCB1 antibody. (A) Confocal 
microscopy images show HeLa cells labeled with endogenous NUCB1 (green) and co-stained with 
the Golgi markers GM130 or TGN46 (red). NUCB1 colocalizes with the cis (GM130) but only 
partially with the trans (TGN46) fraction of the Golgi, as previously reported104. The square 
highlights the zoomed area. Scale bars: 5 µm. (B) HeLa cells were transfected with a commercial 
siRNA (siNUCB1) and analyzed by Western blotting after 48 h. A reduction in the expression of 
NUCB1 was observed in the silenced cells when compared to HeLa cells transfected with an 
siRNA mock (siControl). Β actin was evaluated as loading control. 
 
To evaluate the role of NUCB1 in the trafficking of MMP2, a CRISPR strategy to generate 
stable KO cells lines was used (Figure 40, for more details see materials and methods).  
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Figure 40. Evaluation of CRISPR candidates. The CRISPR-Cas9 system was used to generate 
CRISPR-KO cells of each candidate (NUCB1, EXOC5 and SYPL1) and selected clones were 
evaluated by Western blot and immunofluorescence. Once selected, MMP2 trafficking was 
analyzed in the positive KO clones using RUSH assays. 
sgRNAs targeting NUCB1 were designed to generate HeLa CRISPR KO cells using the 
platform from the Zhang Lab (not available online anymore271). Three different sgRNAs were 
selected according to a score value reporting the reliability of the sgRNA. Table 4 encompasses 
the selected sgRNAs, with their corresponding targeting sequence, as well as the score 
calculated by the Zhang Lab algorithm or the online available tool CRISPOR 
(http://crispor.tefor.net). A minimal score of 81 was accepted for selection.  
Table 4. sgRNAs used for the generation of CRISPR KO HeLa cells 
Gene Gene name 
Guide 
No. sgRNA sequence Score 
No. of 
Off-
targets 
NM_006184.6 NUCB1 
1 AGTCACCAAGAACGCACCGG 93 73 
2 GCTCCTGCTTCGCGCCGTGC 92 80 
3 AAGGACCTCCGGTGCGTTCT 94 38 
 
After cloning each oligonucleotide pair in a pSpCas9 vector and its subsequent transfection in 
HeLa cells, positive single clones were selected and evaluated by Western blot. Three positive 
NUCB1-KO clones were found using the sgRNA No. 2 (Figure 41A). These were later 
confirmed by immunofluorescence (Figure 41B) and clone g2-2-2 was selected as the NUCB1-
KO cell line to perform all the experiments presented in this work. 
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Figure 41. Confirmation of three NUCB1-KO clones in HeLa cells by Western blotting (A) and 
immunofluorescence (B). *: unspecific band. KO: HeLa KO cells, CN: HeLa control. The semi-
quantitative analysis of the Western blot shows the expression level of NUCB1 normalized by β -
actin. Scale bars: 5 µm. 
7.4 NUCB1-KO delays the trafficking of MMP2 
In order to examine the role of NUCB1 in MMP trafficking, RUSH experiments were 
performed using Hela control and NUCB1-KO cells. Briefly, cells were transfected with 
RUSH MMP2 constructs, incubated for 24 h, washed and incubated with biotin for 0, 15, 30 
and 45 min. Afterwards, cells were fixed, co-stained with NUCB1 antibody and evaluated using 
confocal microscopy (Figure 42A). The quantification of cytoplasmic vesicles showed a 
reduced vesicle number in NUCB1-KO cells at 30 min after biotin addition (median: 8, 
interquartile range: 3–26) when compared with HeLa control cells (median: 29 interquartile 
range: 17–52.75), indicating a delay in the trafficking of MMP2 when NUCB1 is absent (Figure 
42B). Importantly, this trafficking delay was rescued when cells re-expressed NUCB1-WT, 
showing similar cytoplasmic vesicle numbers as those observed for HeLa control cells (median: 
36.5, interquartile range: 17–51.75; Figure 42B). 
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Figure 42. Intracellular trafficking of MMP2 is delayed in NUCB1-KO cells. (A) HeLa or 
NUCB1-KO cells transfected with SS-MMP2-SBP-eGFP with or without NUCB1-WT were co-
stained with NUCB1 (red). Fluorescent images were captured after fixing cells at 0, 15, 30, and 45 
min of biotin incubation. Arrowheads point to cytoplasmic vesicles. Scale bars, 5 µm. (B) 
Cytoplasmic vesicle counts from at least 90 cells per condition are plotted as number of vesicles 
per cell. The medians of two independent experiments (±interquartile range) are plotted. 
Significant differences at p < 0.05. X-axis: time after biotin addition in minutes. *p < 0.05; **p < 
0.01; ***p < 0.001. 
To investigate the specificity of NUCB1 depletion on protein trafficking, the same experiment 
was performed using another cargo: RUSH LyzC. LyzC is a soluble protein cargo known to 
traffic through the secretory pathway and is sorted at the TGN in a Cab45-dependent 
manner95,96. Given the differences in trafficking kinetics, cells were incubated for 0, 20, 40 and 
60 min with biotin and subsequently fixed and analyzed by confocal microscopy (Figure 43A). 
LyzC reached the Golgi after 20 min of biotin addition in HeLa control cells and is sorted in 
cytoplasmic vesicles after 40 min. When the number of LyzC cytoplasmic vesicles was 
compared between HeLa control and NUCB1-KO cells, no significant difference was found 
(Figure 43B).  
 99 
 
Figure 43. NUCB1 does not alter the intracellular trafficking of LyzC. (A) HeLa or NUCB1-KO 
cells were transfected with LyzC-SBP-eGFP, fixed, co-stained with a NUCB1 antibody (red) and 
evaluated by confocal microscopy at 0, 20, 40, and 60 min after biotin addition. Arrowheads point 
to cytoplasmic vesicles. Scale bars, 5 µm. (B) Cytoplasmic vesicle counts from at least 42 cells per 
condition. The medians of two independent experiments (± interquartile range) are plotted. X-axis: 
time after biotin addition in min. n.s.: non-significant. 
Furthermore, RUSH experiments using Cathepsin D (a lysosomal hydrolase) showed also no 
differences in vesicle numbers between NUCB1-KO and HeLa control cells (Figure 44), 
suggesting a specific role for NUCB1 in the anterograde trafficking of MMP2. 
 
Figure 44. Cathepsin D trafficking is not affected by the absence of NUCB1. (A) HeLa or 
NUCB1-KO cells expressing SS-SBP-eGFP-Cathepsin D were fixed after 20, 40 and 60 min of 
biotin incubation and acquired  by confocal microscopy. Representative maximum Z-projection 
images show Cathepsin D trafficking from the Golgi to cytoplasmic vesicles (arrowheads). Scale 
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bars: 10 µm. (B) Quantification of cytoplasmic Cathepsin D vesicles from cells shown in (A). Data 
from more than 30 HeLa and NUCB1-KO cells per time point from two independent experiments 
were plotted as mean ± SD. Statistical analysis was performed using a non-parametric Kruskal-
Wallis test with Dunn’s multiple comparison test. No significant differences with p-values < 0.05 
were detected. 
Additionally, RUSH MMP2 secretion assays were performed in order to evaluate if such a 
delay in MMP2 trafficking could also influence the delivery of the protein to the extracellular 
milieu. For these experiments, HeLa control and NUCB1-KO cells were transfected with 
RUSH MMP2 or RUSH LyzC, washed after 24h and incubated with biotin for 0 and 45 min 
(RUSH MMP2 cells) or for 0 and 60 min (RUSH LyzC cells). A reduction in the amount of 
MMP2 was observed on the supernatant of NUCB1-KO cells when compared to HeLa 
control at 45 min after biotin incubation (Figure 45A, 45B). Moreover, the evaluation of 
secreted LyzC showed no reduction in the amount of protein detected on supernatants of both 
NUCB1-KO and HeLa control cells (Figure 45A, 45C), corroborating that LyzC trafficking is 
not affected by the absence of NUCB1. 
Figure 45. MMP2 secretion is reduced in NUCB1-KO cells. (A) Secretion assay using HeLa or 
NUCB1-KO cells transfected with SS-MMP2-SBP-eGFP or LyzC-SBP-EGFP and incubated with 
biotin for 45 or 60 min, respectively. Numbers on the left side of the blots indicate molecular 
weight in kDa. WCL: whole cell lysates. [SNs]: 10X concentrated supernatants. The supernatant 
band intensities were normalized by the lysates and a semi-quantitative analysis from three 
independent experiments is depicted in (B) for MMP2 and (C) for LyzC. 
Another cargo widely studied in the trafficking field is horse radish peroxidase (HRP)272,273. In 
order to evaluate if NUCB1 could have an effect on the trafficking of additional cargo, 
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secretion experiments were performed using Hela control and NUCB1-KO cells stably 
expressing SS-HRP-Flag. For this purpose, cells were first plated in 12-wells and incubated for 
24h. As positive control, a sample was incubated Brefeldin A (BFA, an inhibitor of 
anterograde protein trafficking) for 1h prior to the secretion assay. Afterwards, all samples 
were washed and incubated with fresh medium for 4h with (positive control) or without (HeLa 
control and NUCB1-KO cells) BFA. Finally, supernatants and lysates were evaluated by 
Western blot (Figure 46A) and HRP activity was quantified using a chemiluminescence assay 
(Figure 46B). These results showed no difference in SS-HRP secretion between HeLa control  
and NUCB1-KO cells, suggesting a specific effect on the trafficking of MMPs. 
Figure 46. HRP secretion is not affected by the absence of NUCB1. (A) Whole cell lysates of 
HeLa and NUCB1-KO cells stably expressing SS-HRP-FLAG were analyzed by anti-FLAG, anti-
NUCB1 and anti-β-actin Western blotting. SS-HRP-FLAG is expressed in HeLa and NUCB1-KO 
cells to similar levels. (B) Cell culture supernatants of cells described in (A) were analyzed for HRP 
activity by chemiluminescence after 4h secretion. Brefeldin A (BFA) serves as a positive control 
for perturbed secretion and was added for one hour before HRP secretion analysis. No significant 
differences in HRP secretion were observed between NUCB1-KO and HeLa control cells. *: p-
value < 0.05. Experiments performed by Dr. Mehrshad Pakdel. 
Given that HeLa cells are not constitutively secretory cells, the secretion of endogenous 
MMP2 was evaluated in a different cell system, the breast cancer cell line MDA-MB-231. To 
test MMP2 secretion, MDA-MB-231-MT1-MMP-mCherry cells were double transfected with 
either a mock siRNA (siControl) or one targeting NUCB1 (siNUCB1) in 24 h intervals. Then 
cells were carefully washed and incubated with serum-free medium for 20h. After this time, 
cells were lysed, and supernatants were collected and concentrated 20X using Amicon units. 
MMP2 secretion was evaluated by Western blot (Figure 47A), observing a strong reduction in 
its secretion in siNUCB1 cells when compared to siControl (Figure 47B). These results 
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corroborate our findings in HeLa cells and demonstrate that NUCB1 plays a crucial role in the 
trafficking of MMP2. 
 
 
Figure 47. Endogenous MMP2 secretion is also impaired in NUCB1-silenced MDA-MB-231-
MT1-MMP-mCherry cells. (A) Cells were incubated with serum-free media for 20h. When NUCB1 
was silenced, the secretion of endogenous MMP2 was reduced, confirming the role of NUCB1 in 
the trafficking of MMP2. (B) Semi-quantitative analysis of this assay. [SN]: 20X concentrated 
supernatant. WCL: whole cell lysates. Bar graphs illustrate the mean (± range) of three 
independent experiments. 
7.5 NUCB1-KO is also involved in the trafficking of MT1-MMP 
To assess if the absence of NUCB1 could affect the trafficking of other MMPs, MT1-MMP 
trafficking was analyzed. Given that this is a transmembrane protein and could have alternative 
sorting pathways, an evaluation of its intracellular trafficking was performed using performed 
using an mCherry-tagged RUSH construct (Figure 48A) and transfected in HeLa control and 
NUCB1-KO cells.  
After biotin incubation, cells were fixed and evaluated using confocal microscopy. HeLa 
control cells showed different trafficking kinetics than the ones observed of MMP2: MT1-
MMP reaches the Golgi only after 30 min of biotin incubation and is sorted into cytoplasmic 
vesicles after 60 min (Figure 48B). Additionally, an increase in the number of MT1-MMP 
positive vesicles traveling to the plasma membrane is observed at 90 min, although, unlike 
MMP2, a strong signal remains at the Golgi at this time point (Figure 48B).  
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Figure 48. MT1-MMP intracellular trafficking is also delayed in the absence of NUCB1. MT1-
MMP trafficking was evaluated using the mCherry (mCh) tagged RUSH construct SS-MT1-MMP-
SBP-mCh illustrated in (A). SS: signal sequence. Cyto: cytosolic domain. (B) Confocal fluorescence 
images of HeLa or NUCB1-KO cells transfected with or without NUCB1-WT and fixed after 30, 
60, and 90 min of biotin incubation. Arrowheads depict cytoplasmic vesicles. Scale bars: 5 µm. (C) 
Quantification of cytoplasmic vesicles observed in (B) from at least 24 cells from two independent 
experiments. The bars represent median (± interquartile range). X-axis: time in minutes after biotin 
addition. ***p < 0.001. n.s.: non-significant. 
Moreover, the quantification of cytoplasmic vesicles showed a decrease in vesicle number at 60 
min after biotin addition in NUCB1-KO cells (median, 2.5; interquartile range, 0.25–7) when 
compared to HeLa control (median, 10; interquartile range, 4–36), and this phenotype could be 
restored when NUCB1-WT was re-expressed in NUCB1-KO cells (median, 13; interquartile 
range, 7.5–21; Figure 48C). These results evidence a role of NUCB1 in MT1-MMP intra-Golgi 
trafficking and highlight NUBC1 as a key component for MMP trafficking in general.  
7.6 NUCB1 alters exclusively the intra-Golgi trafficking of MMP2 
To determine where in the secretory pathway the observed delay took place, co-localization 
experiments using RUSH MMP2 and ER, cis- and trans-Golgi markers were performed in HeLa 
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control and NUCB1-KO cells (Figure 49). Co-localization of MMP2 with ERGIC53 (an ER-
to-Golgi marker) is not significantly different between NUCB1-KO and HeLa control cells at 
2.5, 5 and 7 min after biotin addition, excluding a trafficking delay due to ER retention of 
MMP2 (Figures 49A and 49B).  
 
Figure 49. MMP2 trafficking delay occurs exclusively at the cis-Golgi. (A) Fluorescence images 
depicting HeLa or NUCB1-KO cells transiently transfected with SS-MMP2-SBP-eGFP and fixed 
after 2.5, 5, and 7.5 min after biotin addition. Cells were co-stained with an ER marker (ERGIC53, 
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red). Scale bars, 5 µm. (B) Average Pearson’s coefficient per time point. No significant differences 
between the correlation coefficients of HeLa or NUCB1-KO cells per time point were found, 
suggesting that MMP2 trafficking is not impaired at the ER level. (C) Fluorescence images showing 
the colocalization of MMP2 with the cis-Golgi marker GM130. HeLa or NUCB1-KO cells 
expressing SS-MMP2-SBP-eGFP were fixed at 10, 15, 20, and 25 min after biotin addition. Scale 
bars, 5 µm. (D) Average Pearson’s correlation coefficients illustrate a decreased colocalization of 
MMP2 with GM130 at 10, 15, and 20 min after biotin addition. This difference disappeared at 25 
min after biotin addition, suggesting that after this point, MMP2 traffics with the same kinetics in 
both NUCB1-KO and HeLa cells. (E) Fluorescence images of HeLa and NUCB1-KO cells 
expressing SS-MMP2-SBP-eGFP. Cells were fixed at 20, 25, 30, 35, and 40 min after biotin 
addition and co-stained with TGN46 (red). Scale bars, 5 µm. (F) The average Pearson’s coefficient 
shows that after arrival at the trans-Golgi network (TGN), MMP2 is equally colocalizing with 
TGN46 in HeLa and NUCB1-KO cells. PC, Pearson’s correlation coefficient of each picture. *p < 
0.05; **p < 0.01; ***p < 0.001. At least 17 cells per time point were evaluated for colocalization 
with each marker. Experiments performed together with Dr. Mehrshad Pakdel. 
Further evaluation of the cis- and trans-Golgi markers (GM130 and TGN46, respectively) 
showed an exclusive intra-Golgi trafficking defect. Figure 49C illustrates the co-localization of 
GM130 and MMP2-eGFP, with a significant reduction in the signal overlap after 10, 15 and 20 
min of biotin incubation (Figure 49D). Moreover, the co-localization with TGN marker 
TGN46 was lower in NUCB1-KO cells only at 20 and 25 min after biotin addition, suggesting 
that the defect in trafficking occurs exclusively from cis to trans-Golgi (Figure 49E and 49F).  
To precisely determine the point at which this delay occurs, wide field live-cell microscopy was 
used (experiments performed by Dr. Mehrshad Pakdel). Here, HeLa control and NUCB1-KO 
cells were analyzed using the RUSH construct in 1 min time frames (Figure 50). After data 
collection, both number of vesicles and ER-to-Golgi signal ratio were analyzed. In the first 30 
min of biotin incubation, no differences in vesicle numbers were found, as expected since at 
this time MMP2 arrives and traffics through the Golgi (Figure 50A). However, in the time 
frame between 30 and 44 min of biotin incubation, a significantly reduced number of vesicles 
is observed in NUCB1-KO cells (Figure 50B). This difference, nonetheless, disappeared after 
45 min of biotin incubation, supporting our hypothesis of a delay exclusively at the Golgi. 
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Figure 50. Kinetic evaluation of MMP2 RUSH trafficking using live cell microscopy. (A) HeLa or 
NUCB1-KO cells expressing SS-SBP-MMP2-eGFP were analyzed by live-cell wide-field 
microscopy. Representative images show MMP2 trafficking at 0, 30, 35, and 40 min after biotin 
addition for one control and one NUCB1-KO cell. Images were acquired in 1 min frames for each 
analyzed cell. Arrowheads point to cytoplasmic MMP2 vesicles. Scale bars: 10 µm. (B) 
Quantification of cytoplasmic MMP2 vesicles per frame from cells shown in (A). Data from 17 
HeLa and 22 NUCB1-KO cells from two independent experiments were plotted as median ± 
interquartile range. Kruskal–Wallis test with Dunn’s multiple comparison evidenced significant 
differences with p-values < 0.05. n.s.: non-significant. *:p-value < 0.05. (C) Schematic 
representation of ER–Golgi cargo transport analysis, measured by normalized Golgi area over time 
in cells shown in (A). (D) Normalized Golgi area for 15 control and 17 NUCB1-KO cells were 
plotted for each time point as median ± interquartile range. An increased normalized Golgi area in 
the time range 15 to 18 min observed on NUCB1-KO cells when compared with HeLa control 
suggests a delay in trafficking occurring exclusively at the cis-Golgi. A significant difference at t = 
22 min (*: p-value < 0.05) was documented using the non-parametric Mann–Whitney test. 
MMP2 showed a spotty signal in the ER before biotin addition that may lead to an 
underestimation of the vesicle numbers. To avoid such a bias, an ER-to-Golgi signal ratio was 
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calculated as depicted in Figure 50C. Here, the Golgi area was defined by measuring the Golgi 
area at each time frame and normalizing by the ER area at the time 0. At least 15 cells were 
evaluated per time point during 45 min of biotin incubation, finding a significant difference 
between NUCB1-KO and HeLa control cells only between 19 and 24 min, i.e. after the 
protein has already reached the Golgi (Figure 50D). Furthermore, this difference is abolished, 
after 25 min of biotin incubation, showing once more that the delay occurs only in the 
trafficking from cis to trans-Golgi. 
Although NUCB1 is considered to play its main role at the cis-Golgi, a cytosolic version of the 
protein has been shown to interact with G-protein and lysosomal receptors, affecting their 
activation and endosomal trafficking, respectively113,120,121. To evaluate if MMP2 trafficking was 
exclusively influenced by the NUCB1 Golgi resident version, a RUSH experiment using 
MMP2-eGFP co-transfected with the cytosolic version of NUCB1 (NUCB1-cyto, lacking the 
first 26 amino acids from the signal sequence) was performed in NUCB1-KO cells (Figure 
51A). As expected, the number of vesicles at 30 min after biotin addition is reduced in 
NUCB1-KO cells (Figure 51B). In comparison, cells re-expressing NUCB1-cyto showed a 
similar phenotype, indicating that NUCB1-cyto cannot rescue the phenotype and confirming 
once more that this delay happens exclusively at the Golgi.  
 
Figure 51. Cytosolic NUCB1 does not affect the trafficking of MMP2. HeLa or NUCB1-KO cells 
expressing SS-SBP-MMP2-eGFP alone or co-expressed with a cytosolic variant of NUCB1 lacking 
its signal sequence were fixed after 0, 15, 30 and 45 min of biotin incubation and acquired in z-
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stacks by confocal microscopy. Representative maximum Z-projection images show MMP2 
trafficking from the ER to cytoplasmic vesicles (arrowheads). Scale bars: 10 µm. (F) Quantification 
of cytoplasmic MMP2 vesicles from cells is shown in (F). Data from at least 18 HeLa and NUCB1-
KO cells per time point from 2 independent experiments were plotted as mean ± SD. Significant 
differences with p-values < 0.05 were obtained after analysis via non-parametric Kruskal-Wallis 
test with Dunn’s multiple comparison. Experiments performed by Dr. Mehrshad Pakdel. 
7.7 NUCB1 interacts with MMP2 
To further elucidate how NUCB1 is influencing MMP2 trafficking, the interaction between 
both proteins was evaluated via different approaches. The first approach was performing co-
immunoprecipitations overexpressing one of the proteins with a tag and pulling it down. For 
this purpose, HeLa control, NUCB1-KO and NUCB1-KO cells re-expressing NUCB1-WT-
myc were transfected with a pLPCX-Flag-MMP2-HA-eGFP construct. After 24 h incubation, 
cells were lysed and MMP2 was pulled down via its GFP tag using the GFP-Trap® system. 
After centrifugation and elution of protein with Laemmli buffer, the interaction with NUCB1 
was evaluated by SDS-PAGE and Western blot (Figure 52A). A weak interaction was observed 
between NUCB1 and MMP2 in control and NUCB1-KO cells re-expressing NUCB1-myc 
(Figure 52). 
 
Figure 52. Endogenous NUCB1 co-immunoprecipitated with overexpressed MMP2-eGFP. HeLa 
control (CN) or NUCB1-KO (KO) cells transfected with SS-Flag-MMP2-HA-eGFP (MMP2-
eGFP) with or without re-expression of NUCB1-WT-myc were processed for GFP-pull down and 
Western blot analysis. MMP2 interacts with both endogenous NUCB1 and re-expressed NUCB1-
WT in NUCB1-KO cells. Semi-quantitative analysis of the IP signal from two independent 
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experiments is illustrated in (B). CN: HeLa cells. KO: HeLa NUCB1-KO cells. Molecular weights 
are indicated on the left side of the blots. 
To evaluate if this interaction is specific for MMP2, the same approach was used 
immunoprecipitating LyzC-eGFP. As expected, no interaction between endogenous NUCB1 
and overexpressed LyzC was observed in HeLa cells (Figure 53A). Here is important to note 
that during the optimization of this method, NUCB1 re-expression in NUCB1-KO cells 
showed very high expression levels compared to the endogenous protein in HeLa control cells, 
which might explain the high ratio intensity observed in NUCB1-KO cells overexpressing 
NUCB1-WT (Figure 53B).  
 
Figure 53. LyzC does not interact with endogenous NUCB1. (A) GFP-co-immunoprecipitation 
of HeLa or NUCB1-KO cells previously transfected with LyzC-eGFP, with or without NUCB1-
WT. GFP-HA was used as a control. Western blotting showed no interaction between endogenous 
NUCB1 and LyzC or GFP-HA. CN: HeLa control, KO: NUCB1-KO. Semi-quantitative analysis 
of the IP signal intensity from three independent experiments is shown in (B). Bars depict mean 
and whiskers represent range of data.  
To evaluate which domain of MMP2 would be interacting with NUCB1, co-
immunoprecipitation experiments were performed using deletion mutants of the catalytic 
domain (delCD) and hemopexin domain (delHpex) of MMP2 (Figure 54A). Initially, the 
evaluation was made with endogenous NUCB1 (data not shown) but given the weakness of 
the interaction with the MMP2-eGFP full length, new experiments overexpressing NUCB1 
together with the corresponding eGFP construct were performed. Nevertheless, the 
interaction is not lost after deletion of any of these MMP2 domains (Figure 54B). 
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Figure 54. Co-immunoprecipitation of overexpressed MMP2 deletion mutants and overexpressed 
NUCB1. (A) Illustration of the truncation mutants used for evaluation of specific MMP2 domain 
interaction with NUCB1. MMP2: full length protein; MMP-delCD: MMP2 with truncated catalytic 
domain; and MMP2-delHpex: MMP2 with truncated hemopexin domain. (B) GFP 
immunoprecipitation analysis by Western blot showed no loss of the interaction with 
overexpressed NUCB1-WT, suggesting that neither the catalytic nor the hemopexin domain are 
essential for it.  
In order to evaluate if, specifically, the propeptide domain of MMP2 was essential for the 
interaction with NUCB1, experiments using propeptide domain mutants of MMP2 were 
performed. Given that this domain is critical for the inactivation of the protein, two different 
constructs were designed to evaluate the interaction: the first one with a complete deletion of 
the propeptide domain, and the second one with a Cys>Ala substitution at the cysteine switch 
that controls the activation of the protein (Figure 55A). Once again, the co-
immunoprecipitation of NUCB1 with either the propeptide deletion or substitution mutant of 
MMP2, showed no loss of interaction (Figure 55B).  
 
A
B
IP: GFP-tag
10% Input IP
GFP-HA
NUCB1-WT
MMP2-Full
l
l
l
l
l
l
l
l
l
l
130 kDa
100 kDa MMP2-
eGFP70 kDa
GFP-HA35 kDa
NUCB1
55 kDa
70 kDa
l ll ll l
MMP2-delCD
MMP2-delHpex
SS PropeptideFLAG HA eGFPHpexMMP2-delCD
SS PropeptideFLAG Catalytic Domain HA eGFPMMP2-delHpex
SS PropeptideFLAG Catalytic Domain HA eGFPHpexMMP2-Full
 111 
 
Figure 55. Co-immunoprecipitation of MMP2-eGFP mutants with truncated propeptide domain 
or substitution at the cysteine switch. (A) Schematic representation of the propeptide domain 
mutants used to evaluate interaction with NUCB1. MMP2-delProp: MMP2 with truncated 
propeptide domain; MMP2-C>A: MMP2 full length with a C>A (red) substitution at the cysteine 
switch (sequence in green), required for activation of MMP2. (B) Evaluation of the co-
immunoprecipitation of MMP2 propeptide mutants and overexpressed NUCB1 showed that 
neither the complete propeptide domain nor the cysteine switch motif are essential for the 
interaction of MMP2 with NUCB1. 
To further strengthen the obtained results, a different approach using recombinant proteins 
and Golgi membranes was used (see materials and methods). For this purpose, recombinant 
NUCB1-His (rNUCB1-His) was produced using the piggyBac system. First, a cassette 
containing NUCB1 6xHis-tagged C-terminally was cloned in a pB-T-PAF vector and 
transfected, together with pB-RN and pBvase vectors, in HEK293T cells to generate stable 
cell lines. Then, protein production was induced by incubation of the cells with doxycycline 
and aprotinin in serum-free media. After at least 20 h starvation, supernatants were collected 
and rNUCB1-His was purified using immobilized Nickel NTA (NiNTA) beads.  
Protein production was analyzed by SDS-PAGE (Figure 56A) and Western blot (Figure 56B). 
In addition, rNUCB1-His was analyzed by total mass, showing a peak at 53.144 kDa, as 
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expected (Figure 56C). Other peaks with higher molecular weights reflect reported 
phosphorylation and glycosylation sites. Notably, analysis of the NUCB1 sequence evidenced 
that the purified protein lacked the signal sequence, as expected for secreted proteins that 
traffic through the secretory pathway, and described previously for NUCB1106.  
 
Figure 56. Evaluation of His-tag purification of recombinant NUCB1 produced in HEK293T 
cells using the piggy-BAC system. (A) Coomassie stained SDS-PAGE and (B) Western blot 
analysis of the elution fraction (line 4 of Figure 56A). (C) Total mass analysis using microTOF. 
The above panel displays the chromatogram of rNUCB1-His and illustrates the purity of the eluted 
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sample. The lower panel shows the mass spectrometry peak of absorbance for rNUCB1-His. 
Analysis performed by the Core Facility of the Max Planck Institute of Biochemistry. 
To evaluate the interaction of rNUCB1-His with endogenous MMP2, co-immunoprecipitation 
experiments were performed using recombinant GFP-His (rGFP-His) as control. Briefly, the 
recombinant proteins were bound to Ni-NTA beads, washed and incubated with Golgi 
membranes, previously isolated from Hela control cells and lysed with IP buffer, as described 
in the materials and methods section. The interaction was evaluated by Western blot (Figure 
57A) and showed a band corresponding to endogenous MMP2 when rNUCB1-His, but not 
rGFP-His, was pulled down. Three replicates of this experiments confirm the interaction 
(Figure 57B) and strengthen our hypothesis that both proteins interact specifically at the Golgi. 
 
Figure 57. Recombinant NUCB1-His interacts with endogenous MMP2 at the Golgi in HeLa 
cells. (A) His-tag pull down of recombinant NUCB1 (rNUCB1-His) using recombinant GFP 
(rGFP-His) as control. Endogenous MMP2 from isolated Golgi membranes of HeLa cells co-
immunoprecipitated with rNUCB1-His but not with rGFP-His, confirming the interaction 
between both molecules. Molecular weights are shown on the left side of the blots. Semi-
quantitative analysis of the IP signal of three independent experiments is shown in (B). Columns 
on semi-quantitative analysis show mean and bars represent the range of data points. IP pictures 
shown in (A) are the specular image of the photographed blot.  
Furthermore, to determine if such interaction is direct, recombinant MMP2 N-terminally 
tagged with His-SUMO was produced and purified using the same system described for 
rNUCB1-His. After evaluation by Western Blot (Figure 58A), the purity of the protein was 
also confirmed via total mass, finding a peak of absorbance around 88 kDa, as expected; the 
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different peaks around this molecular weight represent glycosylation and phosphorylation sites 
of the protein (Figure 58C). After peptide sequence confirmation using mass spectrometry, 
His-SUMO-MMP2 was conjugated with a Cy3 fluorophore via maleimide labelling with a 20% 
labelling efficiency (Figure 58B). 
 
Figure 58. His-SUMO-MMP2 production and labeling. (A) Western blot analysis of purified His-
SUMO-MMP2 using MMP2 antibody. (B) UV-Vis spectra of Cy3 labeled His-SUMO-MMP2 via 
maleimide labelling. The peaks represent the maximum absorbance peak for the protein (at 280 
nm) and the maximum peak for the dye (at 532 nm). These values were used to calculate the 
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labelling efficiency, as previously described274. (C) Total mass analysis using microTOF. The above 
panel displays the chromatogram of unlabeled rHis-SUMO-MMP2 and illustrates the purity of the 
eluted sample. The lower panel shows the mass spectrometry peak of absorbance for unlabeled r-
His-SUMO-MMP2. Analysis performed by the Core Facility of the Max Planck Institute of 
Biochemistry. 
Then, to evidence a direct interaction with NUCB1, Cy3-labelled-His-SUMO-MMP2 was 
analyzed by analytical ultracentrifugation (AUC) alone (Figure 59B) or in the presence of 
unlabeled rNUCB1-His (Figure 59A). Although further characterization is required, the 
obtained results showed a peak of sedimentation at 4.705 S with a measured Stokes Radius 
(20˚C) of 4.41 nm and a calculated molecular weight of 87.1 kDa for His-SUMO-MMP2, 
which ties with the expected molecular weight. This sedimentation peak shifts towards 3.189 S 
in the presence of rNUCB1-His, with a concomitant increase in the Stokes Radius (20˚C) of 
8.41 nm and a predicted molecular weight of 117 kDa, close to the expected theoretical one 
for the protein complex. This analysis strongly indicates that both proteins interact directly. 
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Figure 59. Analytical ultracentrifugation analyses strongly suggest a direct interaction between 
recombinant NUCB1 and recombinant MMP2. (A) Recombinant His-SUMO-MMP2 was bio-
conjugated with Cy3 via maleimide labeling and subsequently analyzed by analytical 
ultracentrifugation (AUC). The lowest panel shows peak of sedimentation of rHis-SUMO-MMP2 
at 4.705S. (B) AUC profile of rHis-SUMO-MMP2-Cy3 and NUCB1-His. The lowest panel shows 
a peak at 3.189S, indicating a change in the sedimentation velocity associated to a direct interaction 
of NUCB1 and MMP2. These experiments were performed by the Core Facility of the Max Planck 
Institute of Biochemistry. 
Given that NUCB1 influences also MT1-MMP trafficking, I decided to evaluate if an 
interaction between both proteins is also taking place.  For this purpose, HeLa control and 
NUCB1-KO cells were transiently transfected with a pLPCX-MT1-MMP-pHluorin construct, 
incubated for 24 h, lysed and MT1-MMP was immunoprecipitated via its pHluorin tag using 
GFPtrap®. The presence of NUCB1 in the protein complex was evaluated via Western 
blotting (Figure 60A), evidencing an interaction between MT1-MMP-mCherry and 
endogenous NUCB1 (Figure 60A, 60B). This result indicates that, as well as with MMP2, both 
proteins interact at the Golgi. 
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Figure 60. MT1-MMP interacts with NUCB1. (A) GFP co-immunoprecipitation of MT1-MMP-
pHluorin and NUCB1. HeLa or NUCB1-KO cells transiently expressing MT1-MMP-pHluorin 
with or without the expression of NUCB1-WT were pulled down via GFP and evaluated by 
Western blotting. NUCB1 interacts with MT1-MMP but not with the GFP control. CN: HeLa 
control. KO: NUCB1-KO cells. Semi-quantitative analysis of three independent experiments is 
depicted in (B). 
7.8 NUCB1 Ca2+ binding domains are necessary for the trafficking 
of MMP2 
Ca2+ is known to exert a critical function in the trafficking of proteins and one of the main 
functions of NUCB1 is to maintain the Ca2+ homeostasis at the cis-Golgi9,95,107,108. In particular, 
NUCB1 binds Ca2+ via its EF-hand domains and previous reports have documented the 
importance of the NUCB1 EF-hand motifs in Ca2+ storage and protein-protein 
interactions108,275. 
To evaluate the role of Ca2+ in the trafficking of MMP2, three NUCB1 EF-hand mutants 
were generated by substitution of the last amino acid of each EF-hand domain (Figure 61A). A 
glutamate (E) was substituted by a glutamine (Q) in either the first (mEFh1), the second 
(mEFh2) or in both EF-hand domains (mEFh1+2).  
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Figure 61. MMP2-NUCB1 interaction is reduced or lost when EF-hand domains of NUCB1 are 
mutated. (A) Protein model adapted from PDB: ref. 1SNL; the pictures depict only the EF-hand 
domains of NUCB1 (cyan). NUCB1-WT depicts the WT EF-hand domains of NUCB1 with the 
first (D) and last (E) amino acid of the domain in dark blue. NUCB1-mEFh1+2 shows the amino 
acid substitutions E264Q and E316Q in pink. (B) Co-immunoprecipitation of MMP2-eGFP 
transiently expressed in NUCB1-KO cells transfected with or without NUCB1-WT, NUCB1-
mEFh1, NUCB1-mEFh2, NUCB1-mEFh1+2 and GFP–HA. When either one or both NUCB1-
EFh motifs are mutated, the interaction with MMP2 is reduced or lost. The picture is 
representative of at least three biological replicates, and their semi-quantitative analysis is depicted 
in (C). Bars on the graph represent mean ± SD. 
Then, co-immunoprecipitation experiments were performed using NUCB1-KO stable cell 
lines re-expressing the mEFh1, mEFh2 or mEFh1+2 mutants. For this purpose, NUCB1-KO 
cells were transiently transfected with pLPCX-Flag-MMP2-HA-eGFP and either pLPCX-
NUCB1-mEFh1, pLPCX-NUCB1-mEFh2, pLPCX-NUCB1-mEFh1+2 or pLPCX-NUCB1-
WT. After pulling down MMP2 using GFPtrap® as previously described, Western blot 
analysis showed that the interaction of MMP2 and NUCB1 is highly reduced when any of the 
domains is mutated (Figure 61B).  
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Furthermore, to evaluate the effect of the mutations on the NUCB1 EF-hand mutations on 
the trafficking dynamics of MMP2, stable cell lines expressing each of the EF-hand mutants 
(NUCB1-mEFh) were generated. HeLa control, NUCB1-KO, NUCB1-mEFh mutants and 
NUCB1-KO cells re-expressing NUCB1-WT (NUCB1-KO+NUCB1-WT) were then 
transiently transfected with RUSH MMP2, incubated with biotin for 0, 15, 30 and 45 min, 
fixed and co-stained with NUCB1 antibody.  
 
Figure 62. NUCB1 EF-hand motifs are required for the proper intracellular trafficking of MMP2. 
(A) Confocal fluorescence images depict the expression of SS-MMP2-SBP-eGFP in HeLa or 
NUCB1-KO cells co-expressing or not NUCB1-WT or NUCB1-mEFh1+2. After 15, 30, and 45 
min of biotin incubation, cells were fixed and co-stained with NUCB1 antibody (red). Scale bars: 5 
µm. White arrowheads point to cytoplasmic vesicles. (F) Quantification of cytoplasmic vesicles 
shows the medians (± interquartile range) of at least 19 cells per condition from two independent 
experiments. Statistical evaluation was performed via the Kruskal–Wallis non-parametric test with 
Dunn’s multiple comparison of groups. X-axis: time in minutes after biotin addition. *p < 0.05, 
**p < 0.01, ***p < 0.001. These experiments were performed together with Dr. Birgit Blank. 
Evaluation by confocal microscopy showed a delay in MMP2 trafficking in NUCB1-mEFh 
cells (Figure 62A) and further quantitative evaluation evidenced a reduced number of MMP2-
 120 
eGFP cytoplasmic vesicles at 30 min after biotin addition, similar to the one observed in 
NUCB1-KO cells (median mEFh1+2: 20, interquartile range: 8.5 – 42; median KO: 27, 
interquartile range: 12 – 51) and significantly lower when compared to HeLa control (median: 
65, interquartile range: 41 – 93) or NUCB1-KO+NUCB1-WT cells (median: 45, interquartile 
range: 36 – 74; Figure 62B). These results denote the importance of Ca2+ for the proper 
trafficking of MMP2. 
To further evaluate how Ca2+ impacts the conformation and stability of NUCB1, a His-tagged 
recombinant NUCB1 with the described mutation in both EF-hand domains was generated as 
described earlier in this section (rmEFh1+2-His, Figures 63A, 63B) and, together with 
rNUCB1-His, analyzed by circular dichroism (CD). A comparison of both CD spectra showed 
a reduced molar ellipticity of the mutant when compared to rNUCB1-His (Figure 63C).  
 
Figure 63. NUCB1 loses its Ca2+ binding ability when EF-hand motifs are mutated. CD 
measurement of recombinant NUCB1-His and the recombinant mutant mEFh1+2-His under 
presence or absence of 1 mM Ca2+. rNUCB1-His shows a highly α-helical structure that acquires 
a more compact conformation in the presence of Ca2+. When EFh1+EF2 domains are mutated, 
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the protein acquires a structure with higher β-sheet content that is not sensitive anymore to Ca2+ 
addition. 
CD spectra analysis using CONTIN259 evidenced an increased α-helicity in rNUCB1-His upon 
Ca2+ addition (from 0.385 to 0.413) that was not observed for the EF-hand binding mutant. 
Instead, the values obtained from the CONTIN algorithm showed a decrease in α helicity 
upon Ca2+ addition (from 0.256 to 0.147) together with an increase in β-sheet content, 
indicating a shift towards a more unstable state with loss of secondary structure, and 
confirming previous reports that found that the EF-hand motifs of NUCB1 have an open 
conformation that folds only after Ca2+ addition108,117,275.  
 
Figure 64. Ca2+ influx is reduced at the cis-Golgi in the absence of NUCB1. (A) Fluorescent 
images depict HeLa or NUCB1-KO cells expressing the GPP130-Twitch5 cis-Golgi Ca2+ sensor. 
The cells were previously treated with ionomycin for 20 seconds to deplete endogenous Ca2+ at 
the Golgi lumen. Then, 2.2mM Ca2+ were added and the cells were monitored using live-cell 
ratiometric FRET microscopy. The ∆R/R0 FRET ratio (R0: FRET value before addition of 
2.2mM Ca2+) was lower in NUCB1-KO cells compared with HeLa control, indicating the leaking 
of Ca2+ at the cis-Golgi in the absence of NUCB1. (B) Quantification of the cis-Golgi ∆R/R0 
FRET ratio. Both NUCB1-KO cells with or without expression of NUCB1-mEFh1+2 showed a 
reduced Ca2+ influx using the GGP13’-Twitch5 cis-Golgi Ca2+ sensor. Statistical evaluation was 
performed using the Mann–Whitney test. ***p < 0.001, n.s.: not significant. The color code in 
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Figure 64A indicates the ∆R/Ro in % at the cis-Golgi at a specific time point. Experiments 
performed by Dr. Mehrshad Pakdel. 
To deepen into the understanding of the role of NUCB1 in Ca2+ homeostasis, experiments 
using a Fluorescence Resonance Energy Transfer (FRET) Ca2+ sensor for both the cis- and 
the trans-Golgi were performed. For this purpose, both HeLa control, NUCB1-KO cells were 
transiently transfected with the FRET sensors GPP130-Twitch5, localized at the cis-Golgi or 
GoD1-cpv, at the trans-Golgi. After 24 h incubation, Ca2+ was depleted from the intracellular 
acidic compartments with ionomycin and Ca2+ influx was evaluated using live-cell ratiometric 
FRET microscopy. Quantification of FRET efficiency was then calculated as the ratio of 
FRET intensity ∆R/Ro, where ∆R represents the ratio between YFP and CFP intensities at any 
time point, and Ro is the fluorescence intensity of CFP at time 0. 
 
Figure 65. Trans-Golgi Ca2+ influx is not altered in NUCB1-KO cells. (A) Fluorescent images 
illustrate the same experiment described in Figure 64 but using the Go-D1-cpv trans-Golgi Ca2+ 
sensor. (B) Quantification of the trans-Golgi ∆R/R0 FRET ratio showed no difference in Ca2+ 
influx between HeLa control and NUCB1-KO. Quantification was performed with values of at 
least 20 cells and shows the medians (± interquartile range) from at least two different 
experiments. Statistical evaluation was performed using the Mann–Whitney test. n.s.: not 
significant ***p-value<0.001. The color code in (A) indicates the ∆R/Ro in % at the trans-Golgi at 
a specific time point. Experiments performed by Dr. Mehrshad Pakdel. 
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Microscopy images showed an increase in Ca2+ concentration at the cis-Golgi in HeLa control 
cells at 160 sec after 2.2 mM Ca2+ addition to the media (Figure 64A). Contrasting, the signal 
intensity in NUCB1-KO cells was lower than the one registered for control cells, indicating 
that in the absence of NUCB1 the Ca2+ influx to the cis-Golgi is impaired (Figure 64B).  
Furthermore, evaluation of Ca2+ influx in NUCB1-KO cells expressing the mEFh1+2 did not 
restore the phenotype, whereas the ratio of FRET intensity in NUCB1-KO+NUCB1+WT 
cells was similar to the one observed in HeLa control cells. Altogether, these results 
demonstrate that not just the absence of NUCB1, but a single point mutation in its EF-hand 
domains, is enough to impair Ca2+ homeostasis at the cis-Golgi. 
Instead, observations made at the trans-Golgi showed no differences in Ca2+ influx between 
NUCB1-KO and HeLa control cells, strongly indicating that NUCB1 impairs Ca2+ influx 
exclusively at the cis-Golgi (Figure 65A, 65B). Altogether, these results suggest that MMP2 
trafficking is delayed at the cis but not the trans-Golgi of NUCB1-KO cells due to an 
impairment of Ca2+ retention and homeostasis alteration caused by the Ca2+ binding 
incapability of NUCB1.  
7.9 NUCB1-KO impairs matrix degradation in human macrophages 
and cell invasion in MDA-MB-231 cells 
To address the physiological role of the impaired traffic of MMP2 in the absence of NUCB1, 
matrix degradation and invasion experiments were performed in collaboration with the groups 
of Dr. Angelika Haußer in Stuttgart and Prof. Dr. Stefan Linder in Hamburg.  
 
Figure 66. Silencing of MDA-MB-231 cells. (A) Western blot depicts the reduction in expression 
levels of NUCB1 in silenced cells from three independent experiments (R1, R2, and R3). *: 
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unspecific band. GAPDH was used as loading control. Semi-quantitative analysis of silencing is 
depicted in (B). (C) qPCR analysis to evaluate MMP2 reduced relative expression upon silencing in 
MDa-MB-231-MT1-MMP-mCherry cells.  
For this purpose, two different models were studied: the Haußer group evaluated the behavior 
of MDA-MB-231-MT1-MMP-mCherry cells using Matrigel cell invasion and gelatin 
degradation analyses, while the Linder group studied gelatin degradation of primary human 
macrophages. NUCB1 (siNUCB1, Figure 66A, 66B) or MMP2 (siMMP2, Figure 66C) were 
silenced in MDA-MB-231-MT1-MMP-mCherry cells using 2 different siRNAs.  
After 72 h transfection, cells were seeded in transwell inserts on top of Matrigel® (to evaluate 
cell invasion) or on top of fluorescently labeled gelatin (to evaluate matrix degradation). After 
24 h incubation, invading cells were evaluated by microscopy, showing that siNUCB1 cells 
migrated to a less extent compared with siControl (Figure 67A, 67B). Moreover, such behavior 
resembled the one observed when siMMP2 is silenced, indicating that the reduced expression 
of NUCB1 in this cell model impaired the matrix invasion of cancer cells (Figure 67B).  
 
Figure 67. Matrix invasion and degradation are impaired in MDA-MB-231 cells when NUCB1 is 
silenced. Three days post-transfection cells were seeded on (A) Matrigel-coated transwell inserts 
and allowed to invade for 24 h or (C) on Oregon488-conjugated gelatin and allowed to degrade for 
5 h. Cells were fixed and either stained with crystal blue (for the invasion assays) or nuclei 
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counterstained with DAPI (for the gelatin degradation assays). (B) Quantification of the number of 
cells migrating through the Transwell or (D) degraded gelatin showed a marked reduction in 
NUCB1 siRNA-treated cells in both Matrigel invasion and gelatin degradation. Two different 
siRNAs were used to confirm the reduction. Data are presented as median ± interquartile range 
from 3 independent experiments. n.s.: not significant *p <0.05, **p  < 0.01, ***p  < 0.001. 
Statistical significance was evaluated via the Kruskal–Wallis test with Dunn’s multiple comparison 
of groups. Experiments performed by the Haußer group. 
Matrix degradation was evaluated by gelatinolytic assays using both MDA-MB-231-MT1-
MMP-mCherry cells (Figures 67C, 67D) and primary human macrophages (Figure 68). The 
results showed an impaired capacity to degrade gelatin in both cell models when NUCB1 
expression is reduced. Such degradation levels are comparable to the ones observed on MMP2 
silenced cells, strongly suggesting that NUCB1 plays a fundamental role in the overall 
trafficking of MMPs and that its presence is crucial for MMP2 mediated cell migration and 
matrix invasion.  
 
Figure 68. Gelatin degradation is impaired in NUCB1 silenced human primary macrophages. 
Primary macrophages differentiated from human plasma donors were seeded on a gelatin-
Rhodamine substrate and incubated for 6 h. Representative confocal fluorescent images are 
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depicted in (A). Scale bars: 5 µm. (B) Validation of NUCB1 knock down of siRNA1 and siRNA2 
in primary macrophages by western blotting. GAPDH was used as loading control. (C) 
Quantification of gelatin degraded area per cell. Silencing either NUCB1 or MMP2 impairs gelatin 
degradation in human primary macrophages. Two different siRNAs were used to corroborate the 
phenotype. At least eight fields of view per condition were analyzed. Data are represented as 
median (± interquartile range). Kruskal–Wallis and Dunn’s group comparison tests were used to 
estimate statistical significance. ***p < 0.001. Experiments performed by the Linder group. 
Finally, given that MT1-MMP activates MMP2, it could be argued that the reduced availability 
of MMP2 at the plasma membrane is due to an activation defect (caused by the delay on 
trafficking of MT1-MMP) rather than to a trafficking delay. To rule out this possibility, in gel 
zymography experiments were performed using lysates and supernatants of HeLa control or 
NUCB1 cells expressing RUSH MMP2 (Figure 69)). The results obtained showed no 
difference in the activity of MMP2, indicating that the observed phenotype in the matrix 
degradation and invasion experiments is not due to a defect in activation but rather a delay in 
the sorting of MMP2 when NUCB1 is not present. 
 
Figure 69. MMP2 activity is not affected in NUCB1-KO cells. Zymography assay of HeLa cells 
expressing SS-MMP2-SBP-eGFP. After overnight transfection, cells were incubated with 
OptiMEM media + biotin for 45 min and lysates and supernatant samples were prepared for 
zymography evaluation. No differences in gelatin degradation were observed in NUCB1-KO cells 
when compared to the HeLa control. The two bands observed correspond to MMP2-SBP-eGFP 
inactive (~110kDa) and active (~101kDa) versions of the protein. CN: HeLa control cells, KO: 
NUCB1-KO cells, Untsf HeLa: Hela cells without transfection. [SN]: 10X concentrated 
supernatants. The semi-quantitative analysis of this experiment is depicted in (B). 
In conclusion, the results here shown identify NUCB1 as a novel component of MMP2 
trafficking. They show that NUCB1 interacts with MMP2 at the Golgi, exclusively delaying its 
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intra-Golgi trafficking at the cis compartment and, as a consequence, decreasing MMP2 
mediated cell migration and matrix invasion. Moreover, they show that not only MMP2, but 
also MT1-MMP intra-Golgi trafficking is impaired, implying that this mechanism could also 
influence the trafficking of other MMPs. Further studies are required to establish the extent to 
which NUCB1 influences trafficking dynamics of extracellular matrix degrading proteins in the 
cell. 
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8. Discussion 
MMPs are one of the most important components in ECM remodeling186,250,276–278. Profuse 
literature has studied their roles in cell migration and tissue invasion during cancer metastasis, 
as well as in inflammatory processes, where macrophages secrete MMPs in antagonist manners 
and only under certain stimuli184,190,211,215,250. MMPs degrade mainly extracellular substrates, 
though their role in intracellular cleavage has also been demonstrated182,198,279. Although the 
literature describing MMPs multiple functions and their potential role as biomarkers is 
abundant186,188,195,202,204,214,215,279, little is known about their intracellular trafficking mechanisms.  
Some studies have shown that MMPs are transported in kinesin-driven vesicles across 
microtubules from the TGN to the plasma membrane225,241,246,249,280. Also, recent reports haven 
shown that Rab GTPases, such as Rab8, Rab2A and Rab40b are required for MMP transport 
and MT-MMPs recycling212,242,243,245. However, the machinery behind these routes remains 
unknown. The work presented here aimed to elucidate components of MMP intracellular 
trafficking. Hence, this chapter will discuss the findings that revealed NUCB1 as a novel 
component of MMPs intracellular trafficking and outline how Ca2+ is essential for MMP2 
intra-Golgi trafficking. 
8.1 NUCB1 as regulator of anterograde MMP trafficking 
A mass spectrometry approach combined with the synchronized secretion of GFP tagged 
MMP2 allowed to identify NUCB1 as a novel component of MMP2 trafficking. NUCB1 
literature describes its role in G-protein activation113,114,116,117, the inhibition of β-amyloid 
precursor protein (APP) formation118,119,265 and a role in endosomal trafficking120,121, but no 
report so far links NUCB1 with anterograde cargo trafficking. Notably, NUCB1 resides in the 
cis-Golgi, where it is retained for a period of time that varies between 12 and 24 h –depending 
on the cell type– and is then secreted to the extracellular milieu106,112.  Another form of the 
protein localizes in the cytoplasm (sNUCB1) and has been described to activate Giα3 protein 
and exert a chaperone-like function on amyloid-β precursor protein (APP), avoiding its 
aggregation112–114,117–119,265,281.  
In order to determine the effect of NUCB1 on MMP2 trafficking, NUCB1-KO cells were 
generated via CRISPR/Cas9 technology and MMP2 intracellular transport was evaluated using 
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the RUSH system. Results from these experiments (Figures 42A, 42B) showed that MMP2 
trafficking is not altered at the ER and arrives to the cis-Golgi in NUCB1-KO cells with the 
same kinetics compared to HeLa control cells. However, once MMP2 reaches the cis- and 
traffics towards the trans-Golgi a trafficking delay is observed. Particularly, such delay 
disappears once the protein reaches the TGN and can be transported to the plasma membrane 
with no kinetic differences between NUCB1-KO and HeLa control cells. Furthermore, 
evaluation of MT1-MMP trafficking evidenced a similar delay in NUCB1-KO cells without a 
complete block in trafficking. Then the question arises, why is there a delay instead of a whole 
arrest of protein trafficking in the absence of NUCB1? 
One possibility is that another protein interacting with MMP2 at the Golgi could compensate 
for the loss of NUCB1. Calumenin could be a good candidate for such a role since it is also an 
EF-hand protein associated with the ER that localizes to the Golgi before being secreted21. In 
this regard, calumenin could, under impaired Ca2+ homeostasis at the cis-Golgi, compensate 
for the lack of NUCB1 activity. Remarkably, calumenin has been shown to interact with 
thrombospondin-1, an extracellular matrix protein important for coagulation, and is suggested 
to be involved in its trafficking282. Not just calumenin, but also proteins continuously cycling 
between ER and Golgi, such as the complex formed by MCDF2 and LMAN126–28, known to 
participate in the early trafficking of coagulation factors in a Ca2+-regulated manner, could 
also compensate for the lack of NUCB1. Nevertheless, further investigation is required to 
confirm their potential compensation.  
Given that Ca2+ gradients along the Golgi are important for cargo trafficking, another 
possibility is that the absence of NUCB1 causes a local change of Ca2+ concentration 
exclusively at the cis-Golgi. Among the EF-hand proteins present along the secretory pathway, 
NUCB1 and Cab45 have been shown to be essential for keeping Golgi Ca2+ homeostasis103,106. 
Interestingly, both proteins share several similarities: they possess homologous Ca2+ binding 
EF-hand domains, they regulate Ca2+ homeostasis by association with Ca2+ ATPases 
(NUCB1 with SERCA in the cis- and Cab45 with SPCA1 in the trans-Golgi) and in their 
absence cargo trafficking is delayed or blocked9,95,96,104,112.  
Importantly, Cab45 has been shown to be crucial to sort cargo at the TGN in a Ca2+-
dependent manner and previous studies have already evidenced the importance of Ca2+ for 
the proper sorting of soluble cargo at the TGN83,93–96,107,273, therefore, NUCB1 could act as the 
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Cab45 counterpart at the cis-Golgi regulating cargo trafficking in a Ca2+-dependent manner 
(see below). Moreover, results from secretion assays showed that the observed delay at the cis-
Golgi generated a reduced availability of MMP2 in the extracellular milieu, whereas HRP, and 
even LyzC, a protein known to be sorted by Cab45, showed no reduction (Figures 43, 46). 
These results point towards a specific impairment of cis-Golgi Ca2+ homeostasis, rather than 
an overall Ca2+ deficiency and support the hypothesis of NUCB1 as an essential component 
of MMP2 intra-Golgi trafficking. 
8.2 NUCB1 influences MMP2 trafficking exclusively at the cis-Golgi 
Live-cell microscopy experiments using RUSH MMP2 evidenced that MMP2 trafficking delay 
in NUCB1-KO cells occurs exclusively at the cis-Golgi, since kinetics at both ER and trans-
Golgi showed no differences when compared to HeLa control cells. Moreover, Ca2+ influx 
experiments with both NUCB1-KO and NUCB1-mEFh1+2 mutants evidenced an 
impairment in Ca2+ homeostasis at the cis but not the trans-Golgi.  
It is well known that cis and trans-Golgi compartments store Ca2+ at different concentrations 
in a gradient manner, with the higher Ca2+ concentration at the cis (~300 µM)51,52,89,99. SERCA 
pumps provide most of the Ca2+ at the ER and cis-Golgi, whereas at the trans-Golgi is SPCA1 
the main Ca2+ provider49,83,85. In addition, the Ca2+ channel distribution also varies, with the 
IP3 receptors (IP3R) predominantly localizing at the cis and Ryanodine receptors (RyR) at the 
trans85; this differential distribution of Ca2+ effectors pinpoints how the maintenance of Ca2+ 
gradients is essential for Golgi compartmentalization.  
Nowadays the mechanism by which this compartmentalization is maintained, is still under 
debate, however, two main models have been generally accepted: the cisternal 
maturation/progression model and the fixed compartment model (Figure 8)46,48,56. One could 
argue that the observed kinetics of MMP2 transport would support a trafficking model where 
Golgi compartments are fixed given that no differences between NUCB1-KO and HeLa 
control cells were observed before 30 min and after 44 min of biotin incubation. However, 
given the restricted time frame evaluated is not possible to come to this conclusion. Actually, 
one could also argue that after the 45 min evaluated, or even, once the ER is newly refilled 
with MMP2-eGFP, a new Golgi cisterna is generated and, upon recycling of medial-Golgi 
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resident proteins, Ca2+ levels equilibrate and MMP2 can mature and be efficiently sorted into 
secretory vesicles.  
8.3 NUCB1 interacts with MMP2 at the Golgi 
Most of the literature describing NUCB1 function is based on experiments performed with 
sNUCB1, the cytosolic version of the protein113,114,117,119,120. However, results from RUSH 
MMP2 experiments showed that sNUCB1 does not rescue MMP2 trafficking when expressed 
in NUCB1-KO cells. Moreover, my results demonstrate that NUCB1 interacts in a weak 
manner with MMP2 specifically at the Golgi, as shown by IP experiments using Golgi 
membranes, and that such interaction is direct, as evidenced by the analytical 
ultracentrifugation experiments. However, validating this interaction was one of the biggest 
challenges of this work, mainly because it turned out to be very difficult to confirm the direct 
interaction between endogenous proteins using coIP experiments.  
To determine the specific domain of interaction between MMP2 and NUCB1, I generated 
MMP2-domain truncated mutants (Figures 54, 55). Although I could evidence that both 
proteins interact, the specific domain for such an interaction remains unidentified. It is 
possible that the approach I used, with whole cell lysates, did not provide the right 
environment for MMP2 truncated mutants and NUCB1 to interact. In addition, the use of 
overexpressed NUCB1 in whole cell lysates –even though the amount of transfected NUCB1 
was adjusted according to previous titration experiments (data not shown)– may also explain 
why the interaction was always present in the Western blots. Moreover, experiments 
performed with overexpressed MMP2 truncated mutants only, showed inconclusive results 
about the interaction with endogenous NUCB1 (data not shown).  
Nonetheless, I cannot rule out the possibility that a third component is required for the 
stabilization of the interaction between NUCB1 and MMP2. Given that different TIMPs 
interact with MMP2, it is possible to hypothesize that such an interaction could work as a 
scaffold for NUCB1 binding. Also, it is possible that both proteins interact very transiently in a 
switch way, where Ca2+ waves allow transient binding of MMP2 to NUCB1 and reduction of 
Ca2+ concentration towards a medial Golgi, causes MMP2 release. 
 132 
In this regard, my CD measurements showed conformational changes in rNUCB1 that favored 
a more compact form in the presence of Ca2+, a behavior that has been observed in other EF-
hand proteins such as p54/NEFA123 and Cab4595,96. Such changes could expose hydrophobic 
residues that enable further protein-protein interactions. Moreover, similarities between the 
conformational changes of NUCB1 and Cab45 upon Ca2+ addition suggest that Ca2+ is a 
regulator switch that promotes NUCB1-dependent protein trafficking. In this regard, the 
requirement of Cab45 EF-hand domains for its oligomerization and sorting of soluble cargo in 
sphingomyelin-rich vesicles, supports this premise. Furthermore, the impaired interaction 
between NUCB1 and MMP2 when NUCB1 EF-hand motifs 1 and 2 are mutated, strengthen 
the hypothesis of a Ca2+-dependent interaction and posterior delivery of MMP2 to the next 
compartment.  
8.4 Physiological relevance of impaired MMP2 intra-Golgi 
trafficking 
MMP2 is characterized for its upregulation in metastatic cells and its role in promotion of cell 
invasion212–214,216,248. Also, under physiological conditions, MMP2 has been described as a key 
player in neurological development, tissue repair and control of inflammation processes by 
promotion of leukocyte transmigration and active ECM degradation215,218,247,283. Already Yu et 
al. (2014) demonstrated that a general knock out of Rab11a caused a defect in MMP2 secretion 
and a deficient embryo implantation in Rab11null mice284. Also, Wiesner at al. (2013) showed 
that the ablation of Rab5a, Rab8a and Rab14 impaired MT1-MMP delivery to the plasma 
membrane, decreasing the contact between MT1-MMP containing vesicles and podosomes, 
and therefore, reducing proteolytic invasion of human macrophages242.  
Our collaborative work evidenced a reduced invasion of MDA-MB-231 cancer cells and an 
impairment in gelatin degradation, both in MDA-MB-231 cells and human macrophages when 
NUCB1 was silenced. Moreover, the observed impairments highly resembled the phenotype 
observed when MMP2 was silenced, illustrating the role of NUCB1 in proper MMP2 
trafficking and highlighting its relevance for proper ECM remodeling. Here is important to 
highlight that NUCB1 also modulates MT1-MMP intra-Golgi trafficking, which explains why 
its effect in MDA-MB-231 cell invasion is slightly stronger than the one observed in MMP2 
silenced cells (Figure 67). Furthermore, given that MMP2 is mainly activated by MT1-MMP at 
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the plasma membrane, it would be possible that the observed phenotype is due to an MMP2 
activation defect, rather than a delay in trafficking. However, the zymography confirm that it is 
the delay, but not an activation defect, which impairs matrix degradation. 
8.5 A model for NUCB1-dependent MMP intra-Golgi trafficking 
Defining a common model for intra-Golgi trafficking remains a matter of debate in the 
field29,46,61,285. So far, 4 models have been described: vesicular model (VM), diffusion model 
(DM), cisternal maturation-progression model (CMPM)46 and kiss-and-run model (KARM)285. 
In addition, a model in which intra-Golgi trafficking occurs via tunnels generated between the 
Golgi stacks has been used to explain the trafficking of large cargo in mammalian cells29. 
Although there is evidence favoring each model25,48,56,62, no consensus has been reached so far. 
Instead, it has been suggested that, depending on the cargo, the distance and the time 
regulation of membrane fusion and fission, proteins could be transported following different 
models in parallel29.  
A diffusion model where the arrival of cargo from the ER to the cis-Golgi promotes Ca2+ 
efflux and the subsequent formation of Golgi tubules could explain why in the absence of 
NUCB1 there is a delay in trafficking285. Trucco et al. (2004) demonstrated that Golgi tubules 
are destabilized when no Ca2+ is liberated to the cytosol, therefore, an impairment in Ca2+ 
homeostasis at the cis-Golgi would destabilize the tubules around this compartment and delay, 
although not completely block, the transport to the next compartment286 
The results of this work show that NUCB1 impairs MMP2 trafficking exclusively at the Golgi 
in a Ca2+-dependent manner, probably by interacting in a Ca2+-regulated switch-manner at 
specific exit sites in the rims of the cis-Golgi. The accumulation of cargo at the highly curved 
rims of the cis-Golgi is a well-known mechanism for vesicle transport to the medial 
compartment55,56,58–60,64,287,288.  
Although Lin et al. (1998) identified NUCB1 as a luminal protein, it was also present in the 
membrane fraction of Golgi isolations, suggesting its association with Golgi membranes in an 
unknown manner104. Furthermore, Lavoie et al. (2002) found that NUCB1 is associated with 
Golgi membranes in AtT20 cells and Leclerc et al. (2008) identified NUCB1, COX-2 and 
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cytosolic phospholipase A2α (cPLA2α) in Golgi membrane fractions of human neutrophils, 
strengthening the hypothesis of an association with the membrane102,106.  
Lavoie et al. (2002) proposed that NUCB1 could be retained at the cis-Golgi by binding to an 
unknown transmembrane protein. Although no studies have evaluated membrane association 
of cis-resident NUCB1, FRET experiments from Weiss et al. (2002) showed that sNUCB1 
interacts with the heteromeric Gαi3 protein at the cytoplasmic face of the Golgi only when 
Gαi3 is anchored to the membrane via palmitoylation and myristoylation114. Based on these 
findings, it is possible to hypothesize that Golgi-resident NUCB1 uses a similar mechanism to 
associate with and unknown transmembrane candidate that act as an anchor on the luminal 
side of the Golgi.  
Lipid modifications, and particularly myristoylation and palmitoylation, are known to be 
important for the association of proteins to membranes68,70,289. Moreover, N-glycine-
myristoylation is necessary for the correct association of proteins to membranes of an 
intracellular compartment, though, it requires additional lipid modification or the presence of 
positively charged amino acid clusters in the targeting protein68. These additional requirements 
allow that protein myristoylation acts as an activation switch modulated by changes in GTP or 
Ca2+68. 
In this context, it has been shown that myristoylated proteins involved in Golgi structure 
maintenance, such as cPLA2α and GRASP65, localize to the Golgi in a Ca2+-dependent 
manner59,67,70,85. Furthermore, Micaroni et al. (2010) showed that intra-Golgi trafficking induces 
changes in Ca2+ concentration at the cytosol surrounding the Golgi, triggering the recruitment 
of Ca2+-dependent proteins or inducing cytosolic signaling cascades83,85.  
In particular, both cPLA2α C2 domain as well as its catalytic activity are required for the 
maintenance of Golgi curvatures and tubulation59,124. cPLA2α generates wedge-like lysolipids 
by hydrolysis of fatty acids in cylindrical phospholipids85, whereas cPLA2α C2 domain has 
been identified as a Ca2+ sensor important for the translocation of cPLA2α from the plasma 
membrane to Golgi membranes124.  
Moreover, Ward et al (2012) demonstrated that, after membrane binding, the C2 domain of 
CPLA2α is sufficient to induce positive membrane curvature in giant unilamellar vesicles 
(GUVs), whereas only the full-length protein is able to initiate tubulation124. In this regard, the 
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accumulation of wedge-like lysolipids in cPLA2α-induced curved Golgi regions would 
stimulate the formation of vesicles or tubules that interconnect Golgi cisternae59,85. Altogether, 
cPLA2α could be considered a potential candidate for the Ca2+-dependent indirect regulation 
of NUCB1-driven anterograde trafficking (Figure 70). 
 
Figure 70. Model for Ca2+-dependent NUCB1-mediated MMP2 trafficking. In this model, 
MMP2 is transported from the ER to the cis-Golgi in COPII vesicles. The vesicle fusion with the 
cis-Golgi generates a transient increase in local Ca2+ that subsequently promotes Ca2+ efflux, 
which in turn increases Ca2+ concentration in the surrounding cytosol. Such a change induces 
cPLA2α translocation from the plasma membrane to the Golgi and Ca2+ mediated association 
with the Golgi membrane. The translocation of several units of cPLA2α induces positive 
membrane curvature that, after accumulation of wedge-like lysolipids, promotes membrane 
tubulation or vesiculation. In parallel, Ca2+ concentration increase at the luminal Golgi induces a 
conformational change in NUCB1 that enables its interaction with MMP2. Such conformational 
change uncovers negatively charged residues that could induce NUCB1 association to Golgi 
membranes and by an unknown intermediary, transport the NUCB1-MMP2 complex towards the 
rims or, by proximity, towards tubulations that will drive cargo to the next compartment.  
Likewise, Ernst et al. (2018) showed that S-palmitoylation could also work as a biophysical 
switch to accumulate cargo at the rims of the cis-Golgi and promote its trafficking to the next 
compartment60. Interestingly, MT1-MMP is palmitoylated in its cytoplasmic tail and such 
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modification has been shown to be important for its recycling to endosomal compartments via 
clathrin-coated vesicles290. Therefore, we cannot rule out the possibility that its anterograde 
trafficking is mediated by a similar mechanism. Furthermore, given that MT1-MMP and 
MMP2 interact via TIMP2220 it is also possible that MT1-MMP aids in the anterograde 
trafficking of MMP2 by promoting its accumulation at the Golgi rims and posterior transport 
to the medial compartment. 
 
Figure 71. Model for N-myristoylation or S-palmitoylation-dependent MMP2 trafficking. MMP2 
is transported from the ER to the cis-Golgi in COPII vesicles. Once it reaches the Golgi, Ca2+ 
concentration increases in the lumen and induces a conformational change in NUCB1 that enables 
its interaction with MMP2. Such conformational change promotes membrane association via 
interaction with either an unknown palmitoylated protein or an unknown myristoylated partner. 
The accumulation of S-palmitoylated proteins towards the Golgi rims induces accumulation 
NUCB1-MMP2 complexes and further vesicle-mediated transport to the medial-Golgi. 
In conclusion, this work allowed to gain a better understanding on intracellular MMP 
trafficking by uncovering NUCB1 as a novel component of the intra-Golgi trafficking 
machinery for MMP2. Based on these results, we propose 2 models:  
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1. Model for Ca2+-dependent NUCB1-mediated MMP2 trafficking: MMP2 arrival from the ER 
to the cis-Golgi generates a transient increase in local Ca2+ that subsequently promotes 
Ca2+ efflux and a raise of Ca2+ concentration in the surrounding cytosol. This change 
induces cPLA2α translocation from the plasma membrane to the Golgi, where Ca2+ 
mediated membrane association occurs. The translocation of cPLA2α units to the 
Golgi induces positive membrane curvature and accumulation of wedge-like lysolipids 
that promote membrane tubulation or vesicle formation. In parallel, luminal Ca2+ 
concentration increase at the Golgi induces a conformational change in NUCB1 that 
enables its interaction with MMP2. Such conformational change uncovers negatively 
charged residues that could induce NUCB1 association to Golgi membranes and by an 
unknown intermediary, transport the NUCB1-MMP2 complex towards the rims or, by 
proximity, towards tubulations that will drive cargo to the next compartment (Figure 
70). 
2. Model for S-palmitoylation-dependent MMP2-trafficking. Increase in luminal Ca2+ due to 
cargo arrival at the cis-Golgi induces Ca2+-dependent NUCB1 binding with MMP2. 
The interaction generates a conformational change that uncovers potential protein 
interacting regions, promoting NUCB1-MMP2 binding to an unknown S-palmitoylated 
transmembrane protein and anchoring the complex to the Golgi membrane. This 
association accumulates NUCB1-MMP2 complex and other cargo to the Golgi rims. 
The accumulation of S-palmitoylated proteins at the rims acts as a biophysical switch 
that induces an increase in membrane curvature and leads eventually to vesicle budding 
and cargo export to the next compartment (Figure 71). 
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9. Outlook and future perspectives 
The results of this thesis contributed to enlighten the mechanism of MMP2 intracellular 
trafficking by identifying NUCB1 as a critical player in MMP transport. Importantly, this work 
highlights the requirement of Ca2+ for proper trafficking, not just at the TGN, as has been 
documented, but also at the cis-Golgi. Although this is a big step towards the understanding of 
MMP intracellular trafficking, several questions remain unanswered. 
Further investigation should address the specific interacting domains between NUCB1 and 
MMP2. Although I could prove the NUCB1-MMP2 interaction, additional exploration is 
required to identify the interacting regions between both proteins. Also, an evaluation of 
alternative Ca2+ regulators at the Golgi is required to determine if a compensation affect is 
taking place in the absence of NUCB1. A proper characterization of the Ca2+ dynamics would 
give a better insight in how is actually NUCB1 regulating Ca2+ concentrations at the Golgi 
lumen. 
Importantly, further analysis should evaluate changes in tubulation or vesicle formation in 
NUCB1-KO cells. This would give some light into the participation of structural components 
of the Golgi in trafficking. Specifically, an evaluation of cPLA2α activity and localization in 
NUCB1-KO cells will allow to better understand the observed changes in trafficking 
dynamics. 
Finally, NUCB1 interaction with palmitoylated proteins should be evaluated, in particular with 
MT1-MMP, in order to gain a better understanding of the retention mechanism of NUCB1 at 
the cis-Golgi lumen and a deeper insight into the regulation of intra-Golgi protein trafficking. 
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Todo pasa y todo queda 
Pero lo nuestro es pasar 
Pasar haciendo caminos 
Caminos sobre la mar 
Cantares (A. Machado, 1917) 
 
 
